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ABSTRACT 
Intake of the micronutrient selenium, which is incorporated into selenoproteins in humans, 
has been implicated in affecting risk of colorectal cancer. A genetic variant in the gene 
encoding the selenoprotein glutathione peroxidase 4 (GPx4) has been reported to influence 
colorectal cancer risk. In this study the role of GPx4 was investigated in the Caco-2 intestinal 
cell line using RNA silencing.   GPX4 expression was knocked–down by ~60% and an 
unbiased gene microarray analysis of the total Caco-2 cell transcriptome was carried out 
using Illumina HumanHT-12v3 beadchips.  The data were validated by real-time PCR. 
Ingenuity Pathway analysis showed that the major canonical pathways affected by GPX4 
knock-down were oxidative phosphorylation, ubiquinone biosynthesis and mitochondrial 
dysfunction and the top two toxicological lists were mitochondrial dysfunction and oxidative 
stress. Western blotting and real-time PCR confirmed that knock-down affected target genes 
encoding components of respiratory complexes I, IV and V as well as the protein apoptosis-
inducing factor (AIF).  GPX4 knock-down increased levels of mitochondrial reactive oxygen 
species and oxidised lipid, and decreased mitochondrial adenosine triphosphate (ATP) levels 
and mitochondrial membrane potential. Time course experiments showed changes in AIF 
expression preceded those in the respiratory complexes. GPX4 knock-down increased 
apoptosis and changed protein expression of Caspase-9, Bax and Bcl-2. Treatment of cells 
with the antioxidant mitoquinone prevented the effects of GPX4 knockdown on 
mitochondrial reactive oxygen species, oxidised lipid and mitochondrial membrane potential 
but not the effect on AIF. These data suggest that in intestinal epithelial cells GPx4, through 
effects on lipid peroxidation and AIF, plays a complex role in maintaining the oxidative 
phosphorylation system and protecting mitochondria from oxidative damage and apoptosis. 
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Chapter 1. Introduction 
1.1 The importance of micronutrient selenium and its role in human 
health. 
The identification of selenium (Se) as an essential micronutrient was first reported in 
cattle and sheep that exhibited Se-responsive disorders such as white muscle disease 
(Brown & Arthur, 2001). Subsequently, the importance of Se to human physiology was 
highlighted by report of a particular cardiovascular disease known as Keshan disease 
which occurred in the Keshan region of Heilongjiang province in China and which 
responded to Se supplementation. The soil Se is very low in this region (Combs, 2000). 
The aetiology of Keshan disease is not entirely known, however, a possible mechanism 
has been linked to low Se intake and susceptibility to virus infection in human heart 
muscle (Beck, 1999; Combs, 2000). Selenium supplementation of the diet prevented the 
high incidence of Keshan disease in this region of China (Beck, 1999). Health 
implications of Se intake have been widely studied with interest since its implication in 
Keshan disease. Selenium intake has been linked with the ability to protect against viral, 
bacterial infection and in carcinogenesis (review by Fairweather-Tait et al, 2011; 
Rayman, 2012). 
Deficiency in Se has been associated with susceptibility to Coxsackie virus (Beck et al., 
1995; Beck, 1997), human immunodeficiency virus (HIV) (Baum et al., 1997; Fawzi et 
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al., 2005) and influenza virus (Beck et al., 2001; Jaspers et al., 2007). A Coxsackie B4 
strain of virus was isolated from cardiac muscle samples of patients with Keshan disease 
(Beck, 1997), and a study in mice showed that that Coxackie virus reacted more 
virulently, and a benign strain Coxsackie B3 switched and became more virulent at low 
Se intake (Beck et al., 1995; Beck, 1999). HIV patients exhibited a 10 fold lower level 
of plasma Se than healthy controls and these patients demonstrated a 6 fold increased 
risk of mortality from multiple infections in both adults and children (Baum et al., 1997; 
Campa et al., 1999). A clinical trial investigating the effects of Se and TR1 on HIV-1 
encoded transcriptional activator (Tat), and HIV-1 replication, in macrophages showed 
TRI knock-down by small interfering RNA to significantly increase Tat and HIV-1 in 
human macrophages, and 100-200ug/day of Se supplementation to increase TRI 
expression thereby inhibiting Tat and HIV-1 replication. These data might explain Se 
effects on HIV infection (Kalantari et al., 2008). 
Selenium enhances resistance to bacterial infection and low Se intake has been 
associated with increased progression of inflammatory bowel diseases (IBD) (Halliwell 
et al., 2000; Karp & Koch, 2006). The aetiology of IBD has been linked with a 
combination of genetic variant (Hugot et al., 2001; Stoll et al., 2004), microbial 
infection (Marteau et al., 2004; Hisamatsu et al., 2008) and low Se intake (Geerling et 
al., 2000; Karp & Koch, 2006). The colon is often  a site for inflammation due to 
presence of pathogenic or commensal microbes (Wen & Fiocchi, 2004) and Se 
3 
 
supplementation has been shown to be useful in controlling IBD symptoms (Halliwell et 
al., 2000; Tirosh et al., 2007) and may reduce the need for therapeutic steroids as a 
clinical immunosuppressant (Karp & Koch, 2006).  
Increased Se intake has been proposed to reduce cancer risk. Low Se intake has been 
associated with increased risk of developing various cancer types with prostate and 
gastrointestinal cancers showing strongest association (Willett et al., 1983; Russo et al., 
1997; Whanger, 2004). Two analyses from a clinical trial following Se supplementation 
showed that Se lowered risk of prostate, lung and gastrointestinal tract cancer compared 
to placebo (Clark et al., 1996, Duffield-Lillico et al., 2002). The protective effect of Se 
has been implicated in some but not all cancer types, for example no significant 
reduction was observed in skin cancer after Se supplementation (Clark et al., 1996).  
 Supplementation with Se has been reported to reduce gastrointestinal cancers by ~25% 
to 60% and other gastrointestinal associated cancers such as small intestine, biliary tract, 
esophageal, pancreatic, colorectal, gastric and liver (Wang et al., 1994; Bjelakovic et al., 
2008; review by Fairweather-Tait et al., 2011). Dietary supplementation of selenium in 
China showed significant reduction in prevalence of oesophageal cancer (Wang et al., 
1994; Blot et al., 1995) and reduced gastric cancer mortality (Qiao et al., 2009). A study 
of a Chinese cohort supplemented with 50 µg sodium selenite and allitridum (a garlic 
compound) showed significant effect on gastric cancer and overall cancer incidence (Li 
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et al., 2004). The Netherland Cohort study supplemented 2759 cancer esophageal 
patients and controls with Se and observed an inverse association between toenail Se 
content, gastric carcinoma and esophageal squamous carcinoma (Steevens et al., 2010). 
Smokers with low-baseline Se showed significantly reduced incidence of adenomas and 
colorectal cancer (Reid et al., 2006). Combined supplementation of Se and other 
antioxidants such as vitamin E, vitamin C, β-carotene and calcium resulted in the 
reduced incidence of adenomas in Norwegian patients (Hofstad et al., 1998). Combined 
supplementation of Se and other antioxidants reduced the risk of prostate cancer (Meyer 
et al., 2005). A case-control study in the United States reported the association between 
higher serum Se concentration and reduced risk of prostate cancer (Vogt et al., 2003). 
Selenium has been reported to play a crucial role in the brain (see review by Burk & 
Hill, 2009; Rayman, 2012). Selenoprotein P (Sel P) is a selenium derived protein 
responsible for distribution of Se to different organs and tissues. A study in mice lacking 
Sel P reported enhanced spasticity, abnormality in movement and spontaneous seizures 
(Schweizer et al., 2004). Studies in humans implicated Se deficiency in seizures, 
Parkinson’s disease coordination and decline in cognitive capability (Ashrafi et al., 
2007; Mahyar et al., 2010). Children and adults with epilepsy and seizures (Ashrafi et 
al., 2007a;b) and children with febrile seizures (Amiri et al., 2010; Mahyar et al., 2010) 
exhibited significantly lower Se levels than controls and Se supplementation has been 
reported to reduce intractable childhood seizures ( reviewed by Rayman, 2000). Patients 
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with low plasma Se exhibited significant low coordination and a trend towards increased 
risk of developing Parkinson’s disease (Shahtar et al., 2010). Low plasma Se has been 
associated with cognitive decline in a French sample cohort (Akbaraly et al., 2007) and 
cognitive decline in a Chinese sample cohort (Gao et al., 2007). 
The highest Se concentration of all tissues is in the thyroid gland (Schomburg et al., 
2008). Various roles of Se in the thyroid gland have been reported. Iodothyronine 
deiodinases are Se-dependent selenoproteins that produce active thyroid hormone, tri-
oidothyronine (T3) from its inactive precursor thyroxine (T4) (Schomburg et al., 2008). 
GPx3 is a Se-dependent enzyme reported to protect cells from effects of hydrogen 
peroxide in the thyroid gland (Schomburg et al., 2008).  This function is consistent with 
thyroid tissue damage and goitre, thyroid volume and Se status in French women 
(Derumeaux et al., 2003), and the incidence of low prediagnostic serum-Se 
concentration and thyroid cancer in Norway (Glattre et al., 1989). Selenium has been 
widely implicated in Hashimoto’s thyroiditis, the most common type of autoimmune 
thyroid disease. Hashimoto’s thyroditis is characterized by accumulation of 
complement-fixing autoantibodies to thyroid peroxidase and Se supplementation 
between 80 µg to 200 µg per day (in form of sodium-selenite or selenomethionine) was 
effective against Hashimoto’s thyroditis (Nacamulli et al., 2010; Toulis et al., 2010). A 
meta-analysis study and systematic review reported that Se supplementation 
significantly reduced titre of autoantibody targeting thyroid peroxidase at 3 months 
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(Toulis et al., 2010). Se supplementation of 200 µg reduced thyroid inflammation, 
permanent hypothyroidism and post-partum thyroid disease (Negro et al., 2007). 
Selenium supplementation has been reported to reduce effects of Graves disease and 
these patients showed less eye involvement, improved quality of life and reduction 
towards progression to Graves’ orbitopathy after supplementation (Marcocci et al., 
2011). However, a randomized control trial study in elderly UK adults with low-to-
moderate Se levels did not show any evidence of an effect on thyroid hormone (Rayman 
et al., 2008). 
 
1.2 The selenoproteins and their functions 
Twenty seven selenoproteins have so far been identified in the human proteome 
(Kryukov et al., 2003). Glutathione peroxidase (GPx) family (GPx1-7) and the 
Thioredoxin Reductase (TrxR) family (TrxR1-3) are two groups of selenoprotein which 
have been characterized as antioxidants and play crucial role in the reduction of reactive 
oxygen species (ROS) (Lu & Holmgren, 2009; Fairweather-Tait et al 2011). The 
deiodinase (DIO) families (DIO1-3), through their reductive activity, play an important 
role in metabolism of Iodine (I) in the thyroid (Kohrle, 2000; Brown & Arthur, 2001). 
Some other selenoproteins such as selenoprotein W (SelW) and selenoprotein H (SelH) 
have been reported to have antioxidant function (Dikiy et al., 2007), selenoprotein P, 
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(Sel P) is responsible for the absorption and transportation of Se (Kato et al., 1992), and 
selenophosphate synthetase 2 synthesis of SeCys tRNA such as, (SPS2) (Xu et al., 
2007). Seven selenoproteins including Selenoprotein K (SelK), SelM, SelN, SelS, SelT, 
Sep 15 and DIO2 are found in the endoplasmic reticulum (ER) where their functions 
have been suggested to involve modulation of protein folding particularly in response to 
ER stress (Labunskyy et al., 2009; Shchedrina et al., 2010). Table 1 shows the list of the 
27 selenoproteins together with their respective tissue distributions, subcellular 
localizations and functions.  
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Selenoprotein Function Tissue distribution Subcellular localization 
GPx1(c-GPx) Antioxidant All tissues Cytoplasm 
GPx2(GiGPx) Antioxidant Gastrointestinal epithelium, liver Cytoplasm 
GPx3(p-GPx) Antioxidant Circulation plasma Circulation plasma Extracellular 
GPx4(phGPx) Antioxidant All tissues Cytoplasm, Mitochondria 
GPX5 Antioxidant? Unknown Unknown 
GPx6 Antioxidant? Unknown Unknown 
GPx7 Antioxidant? Unknown Unknown 
TrxR1 Antioxidant All tissues Cytoplasm; Mitochondria 
TrxR2 Antioxidant Liver, kidney, heart Mitochondria 
TrxR3 Antioxidant Testis Cytoplasm 
IOD1 T3 T4 metabolism Thyroid Plasma membrane 
IOD2 T3 T4 metabolism Thyroid ER membrane 
IOD3 T3 T4 metabolism Brain, muscle, placenta Plasma membrane 
SPS2 Wide SeCys tRNA synthesis Wide Cytoplasm 
SelS Protein folding Unknown ER 
SelP Se transportation Liver and others? Extracellular 
Sep 15 Protein folding Wide ER 
SelW Antioxidant Muscle Cytoplasm 
SelN Calcium homeostasis Wide ER membrane 
SelR Unknown Liver, kidney, pancreas Cytoplasm 
SelT Protein folding? Prostate Unknown 
SelH Antioxidant Unknown Cytoplasm 
SelI Unknown Unknown Cytoplasm 
SelK Protein folding? Unknown Plasma membrane 
SelM Protein folding? Unknown Perinuclear? 
SelO Unknown Unknown Cytoplasm? 
SelV Unknown Unknown Cytoplasm 
Table 1.  Identified selenoproteins, their possible functions, tissue distribution and subcellular 
localizations. Adapted  from Moghadaszadeh and Beggs, 2006 and modified according to 
Voudouri et al., 2003, Labunskyy et al., 2009, Brigelius-Flohe, 1999, 2008, Shchedrina et al., 
2010, Curran et al., 2005, Dikiy et al., 2007, Jablonska et al.  (?= not well characterized) 
9 
 
As shown in Table 1, the majority of the 27 selenoproteins function as antioxidants and 
have the ability to reduce reactive oxygen species (ROS) due to the presence of SeCys in 
their catalytic sequence. Selenium is a chemical family member of Oxygen (O) and 
Sulphur (S), but it has a high ability to transfer electrons. In the case of glutathione 
peroxidases, two electrons are donated to unsaturated oxygen radicals catalytically and 
this results in a formation of reduced glutathione (Moghadaszadeh & Beggs, 2006; 
Brigelius-Flohe & Kipp, 2009). A typical example is the reaction with hydrogen 
peroxide (H2O2) shown in Figure 1 and the overall resulting reaction is as follows:         
2 GSH+H2O2GSSG+ 2H2O. Following this reaction, glutathione disulphide (GSSG), 
at the expense of NADPH, is recycled to glutathione by Glutathione reductase. In 
addition to H2O2, selenoproteins have the ability to reduce other free radicals such as 
superoxide and lipid peroxide (ROOH) by GPX4 (Imai & Nakagawa, 2003), and 
reduction of thioredoxin by thioredoxin reductase (TrxRs) utilizing NADH as a substrate 
(Ganther, 1999). However, it is important to emphasize that ROS are produced 
continuously in cells and their clearance requires collective cooperation of many 
antioxidants in which selenium and selenoproteins play a crucial role. The pathway 
through which ROS are produced and cleared (Droge, 2002) is shown in Figure 1. 
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Figure 1.The pathway of ROS production and clearance in the cell environment 
A constant production and reduction of ROS occurs in the cell environment. This 
requires a cooperative system of antioxidants to function in ROS clearance, of which 
selenoproteins play a crucial role.( taken from Droge, 2002). 
 
 
 
 
 
11 
 
 1.2.1 Incorporation mechanism of selenium into selenoproteins 
Selenium is incorporated into proteins known as selenoproteins in form of Seleno-
cysteine (SeCys) amino acid (Kryukov et al., 2003). Insertion of the amino acid 
selenocysteine (Sec) is the key step in selenoprotein biosynthesis and this process 
requires a UGA codon in the coding region and the Selenocysteine Insertion Sequence 
(SECIS) in the 3’ untranslated region (UTR) which are present in the mRNA of all 
selenoproteins (Kryukov et al., 2003; Brigelius-Flohe, 2008). Three different triplicate 
nucleotides (UAG, UAA and UGA) function as a stop signal, which stops the synthesis 
of polypeptide during translation. The biosynthesis of protein is not terminated at UGA 
during the coding of selenoproteins because the UGA is translated into amino acid 
SeCys (Bellinger et al., 2009). A stem-loop structure (SECIS) situated within the 
3’untranslated region (3’UTR) of the selenoprotein mRNA recognizes UGA as the 
codon for the SeCys but not as a stop codon (Kryukov et al., 2003). In the 
selenoproteins of eukaryotes, SECIS share a conserved stem-loop structure with low 
similarity between sequence of the selenoprotein mRNA within the 3’UTR (Berry, 
2005). A typical predicted SECIS structure of human GPx4 (Villette et al., 2002) is 
given in Figure 2. UGA codon interacts with SECIS to recruit additional proteins which 
include SeCys-synthesizing tRNA
sec
 (Bosl et al., 1997), an elongation factor EFsec and 
a binding protein known as SECIS-binding protein 2 (SBP2) (Copeland et al., 2000). 
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Typical machinery required for SECIS incorporation is illustrated in Figure 2. Selenium 
incorporation into selenoproteins is crucial as shown by the tRNAsec knock-out mouse 
exhibiting a lethal phenotype of prenatal death (Bosl et al., 1997).  
The importance of SECIS and 3’UTR in Se incorporation is shown by the observation 
that mutations or genetic polymorphisms in regions of the selenoprotein gene 
corresponding to the 3’UTR affects the expression of the selenproteins concerned 
(Hesketh, 2008). Indeed, various polymorphisms with functional implications in the 
3’UTR of selenoprotein genes have been reported: GPX4: 718T/C close to SECIS 
(Meplan et al., 2007) SEP15: 811 C/T and 1125 G/A (Villette et al., 2002; Jablonka et 
al., 2008) and SEL P: r25191G/A (Kumaraswamy et al., 2000). 
The polymorphism 718T/C in the 3’UTR of GPx4 gene has been linked with increase 
risk of colorectal cancer (Bemano et al., 2007; Meplan et al., 2010 ) and alteration in 5-
Lipooxygenase metabolism pathway (Villette et al., 2002). The SEP15 polymorphism 
1125 G/A has been linked with increased susceptibility to lung cancer (Jablonska et al., 
2008). Additionally, early onset myopathy has been associated with mutations in SEPN1 
gene which encodes selenoprotein N (Maiti et al., 2009), a regulator of calcium 
homeostasis in muscle (Arbogast & Ferreiro, 2010).  
Despite the shared stem-loop structure amongst selenoproteins, the variability in their 
SECIS mRNA sequence has influenced their ability to incorporate Se (Kryukov et al., 
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2003; Berry, 2005). Such difference influences the response of selenoproteins to change 
in Se status resulting in differences in selenoprotein hierarchy with some being 
synthesized in higher priority and others in relatively lower priority particularly at low 
Se supply (Bermano et al., 1996; Brigelius-Flohe, 1999). Considering this effect, 
reduction in Se supply has been reported to lower the synthesis of some selenoproteins 
more than others e.g. GPx1, SelW and SelH (Pagmantidis et al., 2005; Sunde et al., 
2009). The order of GPxs hierachy during low Se status are 
GPx2＞GPx4＞GPx1=GPx3. 
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Figure 2 SECIS stem-loop structure and SeCys incorporation during selenoprotein 
biosynthesis.  
Interaction between SECIS (a conserved stem-loop structure in the 3’ untranslated 
region of all selenoprotein mRNA) and UGA is required for appropriate incorporation 
of Se into selenoproteins. (A) SECIS structure of human GPx4 mRNA and (B) 
Recruitment of additional factors such as EFsec, SBP2 and tRNAsec which allows 
SeCys incorporation into selenoprotein sequence by SECIS and UGA codon encoding 
SeCys. (Taken from (Villette et al., 2002 and Meplan et al., 2006) ). 
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1.3 Glutathione Peroxidases (GPxs) 
The glutathione peroxidase family comprises six members (GPx1-7), which are 
evolutionary conserved, particularly in their catalytic sequences. GPx1 to GPx4 and 
GPx6 incorporate SeCys during translation and require Se incorporation for their 
synthesis whereas GPx5 uses cysteine (Brigelius-Flohe, 1999); information about GPx7 
biosynthesis is yet to be elucidated. One of the characteristics of GPxs is their ability to 
catalyze ROS at the expense of glutathione (GSH) which results in the reduction of ROS 
and a balance between ROS production and clearance (redox). Selenoprotein glutathione 
peroxidases vary in their ability to incorporate Se (i.e. in the hierarchy of Se 
incorporation), in tissue distribution and cellular localization, and in their catalytic target 
to oxidative targets (Brigelius-Flohe, 1999). GPx1 and GPx4 are the most widely studied 
glutathione peroxidases and their biological functions are described below: 
1.3.1 GPx1: The ubiquitously expressed GPx1 (Moghadaszadeh & Beggs, 2006) is 
localized in cell cytoplasm and its expression has been reported to exhibit a high 
sensitivity to low Se supply. GPx1 mRNA is reduced to 60% in Caco-2 cells depleted of 
Se (Pagmantidis et al., 2005) and in mice fed with Se deficient diet (Sunde et al., 2009; 
Bermano et al 1995). The major function of GPx1 is to detoxify hydrogen peroxide but 
may also be involved in the clearance of water soluble hydroperoxides (Grossmann & 
Wendel, 1983; Brigelius-Flohe, 2006). Mice lacking GPx1 (GPx1-/-) did not exhibit any 
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apparent abnormalities during embryonic development (Ho et al., 1997), but showed 
high susceptibility to coxsackievirus B3 infection (Beck et al., 1998). This finding 
emulates the aetiology of Keshan diseases where reduced Se intake leads to high 
vulnerability to coxsackievirus infection. Additionally, GPx1 knockout mice (GPx1-/-) 
exhibited increased sensitivity to secondary necrosis and liver injury (Bajt et al., 2002), 
to heart injury induced by doxorubicin (Gao et al., 2008), to brain ischemia reperfusion 
injury (Crack et al., 2006) and increased sensitivity to insulin induced glucose uptake in 
muscle cells (Loh et al., 2009). The lack of antioxidant protection offered by GPx1 has 
been implicated with reduced cell tolerance to oxidative stress and apoptosis (Crack et 
al., 2006; Loh et al., 2009). 
1.3.2 GPx2: GPx2 is a gastrointestinal GPx, known to be localized in the cytoplasm and 
expressed in the liver and gastrointestinal epithelium (Chu et al., 1993). GPx2 
specifically reduce hydrogen peroxide in the same mammer as GPx1 (Brigelius-Flohe, 
1999). As observed in mice fed a Se depleted diet, GPx2 is highest in the Se 
incorporation hierarchy in tissues where it is expressed and as a result GPx2 expression 
is barely affected by Se depletion (Bermano et al., 1995; Sunde et al., 2009; Kipp et al., 
2009). Furthermore, a non-significant increase in GPx2 mRNA expression in cells 
following Se supplementation has been reported (Pagmantidis et al., 2005). As a 
selenoprotein which is specifically expressed in the intestinal epithelium, GPx2 has been 
studied in combination (double knockout model) with GPx1. Mice lacking both GPx1 
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(GPx1-/-) and GPx2 (GPx2-/-) showed increased sensitivity to challenges by microflora, 
resulting in colonic inflammation (Esworthy et al., 2003). Knockout mice of both GPx1 
and GPx2 exhibited increased susceptibility to gastrointestinal cancer probably as a 
result of reoccurring of colitis compared to normal littermates (Lee at el., 2006). The 
double knockout mice also exhibited increased malignancy (tumor growth) mediated by 
Cyclooxygenase (COX) (Banning et al., 2008) and aberrant DNA methylation ( Hahn et 
al., 2008). The protective function of GPx2 has been reported in the intestinal epithelium 
and deficiency in both GPx1 and GPx2 resulting in reduced tolerance to oxidative 
challenges (reviewed by Brigelius-Flohe, 1999). Mice lacking GPx4 exhibited increased 
inflammation and tumor numbers (Krehl et al., 2012). This finding suggests that GPx4 
inhibit inflammation-mediated turmogenesis (Krehl et al., 2012). It has been shown that 
GPx2 promoter is activated by the Wnt pathway and knock out of B-catenin (a subunit 
of the cadherin protein complex, which, acts as an intracellular signal transducer in the 
Wnt signaling pathway) in isolated colonic crypt reduced GPx2 expression (Kipp et al., 
2012). This finding suggests GPx2 as a novel Wnt target, highlighting its potential role 
(s) in proliferation, apoptosis and cancer development (Kipp et al., 2012). 
1.3.3 GPx3: GPx3 is also known as plasma GPx, is secreted from the kidney and has 
been reported to be present in blood circulation (Avissar et al., 1994). The GPX3 gene 
encodes one transcript and is low in the Se incorporation hierarchy. One of its major 
18 
 
functions is to reduce soluble hydroperoxides in extracellular environment (Bjornstedt et 
al., 1994). 
1.3.4 GPx4: GPx4 is also known as phospholipid hydroperoxide GPx. GPx4 is 
ubiquitously expressed in all tissues including the gastrointestinal tract (Imai et al., 
1995). GPx4 is located in the mitochondria and cytoplasm, and is present in the nucleus 
in some cell types e.g. testes cells (Imai & Nakagawa, 2003). GPx4 is an unusual 
selenoprotein with broad substrate specificity and has a protective role in various 
cellular compartments. GPx4 is expressed ubiquitiously in all tissues and cells with the 
highest amount being in the testis (Baek et al., 2007). 
The expression of GPx4 has been shown to be reduced (by ~ 20%) in low Se conditions 
Bermano et al., 1996; Pagmantidis et al., 2005; Kipp et al., 2009) and increased Se has 
been shown to increase GPx4 activity (Bao et al., 1996). The major function of GPx4 is 
the reduction of fatty acid hydroperoxides and removal of phospholipid hydroperoxides. 
A wide range of oxidative targets including phospholipid hydroperoxide (Ursini et al., 
1985), reducing phospholipid hydroperoxide to phospholipid hydroxide (Bao et al., 
1996), reduction of thymine hydroperoxides (Bao et al., 1997) and lipid hydroperoxide 
derived from cholesteryl esters and cholesterol (Thomas et al., 1990) can be catalyzed 
by GPx4. Additionally, GPx4 can use substrates other than glutathione for its catalytic 
function (Aumann et al., 1997). 
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The GPX4 gene produces three different transcript variants (Figure 3), namely: cytosolic 
GPx4 (cGPx4), mitochondrial GPx4 (mGPx4) and nuclear GPx4 (nGPx4). Cytosolic 
GPx4 is located in the cytoplasm (Maiorino et al., 1991) and mitochondrial and nuclear 
GPx4 contain additional leader sequences required for mitochondrial and nuclear 
translocation (Arai et al., 1996; Pfeifer et al., 2001). Nuclear GPx4 has been reported to 
be present only in the testis and to play an important role in sperm maturation.  
 
Figure 3 Structure of the GPx4 gene, and the three types isoforms of GPx4 mRNA.  
Seven exons of human GPx4 gene containning exons of the three types of GPx4 
mRNA. Exon 1a (gray box) contains the translational first start codon ATG (+1) for 
mGPx4 and the second ATG (+82) for cGPX4. Exon 1b (shaded box) contains the 
start codon ATG (+418) for nGPX4. Three transcriptional start codon (ATG) are 
shown on the reverted open triangles; the transcriptional start site for mGPx4 is 
shown in position -147 (M), cGPx4 at position +25 (C) and nGPx4 at position +406 
(N). TGA in exon III encodes selenocysteine and TAG in exon VII encodes the stop 
codon. SECIS is the selenocysteine insertion sequence. (Taken from Imai,  2010). 
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1.4 Proposed roles of GPx4 
GPx4 has been implicated in the repression of oxidative radicals particularly in lipid 
environments and in protecting mitochondria from oxidative damage (Arai et al., 1996; 
Normura et al., 1999; Liang et al., 2007). The biological role of GPx4 has been 
investigated using mouse knockout models. Lack of the GPX4 gene is embryonically 
lethal with the mice dying at prenatal stage with dysfunctional embryonic development 
(Imai et al., 2003).  Failure to restructure cavity development during embryogenesis 
suggests the importance of GPx4 in apoptosis (Imai et al., 2003). GPx4 haploid 
insufficient mice (GPx4+/-) with GPx4 mRNA, protein and activity lowered to 
approximately 50%  exhibited increased sensitivity to oxidative challenges following 
exposure to γ-irradiation and reduced  survival rate compared with normal littermates 
(Yant et al., 2003). Additionally, cultured embryonic fibroblasts from mice lacking a 
copy of GPX4 (GPx+/-) gene showed increased sensitivity to treatment with paraquat, t-
butyl hydroperoxide and hydrogen peroxide, which led to increased membrane 
peroxidation and activation of caspase-3 dependent cell death (Ran et al., 2003). On the 
other hand, GPx4 overexpression in mice liver presented resistance to oxidative 
challenges such as diquat and fibroblasts derived from these mice exhibited resistance 
following treatment with diquat and t-butyl hydroperoxide (Ran et al ., 2004). On the 
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basis of this evidence, GPx4 appears to be crucial for cell protection from oxidative 
stress. 
Compared to other GPx isoenzymes, GPx4 has a unique capacity to repress 12/15- 
lipoxygenase-derived lipid peroxidation and reduce phospholipid hydroperoxides (Seiler 
et al., 2008).  GPx4 has been reported to play a role in preventing mutagenesis through 
its ability to repair oxidatively damaged DNA and through reduction of thymine 
hydroperoxide (Bao et al., 1997).  Murine embryonic fibroblast cells from GPx4+/- mice 
exhibited increased levels of mutagenic DNA adduct and increased sensitivity to 
oxidative stress following exposure to oxidizing agent t-butyl hydroperoxide (t-BOOH) 
(Ran et al., 2003). Identification of a single nucleotide polymorphism (SNP) of human 
GPx4 (718T/C) has been reported (Bermano et al., 2007) and this SNP has been linked 
with increased risk of colorectal cancer and colorectal adenoma (Peters et al., 2008; 
Meplan et al., 2010). GPx4 mRNA transcript is one of the most abundant selenoprotein 
mRNAs in the murine intestine (Hoffmann et al., 2007). GPx4 mRNA levels are 
relatively resistant to Se depletion in Caco-2 cells (Wingler et al., 1999). Contrary to this 
finding, reduced Se was reported to down-regulate GPx1 mRNA and up-regulate GPx2 
mRNA respectively. During limited Se availability, GPx4 maintains a relatively stable 
mRNA level indicating the high ranking of GPx4 in the selenoprotein hierarchy 
(Brigelius-Flohe, 2006). 
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GPx4 is the only GPx with the ability to regulate lipid hydroperoxides and the 
metabolism of arachidonic acid. It is crucial in the detoxification of a broad spectrum of 
hydroperoxide substrates such as complex membrane lipid hydroperoxides as well as 
thymine hydroperoxide ( Bao et al., 1997; Conrad et al., 2007; Yoo et al., 2010). Indeed, 
GPx4 has been reported to possess the highest enzymatic activity (compared to other 
hydroperoxide reducing enzymes tested) against thymine hydroperoxide as a substrate in 
vitro (Bao et al., 1997).  This finding led to a hypothesis suggesting that GPx4 may 
protect DNA integrity against DNA damage-induced lipid peroxidation such as etheno-
nucleotide adducts and repair of oxidative DNA damage caused by DNA adduct such as 
thymine hydroperoxide (Bao et al., 1997; Bartsch et al., 2002). 
To conclude, glutathione peroxidases (GPxs) are important antioxidant selenoproteins 
and their fundamental functions appear to be to reduce reactive oxygen species, reactive 
nitrogen species and to protect cells from lipid peroxidation. However, GPx4 has been 
suggested to have additional biological role. A study of mice with reduced GPx4  
(GPx4+/-) exposed to diquat showed activation of the intrinsic apoptotic pathway and 
damage to mitochondrial inner membrane (Liang et al., 2009). Transgenic mice 
overexpressing GPx4 exposed to diquat presented resistance to oxidative challenge 
through reduced mitochondrial ROS, increased mitochondrial membrane potential and 
ATP compared to wild type controls (Liang et al., 2007). These data suggest the 
importance of GPx4 for functional mitochondria and appropriate regulation of apoptosis. 
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1.4.1 Effects of GPx4 on eicosanoid biosynthesis 
GPx4 has been suggested to repress leukotriene (LT) and prostaglandin (PG) 
biosynthesis through its mediation with cyclooxygenase (COX) and lipooxygenase 
(LOX) catalyzed arachidonic acid metabolic pathways, known for their sensitivity to 
redox signaling, (Brigelius-Flohe, 1999, Imai & Nakagawa, 2003). Leukotrienes are 
fatty acid signaling molecules which are products of 5-LOX. Their formation involves 
conversion of arachidonic acid to 5-hydroperoxyeicosatetraenoic (5-HPETE) by 5-LOX 
and a further dehydration of 5-HPETE is then required to form LT (Hyde & Missailidis, 
2009) (Figure 3). The oxidized 5-HPETE, through an autonomous feedback cycle, 
activates 5-LOX (Rouzer & Samuelsson, 1986). GPx4 has been suggested to reduce 5-
HPETE to 5-HETE, which is then proposed to block the activation feedback of 5-LOX 
pathway (Imai et al., 1998; Straif et al., 2000) (Figure 5). 
 
Figure 4. Repression of 5-LOX activation and Leukotriene production by GPx. 
Leukotriene biosynthesis requires metabolism of arachidonic acid to 5-HPETE by 5-
LOX. 5-HPETE can activate 5-LOX through a positive feedback cycle. A reduction of 
5-HPETE into 5-HETE results to a break in the 5-LOX feedback cycle which inhibits 
leukotriene production and this reduction can be carried out by both GPx1 and GPx4. 
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Likewise, GPx4 has been implicated in the regulation of 12-LOX, 15-LOXS and COX 
pathways, and the repression of their oxidised intermediary products respectively 
(Sakamoto et al., 2000; Chen et al., 2003; Heirman et al., 2006). A number of 
investigations have identified these links and are listed in Table 2. 
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Table 2. Summary of observed effects of GPxs on eicosanoid biosynthesis through 
LOX/COX pathways. 
Cell 
Type 
LOX/COX 
Pathway 
Inhibitor Enhancer Key Observations References 
Rat Basophilic leukemia cell line (RBL-2H3) 
 
5-LOX  GPx4 ↑ 5-HPETE; 
12-HPETE; 
DEM(GPx4 
inhibitor) 
1. GPx4 inhibits 5-LOX activity by reducing 5-HPETE. 
 
(Imai et al., 1998) 
Polymononuclear cells  line (PMNs) 5-LOX GPx4 ↑  n.a. 1. GPx4 is up-regulated by GRO but not TNFα or IL1β. 
2. GPx4 inhibits 5-LOX 
(Hattori et al., 
2005) 
Human Quamous Carcinoma (A431) 12-LOX; 5-LOX; 
 COX; 
GPx4 n.a. 1. GPx4 inhibits of 12-LOX, 5-LOX and COX (Huang et al., 
1998) 
Human Quamous Carcinoma (A431) 5-LOX; 12-LOX;  
15-LOX; 
COX1and COX2 
GPx4 Exogenous 
oxidative stress 
1. 12- and 15-LOX and COX-2 are 10 times sensitive to GPx4 than 
5-LOX and COX-1  
2. Increase levels of GPx4 inhibits 12-LOX. 
(Huang et al., 
1999) 
Human Quamous Carcinoma (A431) COX; 12-LOX 
 
n.a. GPx4 ↓ (antisense). 1. Inhibition of GPx4 enhances the metabolic activity of 12LOX and 
COX. 
(Chen et al., 
2000) 
Monocyte 5-LOX GPx1 n.a. At low thiol concentration, GPx1 but not GPx4 is involved in 
inhibition of 5-LOX in monocytes  
(Straif et al., 
2000) 
Rat insulin-secreting cell line (RINm5f) 12-LOX GPx4 n.a. Treatment with Hepoxilin A3 stimulates GPx4  expression which in 
turn, represses 12-LOX to protect the cells. 
(Zafiriou et al., 
2007) 
Fibrosarcoma cell (L929) and melanoma cell ( 
B16BL6) 
COX-2 GPx4 ↑ n.a. GPx4 represses COX-2 and PGE2 production, which results in 
impediment of tumor growth and malignancy.  
(Heirman et al., 
2006) 
Human colon adenocarcinoma grade II 
(HT29) 
COX-2 GPx2 GPx2 siRNA GPx2 represses COX-2 and GPx2 knockdown enhances tumor 
migration and invasion. 
(Banning et al., 
2008) 
Human colon adenocarcinoma grade II 
(HT29) 
COX-2 n.a. GPx2 siRNA GPx2 knockdown results in enhanced expression of COX-2 and 
following IL1 stimulation, enhanced synthesis of PGE2. 
(Banning et al., 
2008) 
Mice and mouse neurons 12-LOX;  
15-LOX 
GPx4 
PD146176 
GPx4 -/- GPx4 represses 12/15-LOX and GPx4 -/- activates 12/15-LOX and 
AIF-mediated apoptosis 
(Seiler et al., 
2008) 
Human platelets 12-LOX 
 
n.a. Iodoacetate (GPx4 
inhibitor) 
1. GPx4 was found in platelets & megakaryocytes. 
2. GPx4 blocks the 12-LOX pathway and the generation of 
hepoxilins in platelets. 
(Sutherland et al., 
2001) 
Human Quamous Carcinoma (A431) 12-LOX; COX GPx4 ↑ n.a. 1. GPx4 reduces the metabolism of 12-LOX and COX to form 
eicosanoids. 
(Chen et al., 
2002) 
Human Quamous Carcinoma (A431) 12-LOX; COX1 n.a. GPx4 ↓ (antisense). 1. GPx4 depletion by antisense enhances  12-HETE and COX1 
activity. 
(Chen et al., 
2003) 
Submitochondrial particles from beef heart 
mitochondria and Human LDL 
15-LOX GPx4 n.a. 1. GPx4 represses 15-LOX metabolism on mitochondria membrane 
and lipoprotein. 
(Schnurr et al., 
1996) 
Rat Basophilic leukemia cell line (RBL-2H3) COX2 GPx4 ↑ Exogenous 
oxidative stress 
1. GPx4 represses COX2 to convert PGH2 to PGD2 in nucleus and 
endoplasmic reticulum.  
(Sakamoto et al., 
2000) 
Colonic adenocarcinoma cell line (HT29 
cl.19A) 
COX2 n.a. GPx4 ↑ 1. GPx4 enhances COX2 metabolism and activates COX2 mRNA 
expression. 
(Barriere et al., 
2004) 
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Prostaglandins (PG) and Leukotrienes (LT) mediate biological processes such as 
contraction of smooth muscle, vasodilation and pain sensing  using prostaglandin E2 
(PGE2) and prostaglandin 12 (PG12) (Henderson, 1994). LT also play a role in 
leukocyte adhesion using leukotriene B4 (LTB4) and has been associated with 
carcinogenic events, including cell differentiation and apoptosis (Shureiqi et al., 2005; 
Eisinger  et al., 2007;  Sordillo et al., 2008). GPX4 inhibits 5-LOX activity by reducing 
5-HPETE (Imai et al 1998). Metabolic activities of 12/LOX and COX are enhanced as a 
result of GPX4 inhibition (Chen et al., 2000) and treatment with Hepoxilin A3 
stimulates GPX4 expression, which represses 12-LOX and protects Rat insulin-secreting 
cell line from lipid damage and ROS (Zafiriou et al., 2007). 
Platelet-type 12-LOX has been identified as an inducer of inflammation in endothelial 
cells, human monocytes and prostate cancer cells (Laniado-Schwartzman et al., 1994; 
Huang et al., 2004; Kandouz et al., 2003). 12-LOX, COX-2 and 5-LOX have been 
associated with ecosanoid biosynthesis and increased oxidised lipid in guineas pigs 
(Chopra et al., 1992), human neuronal cells (Kaltschmidt et al., 2002) and human 
erythroleukemia cells (Arakawa et al., 1995). Reduced GPX4 in mice cells and mice 
neuron have been linked with activated 12/15 LOX activity (Seiler et al., 2008). 
 
 
27 
 
1.4.2 Mitochondrial regulation by selenoprotein GPx4  
Overexpression studies suggest GPx4 is important in mitochondrial function. A study of 
cardiac function following ischemia reperfusion in transgenic mice overexpressing the 
mitochondria-specific form of GPx4 (mPHGPx) showed reduced lipid peroxidation and 
increased mitochondrial electron transport chain complex I, III and IV activities 
compared to littermate controls (Babkowski et al., 2008). Overexpression of GPx4 
protected cultured lung fibroblasts from phosphatidylcholine hydroperoxide (PCOOH)-
induced loss of mitochondrial membrane potential and blocked apoptosis induced by 
different apoptosis agents (Garry et al., 2008). Transgenic mice overexpressing GPx4 
exposed to diquat showed resistance to loss of mitochondrial membrane potential and 
increased ATP production compared to wild type, suggesting the relevance of GPx4 in 
maintaining mitochondrial function and stability (Liang et al., 2007). 
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1.4.3 GPx4 Protection against cell death  
One of the major known functions of GPx4 is to protect cell membranes against 
oxidative damage particularly since GPx4 has the ability to metabolize phospholipid 
hydroperoxides in membranes. The importance of GPx4 in other aspects of regulation of 
cell function became apparent following overexpression of GPx4 in various cell lines. 
Rat basophil leukemia 2H3 ( RBL2H3) cells overexpressing cytosolic-GPx4 exhibited 
increased resistance to apoptosis induced by free radical initiators and fatty acid 
hydroperoxides (Imai et al., 1996). The guinea-pig cell line 104C1 overexpressing GPx4 
showed increased resistance to oxidative injury caused by exogenous 
phosphatidylcholine hydroperoxide (Yagi et al., 1996). Overexpression of mitochondrial 
GPx4 (mGPx4) in RBL2H3 cells protected the cells from cell death induced by 2-
deoxyglucose (2-DG), etoposide, staurosporine, UV radiation, cycloheximide, and 
actinomycin D, but not from cell-death induced by either Fas-specific antibodies or 
A23187 (a Ca
2+
 ionophore) (Nomura et al., 1999). Cells overexpressing cytosolic-GPx4 
were not protected from apoptosis following exposure to these stimuli (Nomura et al., 
1999). GPx4 overexpression in rabbit aortic smooth muscle cells cultured with sodium 
selenite blocked apoptosis induced by linoleic acid hydroperoxide (Brigelius-Flohe et 
al., 2000). Overexpression of mitochondrial GPx4 protected cells from necrotic cell 
death-induced chemical hypoxia following treatment with mitochondrial respiratory 
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inhibitors rotenone and potassium cyanide (KCN) (Arai et al., 1999). mGPx4 blocked 
hydroperoxide generation, loss of mitochondrial membrane potential and plasma 
membrane potential induced by KCN (Arai et al., 1999). Breast tumor epithelial cells 
(COH-BR1) overexpressing mGPx4 were protected from cell death induction following 
exposure to photochemically generated cholesterol hydroperoxide (Hurst et al., 2001).  
Findings from these studies suggest that overexpression of mGPx4 may prevent 
alterations in mitochondrial functions such as ATP synthesis and apoptosis through 
repressing intracellular hydroperoxides. 
RBL2H3 cells overexpressing mGPx4 are more resistant to apoptosis induced as a result 
of direct damage to mitochondria and exposure to t-butylhydroperoxide, H2O2 and 15-
hydroperoxyeicosatetraenoic acid than cells overexpressing cGPx4 (Arai et al., 1999). 
Human breast cancer cell line (MCF-7) overexpressing mGPx4 showed increased 
resistance to lipid peroxide induced-singlet oxygen and photosensitizer induced cell 
death, whereas cells overexpressing cGPx4 did not (Wang et al., 2001). Increased 
resistance to mitochondrial abnormalities in mouse NSC-34 motor neuron-like cells was 
observed following overexpression of both mGPx4 and manganese superoxide 
dismutase (Mn-SOD) (Liu et al., 2002). Since hydroperoxides in the mitochondria 
ultimately play a crucial role as apoptotic signalling molecules, this overexpression 
study of mGPx4 and Mn-SOD suggest that generation of superoxide, lipid 
hydroperoxide and hydrogen peroxide may activate the mitochondrial apoptosis 
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pathway (Figure 4), and that mitochondrial antioxidant enzymes may effectively 
modulate apoptotic signalling. The findings from these studies indicate that GPx4 may 
have a primary role in protecting cells from mitochondrial oxidative stress. Low GPX4 
expression has been associated with increased levels of 12/15 lipoxygenase-derived lipid 
hydroperoxides and increased Apoptosis inducing factor (AIF)-induced apoptosis 
(Villette et al., 2002; Seiler et al., 2008; Conrad, 2009; Conrad et al., 2010). 
 
1.4.4 The role of mitochondrial GPx4 in apoptosis 
Electrons are shuttled from cytochrome c reductase to cytochrome c oxidase by 
cytochrome c (cyt.c), a mitochondrial peripheral membrane protein functioning within 
the inner mitochondrial membrane of the mitochondrial respiratory chain. Cytochrome.c 
release from the mitochondria, into the cytoplasm, is a crucial step in the activation of 
the mitochondrial apoptotic pathway (Kroemer et al., 1998; Skulachev, 1998). 
Following the release of cyt.c from the mitochondria, pro-apoptotic proteins such as 
caspase-9, and Apaf-1 are activated and as a result may activate caspase-3 (Li et al., 
1997).  
RBL2H3 cells overexpressing mGPx4 exhibited less hydroperoxides and showed 
increased resistance to the release of cyt.c, caspase-3 activation and 2-deoxyglucose (2-
DG) induced cell death (Nomura et al., 1999). The well characterized Bcl-2 and Bcl-xl 
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are anti-apoptotic proteins and their major function is to inhibit the release of cyt.c 
(Yang et al., 1997). Mouse neuron-like cells overexpressing Mn-SOD and/or mGPx4 
exhibited increased resistance to lipid peroxide-induced apoptosis and cyt.c release (Liu 
et al., 2002), suggesting that generation of lipid hydroperoxide in the mitochondria may 
be crucial for activation of apoptotic signalling through the release of cyt.c, and that 
mGPx4 might be an important anti-apoptotic agent. The release of cyt.c from the 
mitochondria into the cytoplasm is an important process of apoptosis. Recently, mGPx4 
has been reported to block the release of cyt.c from the mitochondria into the cytoplasm 
(Schneider et al., 2009).  
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Figure 5. A hypothetical scheme illustrating the relationships of mitochondrial repiration, 
ROS, antioxidant enzymes and cyt. c release.  
The release of cyt. c from the inner mitochondrial membrane is inhibited by mGPx4, resulting 
in reduction of cardiolipin hydroperoxide. Mitochondrial superoxide (
•
O2
−
) and hydrogen 
peroxide (H2O2) generation has been reported in various apoptotic models. The figure 
illustrates possible mechanisms for this. A reaction of H2O2 with iron (Fe
2+
 ) generates highly 
reactive hydroxyl radical ((HO
•
) and the production of lipid hydroperoxide and lipid radicals 
in the mitochondrial membrane. The disassociation of cyt.c from mitochondrial inner 
membrane, the loss of Adenine nucleotide translocator (ANT) activity, the release of cyt.c, the 
loss of mitochondrial respiratory activity and mitochondrial membrane potential are affected 
by the production of cardiolipin in the mitochondria via cardiolipin hydroperoxide (CLOOH) 
cascade. mGPx4 overexpression could inhibit the release of cyt .c through the elimination of 
cardiolipin-induced peroxidation and activation of mitochondrial apoptosis. ANT = Adenine 
nucleotide translocator; CL = Cardiolipin; CLOOH = Cardiolipin hydroperoxide; Cyt. c = 
Cytochrome c; PHGPx = GPx4; cGPx = cytosolic glutathione peroxidase; Mn-SOD: Mn-
superoxide dismutase; TPx = Thioredoxin peroxidase; VDAC: = Voltage dependent anion 
channel (taken from Imai & Nagakawa, 2003). 
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1.4.5 Regulation of spermatogenesis and sperm function by GPx4  
Jones and Mann (1973), were the first to associate male infertility to increased 
susceptibility to oxidative stress in human sperm. A high concentration of 
polyunsaturated fatty acids (PUFA), including docosahexaenoic acid, is found in human 
sperm (Kim & Parthasarathy, 1998; Aitken, 1999).  Sperm are vulnerable to peroxides 
such as oxygen radicals. Generation of ROS and lipid peroxidation of sperm can result 
in sperm motility defects (Alvarez & Storey, 1982), sperm midpiece abnormalities, and 
impaired fusion of sperm and oocyte (Aitken et al., 1989) each of which can inhibit 
fertilization (Rao et al., 1989).  
During mitochondrial respiration, the process which enables ATP synthesis for sperm 
motility, ROS are generated in the sperm mitochondria (Bourgeron, 2000). 
Mitochondrial abnormalities, including those associated with mitochondrial pathologies, 
have been associated with loss of sperm motility and infertility in male (Folgero et 
al.,1993). Various antioxidant enzymes in the spermatozoon and seminal plasma provide 
protection to sperm. GPx4 has been identified in midpieces and sperm heads in 
ejaculated human sperm, and epididymal rat sperm (Godeas et al., 1996; Godeas et al., 
1997; Ursini et al., 1999; Imai et al., 2001). Nuclear GPx4 (nGPx4), has also been 
reported to be present in human sperm and functions as a hydrogen peroxide scavenger 
(Imai et al., 2001). 
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It has been shown in rat epididymal spermatozoa that GPx4 plays an important role in 
protecting sperm from oxidative damage (Weir & Robaire, 2007). Selenium has been 
found to be important for male fertility of rodents (Wallace et al., 1983a). Severe 
deficiency of Se reduced sperm count and motility (Wallace et al., 1983a, b). Sperm 
from Se-deficient rats exhibited abnormal mitochondrial morphology and abnormal 
midpiece formation, which resulted from increased oxidative damage affecting sperm, 
sperm production (Wallace et al., 1983a, b). Complete absence of mitochondrial GPx4 
affects early stages of spermatogenesis (Wallace et al., 1983a, b). Seven out of 73 
infertile men showed reduced level of GPx4 expression in their sperm following an 
immunoblotting study using anti-GPx4 antibodies whereas the expression of GPx4 in 
the sperm of 31 normal volunteers was unaffected (Imai et al., 2001). These seven 
subjects were classified as belonging to the group with oligo-asthenozoospermia which 
is characterized by reduced sperm motility and number. These results suggest that severe 
impairment of fertility may be due to reduced GPx4 expression and this is supported by 
a study which identified reduced mitochondrial membrane potential in sperm with 
reduced GPx4 expression compared with normal sperm (Imai et al., 2001). It is 
proposed that the spermatozoa are defective due to dysfunctional mitochondria and that 
reduced expression of mitochondrial GPx4 in sperm is a contributing factor to infertility 
since reduced expression of GPx4 has been identified in ejaculated sperm from infertile 
males (Imai et al., 2001). 
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1.5 Aims and Objectives 
Generation of ROS results in oxidative stress and oxidative stress has been linked to 
increased apoptosis (Tarin, 1996; Liu & Keefe, 2000; Liu et al., 2000; Fissore et al., 
2002). Cells require a precise control of cellular redox homeostasis that enables regular 
cell function (Castagne et al., 1999).  Cellular redox homeostasis has been widely shown 
to affect various cell functions including ATP synthesis (Noji & Yoshida, 2001), cell 
death, cell proliferation, differentiation and maturation (Salas-Vidal et al., 1998), and 
has also been shown to be involved in the regulation of gene expression (Ufer et al., 
2010). Modification of biological molecules and biological functions by ROS results in 
deleterious outcome and cellular dysfunction, which can induce cell death (Chen et al., 
1999; Hansen, 2006). 
The selenoprotein GPx4 has been reported to have regulatory effects on oxidative stress, 
(Section 1.3.4) eicosanoid biosynthesis (Section 1.4.1), mitochondria regulation (Section 
1.4.2) and apoptosis (Sections 1.4.3 & 1.4.4), but to date little is known about the precise 
role of GPx4 in intestinal cells and how alterations of GPx4 activity affect intestinal cell 
function. For this reason, investigations into the role of GPx4 in human gut epithelial 
cells in response to GPx4 silencing was carried out and this thesis describes studies to 
investigate GPx4 function by silencing its expression using siRNA in Caco-2 cells.  
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The aim was to use gene microarray approach to study the function of GPx4 in intestinal 
epithelial cells using siRNA to knock-down GPx4 expression. The data obtained suggest 
the major effects were on mitochondrial function and therefore the subsequent 
objectives were: 
 To study the effects of GPx4 knock-down on global gene expression in human 
intestinal epithelial cell line (Caco-2 cells). 
 To use real-time PCR to study the effect of GPx4 knock-down on expression of 
genes encoding components of the respiratory complex I and IV in Caco-2 cells. 
 To study the effect of GPx4 knock-down on functional markers of mitochondrial 
electron transport chain complexes I and IV in Caco-2 cells. 
 To study the effect of GPx4 knock-down on oxidative stress and on overall 
mitochondrial function and integrity in Caco-2 cells. 
 To study the relationship between GPx4 and  mitochondria targeting-antioxidant 
Mitoquinone 10 (MitoQ10). 
 To study the effect of GPx4 knock-down on apoptosis in Caco-2 cells.
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Chapter 2. Materials and methods 
2.1 General 
Glassware and microcentrifuges tubes were sterilized with ethanol where necessary and autoclaved at 
121°C and 2100 mBar for at least 20 minutes. All solutions and buffers were sterilized by autoclaving at 
121°C using a pressure thermostat for 20 minutes or where necessary by filtration using a 0.2 µm 
syringe filters (Whatman). Tissue culture experiments were undertaken in a sterile environment, 
employing good cell culture practice. Two hundred and fifty µl of Diethylpyrocarbonate (DEPC) was 
added to 500 ml distilled water to make up DEPC-treated water and this was mixed thoroughly and 
autoclaved at 121°C for 20 minutes. Unless otherwise stated, all DNA, RNA including (cDNA and PCR 
products) and associated buffers and solutions were diluted in DEPC-treated water, RNAase free water 
(Invitrogen), milli-Q water (MQH2O) or deionised water (ddH2O). 
 
2.1.1 Culture of mammalian cells 
Mammalian cell stocks were trypsinized and re-suspended at 3X10
6
 cells/ml in 8ml of complete 
Dulbecco’s modified Eagle medium (DMEM) plus additional 10% fetal calf serum and 10% DMSO. 
Aliquots of cell suspension were transferred into 1.8 ml cryovials and frozen in isopropanol at -80 ºC. 
Following 24 h in isopropanol, cryovials were transferred to liquid nitrogen for storage. 
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2.1.2 Growth and maintenance  
Human colon adenocarcinoma cell line (Caco-2 cells) were cultured routinely in DMEM medium 
(DMEM+GlutaMAX-1 containing pyruvate 4.5g/L D-Glucose (Gibco®) containing 1% (v/v) penicillin-
streptomycin (P/S), 10% (v/v) fetal calf serum (FCS) in either 75 cm
3
 tissue culture flasks, 6 well plates 
or  96 well plates  at 37 °C in an atmosphere of 5% CO2. 
Caco-2 cells were sub-cultured from a 75 cm
3
 flask once they had reached 80% confluence by 
discarding the medium, washing the confluent monolayer with 25 ml of sterile PBS (pH 7.4) and 
addition of 2ml trypsin (10 X Solution Trypsin-EDTA; Sigma). Cells were incubated at 37°C for 5 
minutes, collected from the culture dish into a clean 25 ml universal tube, centrifuged at 1,500 x g for 5 
minutes and the supernatant was discarded. Cells were re-suspended in 10 ml of medium, 1 ml of cell 
suspension was transferred into a new 75 cm
3
 flask, 15 ml of medium was added and cells grown at 37 
°C. The composition of the cell culture medium is shown in Appendix C 
 
2.2 Transient transfection of human intestinal epithelial cells (Caco-2) with small 
interfering RNA (siRNA). 
Small interfering RNA (siRNA) can be delivered into eukaryotic cells through transient transfection 
using a cationic lipid transfection agent. siRNA transfection experiments described in this study used 
Lipofectamine 2000™ (Invitrogen).  siRNA is a small dimeric double-stranded RNA, generally 
consisting of a 21 nucleotide strand with a minimum of a 19 nucleotide complementary sequence and a 
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two nucleotide AA overhang. Experimental design of siRNA requires a 21 nucleotide sequence 
homologous to a target mRNA transcript. Following siRNA delivery into cells, the double stranded 
siRNA disassociates into two strands to bind to the target mRNA. The binding of the siRNA strand to 
the target mRNA recruits an enzymatic complex known as RNA-induced silencing complex (RISC) and 
mRNA degradation by the RISC complex (a process known as RNA interference). Therefore, target 
transcript of cells can be transiently degraded through the use of siRNA and can also be used to reduce 
gene expression for a period between 2-5 days. 
Generally, gene expression is more efficiently reduced by siRNA after 2-3 days; mRNA level is 
generally reduced after 2 days and protein level after 3 days. In the present experiments, siRNAs were 
designed to reduce human GPX4 gene expression both at mRNA and protein levels. Two commercially 
synthesized GPX4-specific siRNA were obtained (20nmol siRNA annealed with standard purity, 
AM16104 Ambion). Additionally, a negative control siRNA was designed by scrambling the sequence. 
Details of the siRNA, negative control siRNA and mRNA target sequences are given in Chapter 3 
Section 3.2.1 and Section 3.2.2.   
Human colonic epithelial cells were transiently transfected with siRNA by seeding 5X10
5
 cells in  a 6-
well plate 24 h before transfection. Each well of the 6-well plate contained 2 ml cell growth medium 
containing  DMEM + GlutaMAX-1 (4.5g/L D-Glucose and pyruvate, Gibco®, 10% (v/v) foetal calf 
serum (FCS) and 1% (v/v) penicillin-streptomycin (P/S). Cells were grown to 30-50% confluence. Prior 
to transfection with siRNA, the cell growth medium in each well was changed with new 2 ml of 
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modified growth medium containing DMEM + GlutaMAX-1 (Gibco®) supplemented with 5% (v/v) 
FCS and no P/S, as recommended in the manuals provided by the manufacturer (Ambion). 
 Additionally, 5 ul of Lipofectamine 2000™ was added to 250 µl Optimem in a universal tube, gently 
mixed and incubated at room temperature for 5 minutes. At the same time, 20 nmoles siRNA or 
scrambled control siRNA was diluted in 200 µl RNAse free H2O to make a 100 µM stock. The 100 µM 
stock was further diluted 1:10 (i.e. 20 µl  of the 100 µM stock into 80 µl of RNAse free H2O) to make 
20 µM working stock. 2.5 and 5 µl of the 20 µM siRNA and scrambled control siRNA was added to 250 
µl Optimem, mixed gently by shaking and allowed to incubate at room temperature for 5 minutes. The 
Lipofectamine mix and the siRNA mix were added together, mixed gently by shaking and left at room 
temperature to incubate for 20 minutes. 500 µl of the transfection mix was added into 6 well containing 
2 ml reduced-serum medium in a drop-wise manner. The 2.5 ml medium containing either siRNA or 
negative control siRNA and Lipofectamin resulted to 20 nM or 40 nM siRNA concentrations. These 
concentrations are within the range of working concentration recommended by Ambion (10-100 nM). 
Following treatment with GPX4 siRNA, cells were grown for 24 h and the medium was discarded and 
replaced with 2 ml serum-reduced medium (5% FCS) for additional 24 and 48 h before harvest. 
Volumes and amount of reagents required for transfections are listed in Table 3. 
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 96 well 6 well 
Surface area (cm
2
) 0.3 10 
Cells 1.5x10
4
 5x10
5
 
Lipofectamine
TM
 2000 (µl) 0.2 5  
Opti-MEM® I Reduced Serum Medium (µl) 7.5 x 2 250 x 2 
siRNA (nM) 20 & 40 20 & 40  
siRNA (µl) 0.1 & 1.5  2.5 & 5  
Plating volume 60 µl 2 ml 
Total volume 75 µl 2.5 ml 
 
Table 3.  siRNA transfection. 
Volumes and amounts of reagents required for transfection in different formats. 
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2.3 RNA lysate preparation using TRIzol® reagent  
Total RNA was extracted from Caco-2 cells using a modification of the method of Chomczynski and 
Sacchi, (1987). Cells were washed twice with 1X PBS and further incubated with 0.5 ml (in each well of 
a 6-well plate) or 1ml (in a 75 cm
3
 flask) of TRIzol® (Invitrogen) for 5 minutes at room temperature. 
Using a cell scraper, cells were detached from the 6-well plate or flask. Each cell sample containing 
TRIzol was transferred into a sterile 1.5 ml microcentrifuge tube and 200 µl of chloroform (Sigma) was 
added. The mixture was vigorously mixed for 15 seconds and further incubated for 3 minutes at room 
temperature. TRIzol comprises of phenol and guanidinium isothiocyanate, guanidinium isothiocyanate 
is used for cell lysing and nucleoprotein complex disassociation whereas phenol and chloroform 
dissolves genomic DNA and RNA and allows the separation of these components. 
Total RNA was retained in the upper clear aqueous phase following centrifugation of samples at 12,000 
x g for 15 minutes at 4ºC. A mixture of un-dissolved DNA and protein and cell debris was retained in 
the white-colour intermediate phase whereas the majority of DNA and protein remained in the pink 
lower organic phase. The upper aqueous phase was carefully transferred into another sterile 1.5 ml 
microcentrifuge tube. 
Five hundred µl of isopropanol (Sigma) was added into the upper aqueous phase solution (~ 200-400 µl) 
to precipitate the RNA and the tube was inverted 10 times to mix the mixture and incubated for 10 
minutes at room temperature. Total RNA was pelleted at the bottom of the tube by centrifugation at 
12,000 x g for 15 minutes at 4ºC. The supernatant was discarded and the RNA pellet was washed once 
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with 1ml 75% ethanol and tube vortexed for 10 seconds. The sample was centrifuged again at 7,500 x g 
for 5 minutes at 4ºC, and the pelleted total RNA was briefly air dried and dissolved in 50 µl of DEPC-
treated water. 
 
2.3.1 Preparation of RNA for microarray and qRT-PCR analysis  
Seventy two hours following transfection with siRNA, cells were harvested and RNA prepared as 
described in Section 2.1. Further purification of RNA was performed using PureLink™ RNA Mini Kit 
(Invitrogen) according to the manufacturer’s instructions.  
2.3.2 Determination of RNA concentration and integrity 
A Nanodrop 1000 spectrophotometer (Thermo Scientific, UK) was used to analyse RNA concentrations. 
RNA with an A260/A280 nm > 2.0 and an A260/A230 nm ≥ 1.8 was considered suitable for further 
analysis. An Agilent 2100 bioanalyser (Agilent Technologies) was used to analyse RNA integrity. 
Samples with a RIN (RNA Integrity Number) above the threshold of seven were judged suitable for 
microarray or qRT-PCR analysis. 
 2.3.3 Reverse transcription of RNA  
Single-stranded RNA can be reverse transcribed into double-stranded DNA (cDNA) by using reverse 
transcriptase (also known as RNA-dependent DNA polymerase). In this study, RNA was reverse 
transcribed using Transcriptor Reverse Transcriptase® kit (Roche) according to manufacturer’s 
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instructions. One microgram of total RNA was used as template and added to 2μl of ddNTP mix 
(Bioline) at a concentration of 10mM, and 0.5μl of RNAse inhibitor (40U/µl) (Roche), 4μl of 5X 
Transcription buffer (provided in kit), 1μl of Oligo(dt)15 primer (100µM) (Roche) and  DEPC-treated 
water to a final  volume of 19.5µl added.  Finally, 0.5μl of Transcriptor Reverse Transcriptase® 
(20U/µl) was added to a total volume of 20 μl and the mixture was mixed gently by pipetting. A 
programme for reverse transcription was set up on a Thermohybaid PX2™ PCR machine allowing 
incubation of samples for 30 minutes at 55°C and then allowed to cool at 4°C. The resulting cDNA was 
stored at -20°C before use. 
2.3.4 Polymerase chain reaction (PCR) and semi-quantitative RT-PCR  
The polymerase chain reaction (PCR), using a thermostable DNA polymerase enzyme allows the 
amplification of DNA. A combination of reverse transcription and RT-PCR is used frequently for gene 
expression studies and the process of involves the amplification of the cDNA product.  
The first step of PCR (Denaturation stage) requires the dissociation of double-stranded DNA into single 
stranded DNA by denaturing the DNA through heating at 94ºC for 5 minutes. Subsequent DNA 
amplification utilizes a pair of short oligonucleotides (single-stranded DNA also known as forward and 
reverse PCR primers) designed to complement the DNA template. 
Initial denaturation involves a brief heating of the template DNA and primer DNA at 94ºC for 30 
seconds, after which the temperature is lowered to 50-70ºC for 30 seconds. The denatured single-
stranded primer DNA anneals to the DNA template at an annealing temperature which varies according 
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to the GC content of the oligonucleotide primers. The next stage of the  PCR process is the elongation 
stage, which involves heating of the template DNA and primer at 72ºC for 1 minute and a new DNA 
strand is synthesized by the DNA polymerase from the 3’end of the oligonucleotide primer in the 
presence of dNTP (10 mM each dATP, dTTP, dCTP and dGTP). Altogether, a single cycle of PCR 
amplification comprises all of the above three steps series denaturation, annealing and elongation. A 
continuation of one cycle after another allows increased copy numbers and around 20-40 cycle numbers 
are generally used in PCR amplification. Following PCR amplification, the last stage is to heat the PCR 
sample for 12 minutes at 72ºC. In this study, the programme used for PCR in a Thermohybaid PX2™ 
was as follows:                            
95˚C 5 minutes initial denaturation 
95˚C 30 seconds denaturation 
29-35 cycles   *55 - 66˚C 30 seconds -1 minute annealing  
72˚C 1 minutes elongation 
72˚C 12 minutes 
4˚C hold 
 
* At temperature given in Table 4 for specific primer pairs 
PCR primers (MWG Biotech) were designed to be 19-24 bases in length, to optimally have 50 % GC 
content and to preferably terminate at both ends in a G or a C. All primers used are listed in Table 4. 
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Each PCR reaction contained 0.5 µl of cDNA sample (RT product used as a template DNA), 2.5 µl of 
10X PCR buffer (Bioline), 2.5 μl of 10 mM dNTP mix (Bioline), 1.2 μl of 50 mM MgCl2, and 2.5 μl of 
forward and reverse primers (each in solution at concentration of 20 pmol/ μl) and to 0.5 μl of Taq 
polymerase (Bioline). The final volume of each samples was adjusted to 20 μl with the addition of 
DEPC-water.  
One of the principles of semi-quantitative RT-PCR is that amplification of the PCR is required to be at 
the linear stage before saturation, which ensures effective amplification of the PCR in all samples and 
ensures reliability of the semi-quantification. For each set of primers used, the cycle number was 
optimized experimentally. For instance to compare the expression of GPX4 in Caco-2  cells treated with 
negative control siRNA and cells treated with GPX4-siRNA, amplification of GPX4 expression by PCR 
was performed at 25, 27, 29 and 31 cycles and results showed that PCR cycle 29 or 30 was appropriate 
for both samples at the linear stage.  
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Primers Sequences Tm ˚C b 
GPX4 FWD 5’-CGA TAC GCT GAG TGT GGT TTG C-3’ 66 22 
GPX4 REV 5’-CAT TTC CCA GGA TGC CCT TG-3’ 20 
GPX4 m-FWD 5’-CAT TGG TCG GCT GGA CGA G-3’ 65  19 
GAPDH FWD 5’-TGA AGG TCG GAG TCA ACG GAT TTG-3’ 55  
 
24 
GAPDH REV 5’-CAT GTA AAC CAT GTA GTT GAG GTC-3’ 24 
AIF FWD 5’-ACA TAG TGG CAG CTG TGG GC-3’ 60 
 
20 
AIF REV 5’-CAT GGT GCT CTA CCC GCC TC-3’ 20 
COX17 FWD 5’-AGT GAC TGC GGA CGA ATC GG-3’ 60  
 
20 
COX17 REV 5’-TTC TTG GTC TCC GGG CAA GC-3’ 20 
NDUFA10 FWD 5’-CAG TTC AGA GAG CTG CCG GG-3’ 62  
 
20 
NDUFA10 REV 5’-CCA GGA GAG TGC GGC TGA TG-3’ 20 
NDUFB6 FWD 5’-GTC CGT AGT TCG AGG GTG CG-3’ 60  
 
20 
NDUFB6 REV 5’-TCA GCC ATC GCC TTC TCA GC-3’ 20 
BAX FWD 5’-TGG ACT TCC TCC GGG AGC GG-3’ 60  
 
20 
BAX REV 5’-TGG TGA GTG AGG CGG TGA GCA-3’ 21 
βeta-Actin FWD 5’-TGT TAC AGG AAG TCC CTT GCC ATC-3’ 60  24 
βeta-Actin REV 5’-CTC CCC TGT GTG GAC TTG GG-3’ 20 
 
Table 4. List of primers for generating products from cDNA by semi-quantitative RT-PCR or by real-
time PCR. Tm (˚C )=Primer annealing temperature, b= number of primer bases. 
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2.3.5 Agarose gel electrophoresis  
Negatively charged DNA molecules migrate towards the positive electrode in agarose gel 
electrophoresis. Large sized DNA molecules electrophoresce move slowly through the agarose gel 
compared to small DNA molecules resulting in less migration during electrophoresis. The use of 
agarose gel electrophoresis allows the separation of DNA molecules on the basis of size and this 
approach is used frequently for separation of DNA fragments harvested from PCR. Known sized DNA 
molecules (DNA markers) are generally co-electrophoresized alongside the DNA fragment and 
comparison between the two allows the estimation of the size of the DNA products. 
In the present experiments, PCR products were analysed on 1% agarose gels. The gel was prepared by 
boiling 0.5 g Agarose (Sigma) in 50 ml of 1X TAE buffer (Promega) diluted from a stock of 10X TAE 
buffer (Tris base 242 g, Glacial acetate acid 57.1 ml, EDTA 100 ml of 0.5 M pH 8, 1 L MQH2O pH 8.3) 
plus 2 μl of 10 mg/ml ethidium bromide (EB Promega) added to enable DNA visualization. The mixture 
was poured into a gel casting tray containing a comb to generate spaces for loading DNA samples and 
left at room temperature until solid. Two microlitres of 5X loading dye (50 mM Tris-HCl pH 8, 5 mM 
EDTA, 20 % glycerol and 0.1 % Bromophenol Blue) (Bioline) was mixed with 8 μl of the PCR product 
and samples were loaded onto the gel. 
The samples were electrophoresized for 40 minutes at 70 V and DNA bands were visualized using a gel 
documentation system (Uvitec (model BTS-26M), UK) under UV light. For semi-quantitative RT-PCR, 
the intensity of the band was measured using the Uvitec software. 
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2.3.6 qRT-PCR (Real-time PCR) 
2.3.7 DNase treatment of RNA used for qRT-PCR 
Prior to qRT-PCR, RNA was treated with DNAase to remove any contaminating DNA. Four and a half 
(4.5) μg of RNA was added to a mixture of 2 μl 10X DNase buffer (Roche), 4.5 U DNase (Roche) with 
RNase free water to a final volume of 20 μl (Invitrogen). The reaction was incubated for 30 minutes at 
37 °C after which 4 μl of stop solution (EDTA, 20 mM, pH 8.0) was added. Further incubation for 10 
minutes at 65 °C was carried out and the RNA was placed on ice or stored at -80°C for future use. 
 
 2.3.8 Reverse transcription of RNA used for qRT-PCR 
RNA used for qRT-PCR was reverse transcribed at described in section 2.3.3 
2.3.9 qPCR using the Roche LightCycler® 480  
Real time PCR was performed on the Roche LightCycler® 480 (Roche). PCR reactions were set up in 
LightCycler®  480 96 Multiwell plates (Roche) using SYBR Green I Master (Roche). One microlitre of  
cDNA was used in a standard reaction PCR using primers for the target and housekeeping genes. PCR 
products were purified using PCR purification kit (Qiagen). One in 10 serial dilutions of the PCR 
products were prepared in triplicate in order to construct a standard curve. One in 10 serial dilutions of 
the cDNA was also prepared for each target gene and housekeeping gene sets. Each PCR reaction 
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contained 3 µl of water, 1 μl forward and reverse primers (MWG) (Table 4), 10 μl LightCycler® 480 
SYBR Green I Master (Roche) and 5 µl of the serial dilution or the target samples were added to a final 
volume of 20 μl. The plates were sealed with Roche LightCycler® 480 plate sealing foil (Roche) and 
centrifuged at 1500 x g for 2 minutes at 4˚C. Samples were analysed using the following cycling 
parameters: 
 95˚C 5 minutes initial denaturation  
  95˚C 10 seconds denaturation  
      45 cycles   *55-66˚C 10 seconds annealing  
  72˚C 15 seconds elongation 
* At temperature given in Table 4 for specific primer pairs.  
Fluorescence for each PCR cycle was detected and the threshold crossing points (CT values) 
determined. At the end of all reactions, a melting curve peak analysis was carried out to ensure single 
product amplification. Each PCR sample was measured in duplicate and typical amplification curves for 
each analysed gene are shown in Appendix B. 
To calculate the expression of all target and reference genes for each samples the gene specific standard 
curve generated during each run was used. Using the cDNA samples, each target cDNA concentration 
was normalised to the average value of the reference gene. Relative mRNA levels of GPX4, AIF, BAX, 
NDUFA10, NDUFB6, COX17, βeta-Actin and GAPDH of the negative control siRNA and siRNA 
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samples were determined using the △ cycle threshold (△Ct) method as outlined in Livak’s protocol. 
(Livak &. Schmittgen 2001). In brief, a △Ct value was the Ct difference between the target gene and 
the reference genes (△Ct = CTtarget−CTreference). GAPDH and βeta-Actin were used as the reference 
genes. Data were calculated as a %  mean of value for cells treated with negative control siRNA. 
 
 2.3.10 Global mRNA expression analysis  
RNA was extracted from Caco-2 cells as described in Section 2.3 and 2.3.1, and quality and integrity 
was checked as described in Sections 2.3.2. RNA of sufficient integrity was sent for analysis. After 
being re-checked by Service XS, RNA were labelled, hybridized and scanned as described in Chapter 3 
Section 3.4.1. 
 
2.4 Whole cell lysate preparation, protein analysis and Western blotting 
2.4.1 Cell lysate preparation 
Cells were harvested 72 h (except where stated otherwise) following transfection. Cells in each well  of 
a 6-well plate were washed with 1 ml of ice cold PBS, and collected into 1 ml  cold  PBS containing 1 
protease inhibitor  (Roche). Cells were collected using a cell scraper (Greiner), transferred into a 1.5 ml 
microcentrifuge  tube and  centrifuged at 13,000 x g for 15 minutes at 4 ºC. The supernatant was 
discarded and the pellet was resuspended in 200 µl  PBS containing 0.1% (v/v) Triton.  The cell 
suspension was sonicated twice for 10 seconds with a 30-50% pulse using a sonicator (4710 Series Cole 
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Palmer) to cause cell disruption. Cells were further centrifuged at 3,500 x g for 10 minutes at 4 ºC. The 
resulting supernatant was collected, snap-frozen in liquid nitrogen and further stored at -80 ºC until 
analysis.  
2.4.2 Preparation of mitochondrial and cytosolic fractions 
Cells were washed in ice-cold PBS and re-suspended in 2 ml of homogenisation buffer containing 0.6 M 
mannitol, 10 mM Tris-HCL pH7.4, 1 mM EGTA, 1 mM  phenylmethylsulfonyl fluoride (PMSF) and 
0.1% BSA. The cell suspension was subjected to 15 homogenisation passes with a glass-teflon 
homogeniser, followed by centrifugation at 400 x g for 10 minutes at 4°C. The supernatant fluid 
containing the cytosolic fraction was kept on ice, whilst the remaining pellet was re-suspended in 2 ml 
of homogenisation buffer and the homogenisation and centrifugation steps were repeated. The combined 
supernatant fluids were centrifuged at 12,000 x g for 10 minutes at 4°C and stored at -80°C (cytosolic 
fraction). The resulting mitochondrial pellets were re-suspended in homogenisation buffer, combined 
into one tube and centrifuged again at 12,000 x g for 10 minutes at 4°C. The resulting final pellet 
(mitochondrial fraction) was re-suspended in a small volume of homogenisation buffer (without BSA), 
snap-frozen in liquid nitrogen and further stored at -80 ºC for further analysis. 
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2.4.3 Determination of protein concentration  
Protein concentration was determined using the Bradford assay. Standards of 0, 20, 40, 60, 80 and 100 
μg/ml were made in triplicate using a 100 μg/ml bovine serum albumin standard solution and 50 μl of 
each were pipetted into a 96 well plate (SLS Ltd, UK). Cell lysates were diluted 1 in 50 for analysis and 
50 μl was used in the assay. Biorad dye reagent (Biorad, UK) was diluted 1 in 5 from the stock with 
MQH2O and 200 μl was added to the 96 well plate containing the samples and standards, and 
absorbance was the measured at 595 nm on a multiwall plate reader (ThermoLab Systems Multiscan 
Ascent). 
 
2.4.4 Sodium dodecyl sulphate-polyacrylamide gel electrophoresis 
Sodium dodecyl sulphate-polyacrylamide gel electrophoresis (SDS-PAGE) is an electrophoretic 
approach, which allows separation of protein molecules according to their molecular weight. Binding of 
SDS to the polypeptide sequences results to a disruption of the non-covalent bonds and opening of their 
folding confirmation resulting in distribution of negative charges on the SDS-polypeptide proportional 
to the polypeptide length.  
Work described in this study separated protein molecules using 12.5% SDS-polyacrylamide gels prior to 
Western blotting. The 12.5% SDS-polyacrylamide gel (resolving gel) was prepared by mixing together 
3.75 ml of  1 M Tris-HCl buffer (pH=8.8) (Promega), 2.925 ml of ddH2O, 100 µl of 10% SDS solution 
(obtained from 20% SDS stock solution, Sigma), 3.125 ml of 30% Acrylamide/Bis-acrylamide solution 
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(ratio 29:1) (Sigma), 10µl of N, N, N', N'-tetramethylethylenediamine (Sigma) in 10 ml total volume 
and 100 µl of 10% Ammonium persulphate  (Sigma). The same procedure was used to prepare the 
stacking gel except 3.75 ml of  1 M Tris-HCl buffer (pH=6.8) was used. The 1 X SDS-PAGE running 
buffer was diluted from 5 X stock. To prepare the 5 X running buffer,  144.1 g Glycine, 65 g SDS  and 
0.6 g Tris-HCl (Promega) were dissolved in 800 ml of water, adjusted to pH 8.8 and water added to a 
final volume of 1000 ml. To prepare a 5 x protein loading buffer, 5 ml of Glycerol (Sigma), 2.5 ml of 1 
M DTT, 2.25 ml of 1 M Tris-HCl solution (pH=6.8) and 0.5 g SDS (Promega) was mixed and dissolved. 
Ten milliliter of each stock solution was aliquoted and stored at -20ºC before use. Twenty micrograms 
of protein cell lysate was mixed with the 5 X loading buffer in a ratio of 1:1 (v/v) for each sample.  To 
denature the protein molecules, the mixture of protein samples and protein loading buffer was heated at 
90ºC for 5 minutes. Following incubation, protein samples were loaded into wells in the stacking gel 
and electrophoresis was performed at 80-120 V for 1 h and 30 minutes. 
 
2.4.5 Western Blotting and detection of protein  
Following separation by SDS-PAGE proteins were transferred to a PVDF membrane (Roche) and the 
protein of interest detected with specific antibodies. The gel was placed next to a sheet of PVDF 
membrane with two pieces of filter paper (Whatman) above and below, placed on the bottom of transfer 
apparatus (Atto, GRI, UK) and wetted lightly with transfer buffer. To prepare the transfer buffer, 1 X 
SDS-PAGE running buffer was mixed with methanol (Fisher Scientific) in a ratio of 4:1 (v/v) and the 
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stack was gently rolled with a roller to squeeze out air bubbles between gel and PVDF membrane. To 
avoid the membrane becoming over-dry, a small amount of the transfer buffer was pipetted on top of the 
stack and transfer was carried out for 1 h at 15 volts.  
The PVDF membrane was placed into 10 ml of 5% (w/v) non-fat milk powder solution in 5 x TPBS 
buffer and incubated either for 1 h at room temperature or overnight at 4ºC. To prepare the TPBS, 
0.05% (v/v) Tween-20 (Sigma) was added into 1X PBS and was thoroughly mixed. This blocking step 
was designed to prevent non-specific binding of antibodies to the PVDF membrane. The PVDF 
membrane was incubated with the primary antibody for 1 h diluted in 3% (w/v) milk-TPBS. The 
membrane was washed three times using 10 ml of TPBS, each time for 10 minutes. Incubation of the 
PVDF membrane with a secondary antibody was carried out for 1 h with horseradish peroxidase (HRP)-
labeled anti-rabbit IgG diluted in 3% (w/v) milk-TPBS. Ten milliliter of PBS was used to wash the 
membrane three times, each time for 10 minutes. A list of primary and secondary antibodies used in 
work described in this thesis, and the dilutions used is given in Table 5. 
Hyperfilm ECL™ reagent (GE Healthcare) was used to detect the bound secondary antibody. Two 
milliliters of Solution A and Solution B of the ECL solution in a ratio of 40:1 were gently mixed and 
added to the PVDF membrane, covered with plastic film and incubated for 5 minutes in darkness. ECL 
allows emission of fluorescence following catalysis by HRP and the fluorescence signal can be captured 
on Kodak Biomax XAR film in a Hypercassette™ (Amersham Bioscience) film using Kodak GBX 
developer (Sigma). The intensity of the fluorescent signal reflects the abundance of protein blotted on to 
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the membrane.  Band intensities of proteins were assessed using densitometry software (UVItec 
(UVIBand software), UK) on a gel documentation system (UVItec (model BTS-26M), UK). 
 
2.4.6 Staining of protein  
To assess transfer efficiency of proteins onto a membrane, PVDF membranes were stained with a 
Ponceau S staining kit (Sigma) according to the manufacturer’s instructions. The membrane was 
incubated (with shaking) in 100 ml Ponceau S stain for 1 h. After 1h incubation, the membrane was 
washed twice and further incubated in 200 ml of deionised water until the background of the PVDF 
membrane became clear. 
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1º ANTIBODY SOURCE DILUTION CAT-NO 
Rabbit Anti-Human GPX4 ABCAM 1 in 500 AB41787 
Rabbit Anti-Human AIF SIGMA 1 in 1000 A7549 
Rabbit Anti-Human BAX SIGMA 1 in 1000 B3428 
Rabbit Anti-Human Bcl-2 SIGMA 1 in 1000 PRS3337 
Rabbit Anti-Human CASPASE-3 CELL 
SIGNALLING 
1 in 1000 #9662 
Rabbit Anti-Human CASPASE-9 PTGLAB 1 in 1000 10380-1-
AP 
2º ANTIBODY 
Anti-Rabbit IgG-peroxidase produced in goat, affinity isolated antibody adsorbed with human 
IgG 
SIGMA 1 in 5000 A0545 
Mouse- Anti-Human COX2 MitoScience 1 in 1000 AB110258 
Mouse- Anti-Human NDUFB8 MitoScience 1 in 1000 AB110242 
Mouse- Anti-Human SDH ABCAM 1 in 1000 AB14714 
Mouse- Anti-Human β-Actin SIGMA 1 in 2000 A1978 
2º ANTIBODY 
Anti-Mouse IgG-peroxidase produced in rabbit, IgG fraction of antiserum 
SIGMA 1 in 10000 A9044 
 
Table 5. List of primary and secondary antibodies used for Western blotting. 
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2.5 Cell viability assay  
CellTiter-Blue® provides an absorbance and fluorometric approach to estimate the number of viable 
cells in a multiwell plate assay. It  uses resazurin indicator dye to assess the metabolic capacity of viable 
cells. The ability to reduce resazurin into resorufin is retained in viable cells and the resulting resorufin 
is highly fluorescent (Figure 6). Non-viable cells lack the ability to reduce resazurin into resorufin. 
Resazurin has little intrinsic fluorescence and remains dark blue until it is reduced to resorufin which, is 
pink in colour and highly fluorescence (579Ex/584Em). Either fluorescence or absorbance can be used 
to measure cell viability results. The maximum absorbance for resazurin is 605 nm whereas that of 
resorufin is 573 nm. 
 
 
Figure 6. Conversion of resazurin to resorufin by metabolically active cells results in the generation of a 
fluorescent product or a change in absorbance wavelength 
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For work described in this thesis, 96 well plates were seeded with 1 × 10
4
 cells/well, and after 24 h, half 
the cells were treated with GPx4 siRNA and half with the scrambled control siRNA. 72 h following 
transfection, medium was removed and 180 μl fresh medium added to the cells. Cell viability was 
assessed by the addition of 20 μl of CellTiter-Blue® reagent (Promega) and after 4 h absorbance was 
measured at 573 nm using (Thermo Labsystem Multiscan Ascent). 
 . 
2.6 Thiobarbituric acid reactive assay substance (TBARS) assay for lipid 
peroxidation. 
Measurement of lipid peroxidation is widely used as a marker of oxidative stress in cell and tissues. Due 
to their unstable nature, lipid peroxides, decompose to form a series of complex compounds which 
include reactive carbonyl compounds, such as malondialdehyde (MDA). Measurement of MDA is 
widely recognised as an indicator of lipid peroxidation and thiobarbituric acid reactive substance 
measurement (TBARS) is a well established approach to measure MDA and lipid peroxidation. The 
MDA-TBA adduct is formed by the reaction of MDA and TBA (Figure 6) under high temperature (40-
100°C) and acidic conditions. The MDA-TBA can be measured colorimetrically at 530-540 nm or 
fluorometrically at an excitation wavelength of 530 nm and emission wavelength of 550 nm.  
 
60 
 
 
Figure 7. Formation of a MDA-TBA adduct.  
A typical MDA-TBA adduct formed by the reaction of MDA and TBA under high temperature ( ~ 90-
100°C). 
 
To prepare the colour reagent used for both the sample and standards, 530 mg of TBA (Sigma) was 
added to 50 ml of TBA acetic acid solution (TBA acetic acid Sigma) diluted 1 in 50. 50 ml of TBA 
sodium hydroxide (Sigma) diluted 1 in 50 was added to the mixture and mixed until the TBA is 
completely dissolved. 
For colorimetric standard preparation, 250 µl of the MDA standard (Sigma, UK) was diluted with 750 
µl of water to obtain a stock solution of 125 µM and target concentrations of standards were 0-50 µM. 
Caco-2 cells were grown to confluency in 6 well plates, washed with PBS, trypsinised and transferred 
into 1.5 ml microcentrifuge tubes and centrifuged at 12,000 x g for 10 minutes. Cells were transferred 
into fresh 1.5 ml microcentrifuge tubes containing PBS and sonicated 3X for 5 seconds intervals at 40V 
setting over ice. Two hundred µl ice cold 10% trichloroacetic acid was added to 100 µl cell lysate, 
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incubated on ice for 15 minutes and centrifuged at 2,200 x g for 15 minutes at 4°C. 200 µl supernatant 
were transferred to a clean 1.5 ml microcentrifuge tubes each containing 100 µl of TBA sodium 
hydroxide (adjusted to pH 8.3)  and mixed. Tubes were placed in vigorously boiling water for 1 h, and 
then placed in ice for 10 minutes to stop the reaction. The microcentrifuge tubes containing the mixture 
were centrifuged at 1,600 x g for 10 minutes at 4°C and left to stabilize at room temperature for 30 
minutes. 150 µl of the mixture from the tubes were loaded in duplicate into 96-well plate and 
absorbance measured colorimetrically at 532 nm using a colorimetric plate reader (Thermo Labsystem 
Multiscan Ascent). 
The average absorbance of each standard and samples were calculated, and the absorbance value of 
standard A (0 µM) was subtracted from all other values (both standards and samples) and this was 
considered a corrected absorbance. The corrected absorbance values of each standard were plotted as a 
function of MDA concentration and the values of MDA for each sample calculated from the standard 
curve. 
 
2.7 Measurement of ROS levels using carboxy-H2DCFDA 
Detection of reactive oxygen species (ROS) can be carried out through the use of the cell membrane-
permeable fluorescent dye 5-(and-6)-carboxy-2´,7´-dichlorodihydrofluorescein diacetate (carboxy-
H2DCFDA). Following cleavage of the compound by ROS, a luminometer or fluorescence microscope 
can be used to capture the fluorescence emission of the product. Comparison of ROS levels in  test and 
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control groups can be performed in a semi-quantitative manner and data expressed as a percentage 
relative to the level of control. 
ROS levels were assessed by staining cells with Image-iT™ LIVE Green Reactive Oxygen Species 
(ROS) Detection Kit (Invitrogen) according to manufacturer’s instructions and the carboxy-H2DCFDA 
fluorescence signal was read using a luminometer (POLARstar Omega). The ROS Detection Kit 
(Invitrogen) comprises Component A (carboxy-H2DCFDA as powder, 275 µg/vial), Component B 
(Hoechst 33342, 400 µl of a 1 mM solution), Component C (tert-butyl hydroperoxide solution) and 
Component D (500 µl DMSO). A stock of 10 mM solution of carboxy-H2DCFDA was prepared by 
adding 50 µl of DMSO into one vial of carboxy-H2DCFDA and mixed to dissolve. To prepare a 
working 25 µM solution of H2DCFDA 5 µl of 10 mM stock solution was added to 2 ml of pre-warmed 
1X HBSS/Ca/Mg solution and gently mixed. Additionally, a nucleic acid targeting dye Hoechst 33342 
was used as a control dye. Two microlitres of 1 mM Hoechst 33342 solution was mixed with 2 ml of 25 
µM carboxy-H2DCFDA working solution to make a final concentration of 1 µM Hoechst 33342.  
Cells were grown to confluency in 96-well plates. 50 µl of carboxy-H2DCFDA-Hoechst 33342 was 
added to each well and incubated for 30 minutes at 37ºC.  Due to the light sensitivity of the assay, the 
96-well plate was wrapped with foil. Following incubation, cells were washed three times with 100 µl of 
warm 1 X HBSS/Ca/Mg solution per well and 50 µl of 1X HBSS/Ca/Mg solution was added into each 
well. Fluorescent signal for carboxy-H2DCFDA was read at 495/529 nm (emission/excitation) 
wavelength whereas that of Hoechst 33342 was read at 350/460 nm using a POLARstar Omega 
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fluorometer. Twenty repeat measurements were taken for each signal in each well and calculation of the 
signal value was taken from the average of the 20 readings. The difference in ROS level of cells treated 
with GPX4-siRNA was compared using the carboxy-H2DCFDA signal value of cells treated with 
negative control siRNA expressed as a percentage of the average value. Readings from the Hoechst 
33342 analyses used as a control for cell number and staining efficiency. 
 
2.7.1 Measurement of superoxide production using MitoSOX™ 
Superoxide indicator MitoSOX™ Red is a fluorogenic dye, which is selective for detection of 
mitochondrial superoxide in live cells. The dye selectively and rapidly targets the mitochondria. 
Superoxide dismutase (SOD) prevents the oxidation of MitoSOX™ but once oxidized by superoxide in 
the mitochondria MitoSOX™ exhibits red fluorescence. Although MitoSOX™ Red has been suggested 
to specifically detect superoxide in the mitochondria there are some reports which have also implicated 
its oxidation by other ROS generating systems (Kalyanaraman et al., 2012). Following its cleavage by 
ROS MitoSOX™ Red emits a fluorescence signal and this signal can be captured using a luminometer. 
This method was used to analyse the effect of GPX4 knock-down on mitochondrial superoxide levels in 
Caco-2 cells. 
 
Caco-2 cells were seeded to a black, flat-bottomed 96-well plate (Greiner) at 3X10
4
 cells/well, washed 
gently with 100µl/well of pre-warmed 1X HBSS (Hank’s Balanced salt Solution)/Ca/Mg solution 
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(without phenol red;Sigma) and mitochondrial superoxide formation measured using the MitoSOX™ 
LIVE Detection Kit (Invitrogen) following the manufacturer’s instructions. Essentially, twenty five µl 
of MitoSOX-Hoechst 33342 mix was added to each well of a 96-well plate and incubated at 37ºC for 10 
minutes whilst wrapped in foil. After incubation, cells were washed three times with 100 µl/well of pre-
warmed 1X HBSS/Ca/Mg solution, and finally 50 µl of 1X HBSS/Ca/Mg solution was added. MitoSOX 
fluorescent signal was measured at 510/580 nm (emission/excitation) wavelength and the Hoechst 
33342 fluorescent signal read at 350/460 nm using a fluorometer (POLARstar Omega-BMG Labtech); 
the Hoechst 33342 fluorescence was used as a control for cell number and staining efficiency.  
 
2.8 Measurement of mitochondrial ATP production using a luminometer based 
luciferase assay. 
A luciferase based assay using Molecular Probesʼ  ATP Determination Kit containing recombinant 
firefly luciferase and its substrate D-luciferin was used for a quantitative determination of ATP. This 
assay offers a convenient bioluminescence approach for ATP determination and is based on luciferaseʼ s 
requirement for ATP in producing light (emission maximum ~560 nm ) from the reaction below: 
 
This assay is sensitive and can detect as little as 0.1 picomole of either  pre-existing ATP, or ATP as it is 
being formed in kinetic systems. Cells were washed with ice cold PBS before the addition of 50 µl ice 
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cold lysis buffer (25 mM HEPES pH7.8, 5 mM MgCl2, 140 mM NaC1) and a detergent supplied with 
the kit which releases ATP. Briefly, 1 ml of a 10 mM D-luciferin stock solution was prepared by adding 
1mL of 1x reaction buffer to one vial of D-luciferin. This mixture was protected from light until it was 
ready to be used. 100 mM  DTT stock solution was prepared by adding 1.62 ml of dH2O to the bottle 
containing 25 mg of DTT and was aliquoted into ten 160 µl volumes and stored frozen at -20 ºC until it 
was ready to be used. 1µM ATP standard solution was used. To prepare a 10 ml standard reaction 
solution, 8.9 ml dH2O was added to 0.5 ml of 20X reaction buffer, plus 0.1mL of 0.1 M DTT, 0.5 ml of 
10 mM D-luciferin and 2.5 µl of firefly luciferase 5 mg/ml stock solution. The tube was gently inverted 
to avoid denaturation of the firefly luciferase enzyme, and was kept away from light. 
 
Background luminescence was measured by taking a luminescence reading of 100 µl of a standard 
reaction performed by adding 10% of the diluted ATP standard solution to the standard assay solution 
(i.e. 10 µl of ATP standard solution in 90 µl of standard reaction solution). Background luminescence 
was subtracted, and a standard curve for series of ATP concentration of 0,0.2,0.4,0.6,0.8 and 1 µM/µl 
was measured using the luminometer (POLARstar Omega-BMG Labtech). The amount of ATP in the 
experimental samples were calculated from the standard curve. 
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2.9 Measurement of mitochondrial membrane potential using the JC-1 5,5',6,6'-
tetrachloro-1,1',3,3'-tetraethylbenzimidazolylcarbocyanine iodide assay 
One of the hallmarks of apoptosis and mitochondrial damage is the loss of mitochondrial membrane 
potential. A unique cationic dye JC-1 (5,5’,6,6’-tetrachloro-1,1’,3,3’- 
tetraethylbenzimidazolylcarbocyanine iodide) can be used to detect the loss of mitochondrial membrane 
potential. The mitochondria stains bright red in healthy cells since the mitochondrial membrane 
potential allows the dye to accumulate and aggregate in the mitochondrial matrix where it fluoresces 
red. The collapse of mitochondrial membrane potential inhibits the accumulation of JC-1 within the 
mitochondria and JC-1 remains in a green fluorescent monomeric form in the cytoplasm. The aggregate 
red form has absorption/emission maxima of 585/590 nm whereas the green monomeric form has 
absorption/ emission maxima of 510/527 nm. Mitochondrial depolarization is consequently detected by 
reduction in red/green fluorescence intensity ratio.  
 
10X JC-1 assay buffer (Biotum) was heated in a warm water bath for 10 minutes to dissolve any crystals 
that may be present in the JC-1 reagent. Assay buffer was diluted 1:10 in DI water. 100 X JC-1 reagent 
(Biotum) was diluted 1:100 in 1X assay buffer to generate JC-1 working solution. 1 X 10
6
 cell/ml 
(i.e.10
4
 cells/well) Caco-2 cells were seeded in 96 well plates and were grown for 24 h before treatment 
with siRNA. Three days following cell treatment, medium was aspirated out of the wells, cells washed 
twice with 100 µl PBS and then incubated for 30 minutes with 100 µl of 10 ug/ml JC-1 at 37˚C. Cells 
were washed twice more with 100 µl PBS, 100 µl PBS was added to cells and fluorescence was 
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measured at excitation 550 nm, emission 590 nm (red) and fluorescence excitation 480 nm, emission 
520 nm (green) using a fluorescence plate reader (POLARstar Omega-BMG Labtech).The ratio of red 
fluorescence to  green fluorescence was calculated. 
 
2.10 Measurement of mitochondrial respiration  
Cellular oxygen consumption activities of mitochondrial complex I, IV and V were measured in a 
respirometer (Oroboros Oxygraph 2k). 5 x 10
6
 cells/ml Caco-2 cells were washed twice with warm PBS 
and trypsinized. Cells were collected into universal tubes each containing 5 ml of glucose-free DMEM 
with 10% FCS, 0.11 mg/ml Na pyruvate, 0.9 mg/ml galactose and centrifuged at 12,000 x g at 4˚C for 5 
minutes. Cells were re-suspended in 250 µl of glucose free medium, 80 µl of these re-suspended cells 
were added into each oxygen electrode chamber resting respiration measured. Oxygen consumption was 
measured successively in presence of 2 µg/mL Oligomycin, 0.5 µM Carbonyl cyanide p-
(trifluoromethoxy) (FCCP), 0.5 µM Rotenone and 2.5 µM Antimycin A with the respiration rate being 
allowed to stabilise between additions. 
 
2.11 DNA fragmentation assay. 
DNA fragmentation is considered as a hallmark of apoptosis (Nagata, 2000). Towards the end stage of 
apoptosis, the higher order chromatin structure of DNA is degraded into fragments of 50 to 500 kilo 
bases pairs in length by activated nucleases. The fragmented DNA can be extracted from cells and 
visualized by agarose gel electrophoresis and ethidium bromide staining. 
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Cells were grown in 6-well plate, washed with 1 ml 1X PBS, trypsinized with 0.5 ml trypsin (10 X 
Solution Trypsin-EDTA; Sigma) and cell count was performed. Following cell counting, 5 X 10
5
  cells 
were resuspended in 2 ml of DMEM medium. 1 ml of cell suspension was aliquoted into a fresh 1.5 
microcentrifuge tube and centrifuged at 2,000 x g for 5 minutes at 4ºC. The supernatant was discarded 
and 200 µl of lysis buffer (20 mM EDTA, 100 mM Tris HCL pH 8.0, 0.8% (w/v) SDS) was added to the 
cell pellet.  Cells were lysed by repeated (10 X) homogenisation with a glass homogeniser. The cell 
lysate was stored at -80 ºC for further analysis. 
 Genomic DNA was extracted from Caco-2 cells using the DNA Isolation Kit (Ambion). Briefly, 10 µl 
of  RNAase A/TI cocktail mix ( 500 units/ml  RNAase A, 20,000 unit/ml RNAase TI ) (Ambion) was 
added to the cell lysate and mixed well by flipping the tip of the tube. The mixture was incubated at 
37ºC for 90 minutes, 10 µl of proteinase K (20 mg/ml) (Ambion) was added, mixed  and further 
incubated at 50ºC for 90 minutes. 2 µl of 5X DNA loading dye (50 mM Tris-HCl pH 8, 5 mM EDTA, 
20 % glycerol and 0.1 % Bromophenol Blue) and 18 µl of the DNA was loaded into  dry wells (DNA 
was viscous and had to be loaded into a dry well before adding TAE run buffer)  of a 1.5% agarose gel 
in 50X TAE buffer (Tris base 242 g, Glacial acetic acid 57.1 ml, EDTA 100 ml of 0.5 M pH 8, 1 L 
MQH2O pH 8.3)  ( containing ethidium bromide). Hyperladder IV (Bioline) (a 1000 bp ladder) was used 
as DNA size markers. Electrophoresis was carried out in TAE buffer at 35V for 30 minutes and DNA 
bands were visualised under UV light using a gel documentation system (Uvitec model BTS-26M, UK). 
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2.11.1 Measurement of Caspase 3/7 activity  
The luminescence-based Caspase-Glo assay measures the combined activities of caspase-3 and-7. The 
Caspase-Glo assay kit provides a luminogenic caspase-3/7 substrate containing tetrapeptide sequence 
DEVD and optimized reagents for detection of luciferase activity and cell lysis. In the assay the 
proluminecent caspase substrate containing DEVD is cleaved to aminoluciferin which in turn is a 
substrate for luciferase. The amount of luminescence present is proportional to the amount of caspase 
activity present and the reagent relies on the properties of thermostable luciferase (Ultra-Glo™ 
Recombinat Luciferase) that is generated to produce a luminescent signal. 
Caspase-Glo assay was used to investigate the activation of caspase-3 and -7 activity in cells treated 
with GPX4-siRNA or negative control siRNA. The following reactions were prepared: Blank reaction-
Caspase-Glo®3/7 reagent (Promega), DMSO (Sigma) and DMEM medium without cells, Assay 
reaction-Caspase-Glo®3/7 reagent or cells treated with siRNA and scrambled control siRNA in DMEM 
medium. 
 Caspase-Glo®3/7 reagent was allowed to equilibrate to room temperature for 20 minutes and the 96-
well plate containing cells from the incubator was also allowed to equilibrate to room temperature for 10 
minutes. 100 µl Caspase-Glo®3/7 reagent was added to each well of a white walled 96-well plate 
(Greiner) containing 100 µl of blank reaction, negative control siRNA treated cells or siRNA treated 
cells in culture medium and the plate sealed with a plate sealer. Well contents were gently mixed using a 
plate shaker at 500 x g for 30 seconds and incubated at room temperature for either 30 minutes, or 60 
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minutes, or 90 minutes, and 120 minutes. Luminescence of each sample was measured in a plate reader 
(POLARstar Omega-BMG Labtech).  
 
2.11.2 Flow cytometry analysis of apoptosis  
Detection of apoptosis by Annexin V-FITC is based on the observation that phosphatidylserine (PS) is 
translocated from the inner face of the plasma membrane to the cell surface at the onset of apoptosis. 
Once PS is on the cell surface, it can be detected easily by staining with a protein that has a high affinity 
for PS such as Annexin V-FITC. Detection of apoptosis using Annexin V can be determined by flow 
cytometry or by fluorescence microscopy. Differentiation between apoptotic cells vs necrotic cells can 
be performed using both Annexin V-FITC and Propidium iodide (PI) staining. 
For the analysis of apoptosis in this study, Caco-2 cells were treated with Annexin V-FITC Apoptosis 
Detection kit (Abcam). Cells were seeded and allowed to grow to 30-50% confluency before 
transfection with either GPX4-siRNA, negative control siRNA or siRNA plus Mitoquinone 10 
(MitoQ10) (a blocker of lipid peroxides). Seventy two hours following transfection, cells were washed 
with PBS and collected into microcentrifuge tubes and centrifuged at 12,000 x g for 5 minutes at 4ºC. 
The supernatant was discarded and the pellet resuspended in 500µl of Solution A (1x Annexin binding 
buffer solution Abcam). This was repeated twice more to remove any remaining media. A cell count 
was performed and 5X10
5
 cells were taken and resuspended into 500 µl 1x Annexin binding buffer 
solution. This was incubated for 10 minutes at room temperature, then 5 µl of Solution B (Annexin V-
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FITC) and 5 µl of Solution C (50mg/ml propidium iodide stain solution) was added to the suspension 
and incubated for further 10 minutes in the dark at room temperature. Annexin V-FITC binding  was 
analyzed by flow cytometry (Exitation=488 nm; emission=530 nm) using  FITC signal detector (FL1)  
and PI staining by the phycoerythrin emission signal detector (F2) with FACS Canto (USA)  and 
analyzed statistically using FACSDiva software. 
 
2.12 Mitoquinone10 treatment on Caco-2 cells. 
MitoQuinone10 (MitoQ10) is a ubiquinone that accumulates within mitochondria driven by a conjugated 
lipophilic triphenylphosphonium cation (TPP
+
) attached to a ubiquinone moiety by saturated 10-carbon 
chain. Once there, MitoQ10 is reduced to its active ubiquinol form. The lipophilic cation leads to the 
extensive accumulation of MitoQ10 within mitochondria where the ubiquinone is reduced to its active 
antioxidant ubiquinol form. Accumulation and subsequent reduction of MitoQ10 leads to protection 
against mitochondrial oxidative damage in a number of in vitro and in vivo systems (Orsucci et al., 
2001; Cortes-Rojo & Rodriguez-Orozco, 2011).  
Caco-2 cells were seeded and grown for 24 h before transfection with siRNA and negative control 
siRNA and addition of 1 µM MitoQ10 or its control compound, decyltriphenylphosphonium bromide 
(DecylTPP). 1 µM was considered optimal dose for MitoQ10 and DecylTPP as recommended by the 
supplier (Dr R.A.J. Smith, Department of Chemistry, and University of Otago, New Zealand). Twenty 
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four, 36 and 72 h post-transfection, cells were washed with 1X PBS and parameters such as levels of 
lipid peroxide, mitochondria superoxide, mitochondrial membrane potential and apoptosis were 
measured as described in sections 2.6, 2.7.1, 2.9 and 2.11.2.  
 
2.13 Statistical Analysis  
All the data described in this thesis except for the microarray data was analyzed statistically using SPSS 
17.0 (Statistical Product and Service Solutions 17.0, Chicago, IL, USA). Where necessary, results were 
presented as mean ± standard deviation (SD) and standard error of mean (SEM). A Mann-Whitney U 
test was performed for statistical analysis, and a P-value of < 0.05 was considered significant. 
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Chapter 3: Investigation into the biological functions of GPX4 and downstream 
effects of altered GPX4 expression in Caco-2 cells. 
3.1 Introduction 
Glutathione peroxidase 4 (GPX4), a phospholipid hydroperoxidase gene, has been shown to be 
ubiquitously expressed in various tissues including the gastrointestinal tract (Imai et al., 1995). GPx4 
variants are localized in the mitochondria and cytoplasm, and are associated with cell membranes, (Imai 
and Nakagawa, 2003). GPx4 is a catalyst of a wide range of oxidative targets such as thymine 
hydroperoxide (Bao et al., 1997), lipid hydroperoxides (from cholesterol and cholesteryl esters) 
(Thomas et al., 1990), phospholipid hydroperoxides (Ursini et al., 1985), and additionally has the ability 
to use other substrates in catalysis of oxidative targets outside glutathione (GSH) (Aumann et al., 1997). 
Overexpression of GPX4 in transgenic mice helped protect from oxidative damage (Ran et al., 2004; 
Liang et al., 2007). Overexpression studies have also suggested that GPx4 has a role in mitochondrial 
function, eicosanoid metabolism and apoptosis. Using a hypothesis-free approach, this study aimed to 
investigate the effects of altered expression of GPX4 in a human gut epithelial cell line through the use 
of GPX4-targeting siRNAs.  
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3.2 Design of GPX4 siRNA and knock-down of GPX4 mRNA and protein 
The use of synthetic microRNAs (siRNA) has become an effective tool for gene silencing within 
mammalian cells. siRNA act upon an mRNA target sequence for degradation and this mechanism has 
been widely accepted for the study of effects of gene knockdown.  RNA interference (RNAi) is a 
process by which a gene loses its function through processing of dsRNA into smaller (~21 nucleotides) 
RNAs by an enzyme known as dicer and their incorporation into a RNA-induced silencing complex 
(RISC). This allows the loading of the siRNA antisense strand which recognises and cleaves the target 
mRNA sequence by the complex. In this way, mRNA that has been cleaved is targeted for degradation 
and ultimately prevents protein synthesis. siRNA are processed by dicer when introduced into cells. To 
achieve GPX4 knockdown in the Caco-2 cell line, two non-overlapping siRNAs targeting GPX4 mRNA 
were designed (Guanyu Gong, personal communication) and purchased from Ambion. Knockdown was 
assessed using 20 and 40 nM siRNA at 48 and 72 h after transfection to ascertain the most effective 
concentration and time. 
Three different transcript variants are encoded in the GPX4 gene; namely cytosolic GPX4 (cGPX4), 
mitochondrial GPX4 (mGPX4) and nuclear GPX4 (nGPX4) (Arai et al., 1996, Pfeifer et al., 2001). An 
initial experiment was carried out to determine which GPX4 transcript variants are expressed in Caco-2 
cells. Caco-2 cells were seeded at 3 x 10
5
 cells/well in a six well plate and allowed to grow to 80% 
confluency before extraction of RNA.  The extracted RNA was reverse transcribed and the resulting 
cDNA was amplified by PCR using primers specific to either all GPX4 or only mGPX4 and to the 
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reference gene GAPDH as a control. Primer sequences and annealing temperatures are described in 
Table 4. Using RT-PCR, as shown in Figure 8, amplification of both cGPX4 and mGPX4 isoforms was 
achieved but, the expression of mGPX4 was very low. Thus, the short form is the major GPX4 isoform 
in undifferentiated Caco-2 cells, as reported to be the case in other somatic cells. 
 
Figure 8. Detection of GPX4 transcript variants in Caco-2 cells. 
Duplicate RNA samples from Caco-2 cells were reverse transcribed and the cDNA subjected to PCR 
using primers specific to GPX4 and GAPDH. PCR amplification was carried out for 30 cycles, the 
expression of GPX4 transcript variants in Caco-2 cells was detected using RT-PCR. GAPDH (house 
keeping gene), All-GPx4: amplification of both cytosolic GPX4 and mitochondrial GPX4; M-GPx4: 
amplification of mGPX4 only. 
Following the published methods of (Reynolds et al., 2004, Ui-Tei et al., 2004), two GPX4-specific 
siRNA were designed (GPX4-siRNA(1) and GPX4 siRNA(2) that had low sequence homology (>15nt 
out of 21nt length of siRNA) with other human mRNA transcripts so as to limit the non-specific binding 
of siRNA to off target mRNAs. The sequences of both GPX4-siRNAs together with the corresponding 
sequence information for the GPX4 mRNA transcripts are shown in Figure 9. 
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3.2.1 Sequence of GPX4 mRNA transcript and specific siRNA 
A Exon 1a: 
[ATGAGCCTCGGCCGCCTTTGCCGCCTACTGAAGCCGGCGCTGCTCTGTGGGGCTCTGGCCGCGCCTGGCCTGGCCGGGACCATG]  
Exon 2-7: 
[TGCGCGTCCCGGGACGACTGGCGCTGTGCGCGCTCCATGCACGAGTTTTCCGCCAAGGACATCGACGGGCACATGGTTAACCTGGACAAGT
ACCG][GGGCTTCGTGTGCATCGTCACCAACGTGGCCTCCCAGTGAGGCAAGACCGAAGTAAACTACACTCAGCTCGTCGACCTGCACGCCC
GATACGCTGAGTGTGGTTTGCGGATCCTGGCCTTCCCGTGTAACCAGTTCGGGGAAGCAG][GAGCCAGGGAGTAACGAAGAGATCAAAGAG
TTCGCCGCGGGCTACAACGTCAAAATTCGATATGTTCAGCAAGATCTGCGTGAACGGGGACGACGCCCACCCGCTGTGGAAGTGGATGAA
GATCCAACCCAAGGGCAAGGGCATCCTGGGAA][TGCCATCAAGTGGAACTTCACCAAG][TTCCTCATCGACAAGAACGGCTGCGTGGTGAA
GCGCTACGGACCCATGGAGGAGCCCCTG][GTGATAGAGAAGGACCTGCCCCACTATTTCTAG] 
B GPX4 siRNA (1) 
Target mRNA: AAGACCGAAGTAAACTACACT 
     GACCGAAGUAAACUACACU-UU   (sense strand) 
UU-CUGGCUUCAUUUGAUGUGA (antisense-strand) 
 
C Sequence of GPX4 siRNA (2) 
Target mRNA: AATTCGATATGTTCAGCAAGA 
 
SiRNA(2): UUCGAUAUGUUCAGCAAGA-UU (sense strand) 
       UU-AAGCUAUACAAGUCGUUCU (antisense-strand) 
 
Scrambled negative control siRNA: CAGUCAGAUCAAUUAGAACCU (sense strand) 
      UCCAAGAUUAACUAGACUGAC (antisense-strand) 
Figure 9. Sequence information of GPX4 mRNA transcript and GPX4 siRNA(1), (2) and scrambled 
negative control siRNA. 
(A)The GPX4 gene encodes 7 exons (exon 1a and exon 2 to 7). mGPx4 is transcribed from exon 1a to 
exon 7 and cGPX4 is transcribed from exon 2 to 7. GPX4 gene also encodes an alternative exon 1 as 
exon 1b, which is use to transcribe nGPX4 but this is not shown above. Exon 1a suggested to 
translate a mitochondrial translocation leader sequence whereas exon 2 to 7 was suggested to 
translate the main part of GPX4 with catalytic function (Arai et al., 1996). Exons are separated by 
brackets and the mRNA targets of GPX4 siRNA (1) and GPX4 siRNA (2) are respectively underlined. 
(B) Sequence of GPX4 siRNA (1) (design 1) and GPX4 (design 2). 
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Since a short sequence of 84 nucleotides is the only differential sequence between mGPX4 and cGPX4 
both GPX4-siRNAs was designed to sequences within exon 3 and exon 4. 
GPX4 siRNA(1) and GPX4 siRNA(2) target sequences were present in both cGPX4 and mGPX4 
transcripts and therefore these siRNAs were unable to differentiate between the cGPX4 and mGPX4 
transcripts expressed and would deplete both the cGPX4 and mGPX4 in Caco-2 cells. However, as 
indicated by RTPCR cGPX4 is the major form in these cells. 
 
3.3 Effect of GPx4 knock-down on GPX4 mRNA and protein expression 
To test the ability of siRNA to knockdown GPX4 expression, Caco-2 cells were seeded in a 6-well plate 
24 h before transfection with either 20 or 40 nM of GPX4-siRNA (1), or scrambled control siRNA.  
Treatment with siRNA was maintained for 48-72 h following transfection and knock-down at mRNA 
level assessed by semi-quantitative RT-PCR using total RNA harvested from cells after 48 h. The 
mRNA expression of GPX4 and GAPDH was assessed; the ratio of GPX4/GAPDH was calculated and 
further normalized as mean percentage of the scrambled control siRNA. To assess the knockdown at the 
protein level, treatment by each GPX4-siRNA was maintained for 72 h following transfection.  Total 
cell lysate was harvested and GPx4 expression was determined by western blot using polyclonal anti-
GPx4 as described in (Chapter 2 Section 2.4-2.4.6).  
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Figure 10. Knock-down of GPX4 mRNA expression in Caco-2 cells.  
Undifferentiated Caco-2 cells were treated with 20 or 40 nM GPX4-siRNA(1) or a scrambled negative 
control siRNA for 48 h. RNA was isolated, reverse transcribed and subjected to PCR using primers 
specific to both long and short forms of GPX4. Semi-quantitative RTPCR was used to assess levels of 
GPX4 knock-down at mRNA level (SR=siRNA, C=negative control siRNA). GPX4 mRNA levels were 
calculated relative to that of the GAPDH transcript and expressed as a percentage of the mean value 
for cells treated with the scrambled negative control siRNA. Values shown are mean ± s.e.m. of n=6. 
Groups were compared using a Mann-Whitney U test, * p<0.05, ** p<0.01. 
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Figure 11. Knockdown of GPx4 expression at the protein level.  
Caco-2 cells treated with either 20 or 40 nM of GPX4-siRNA(1) or a scrambled negative control for 
72 h. Following transfection, total protein was extracted and protein expression assessed by Western 
blotting using an anti-GPx4 antibody. Protein expression was calculated relative to that of  B-Actin 
and then as a percentage of the mean value for cells treated with the scrambled negative control 
siRNA. Western panels =2 wells, values shown are mean ± S.D of n=6. Groups were compared using 
a Mann-Whitney U test, * p<0.05, ** p<0.01. 
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As shown in Figure 10, treatments with 20 and 40 nM of GPX4-siRNA(1) resulted in a clear decrease in 
GPX4 mRNA expression, compared to the control group treated with scrambled negative control 
siRNA.  In addition, GAPDH expression was not affected by GPX4-siRNA treatments. Quantification 
by densitometry of the RT-PCR bands allowed calculation of the GPX4 expression as a ratio of 
GPX4/GAPDH transcript levels. As shown in Figure 10, GPX4 mRNA levels were reduced by ~50-60% 
with 20 and 40 nM respectively, compared to the group treated with scrambled control siRNA. 
Therefore, GPX4-siRNA was able to cause GPX4 knockdown in Caco-2 cells. Cells treated with 40 nM 
GPX4-siRNA appeared to have a greater knockdown effect.  
In order to test GPx4 knockdown at the protein level, treatments with 20 and 40 nM GPX4-siRNA(1) 
were maintained for 3 days. As shown in Figure 11, groups treated with GPX4-siRNA exhibited reduced 
GPx4 protein expression to various extents when compared to the scrambled negative control group.  
Significant knockdown of GPx4 protein was observed in both groups treated with 20 and 40 nM siRNA; 
40 nM treatment appeared to have greater knock-down effect on GPx4 protein level. Using 
densitometry, quantification of the protein bands was carried out and levels of GPx4 protein calculated 
as a ratio of GPx4/B-Actin protein levels, and further normalized as a mean percentage of the scrambled 
control. GPx4 protein expression was reduced by ~60% and ~85% by treatment with 20 and 40 nM 
siRNA respectively. Therefore, treatment with 20 nM siRNA was found to achieve a similar knockdown 
in GPx4 expression (~50-60%) at both mRNA and protein levels, and treatment with 40 nM siRNA was 
found to result in a greater effect on GPx4 protein expression with knockdown of around 85%.  
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3.4 Investigating the genome-wide effects of GPX4 on gene expression  
To investigate the function of GPX4, direct effects of GPX4 manipulation (knock-down) on global gene 
expression was investigated. Microarray-based techniques allowed for the genome-wide effects of 
GPX4 manipulation to be probed, profiling global gene expression changes in response to changes in 
GPX4 levels. RNA for transcriptome analysis under conditions of GPX4 knockdown was obtained from 
cells treated as described in Chapter 2, Section 2.2 to 2.31. RNA for expression analysis was prepared 
from three independent experiments to produce three biological repeats for each condition (GPX4 
knockdown and corresponding controls), of which all three biological replicates for GPX4 knock-down 
and control were hybridised to the expression array. After confirmation that siRNA treatment knocked-
down GPx4 protein expression at 72 h following treatment with 20 and 40 nM siRNA, gene expression 
profiles were measured using the Illumina Gene Expression Service provided by Service XS (Leiden, 
The Netherlands). Prior to microarray analysis, each RNA sample was subjected to quality and integrity 
checks before global gene expression. RNA quality was assessed by spectrophotometry and integrity 
was assessed using Bioanalyser; the integrity output of the Bioanalyser for the samples analysed by 
microarray hybridisation are shown in Figure 12. 
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B 
 
Figure 12. Integrity of RNA used for microarray analysis.  
(A) Gel-like electropherogram output image generated from the bioanalyser for 12 samples. (B) 
Bioanalyser electropherogram output for the samples showing 2 clear bands indicative of good 
quality RNA. An RNA integrity number (RIN) of 7 or more indicates RNA of sufficient quality. 
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3.4.1 Microarray hybridisation  
The Illumina HumanHT-12 v4 Expression BeadChip comprises 12 identical arrays targeting over 
47,000 probes covering genes, gene candidates and splice variants from the 2009 NCBI RefSeq Release 
38. RNA samples from 20 and 40 nM siRNA and scrambled negative control treatment were reverse 
transcribed to produce a cDNA template that was transcribed in vitro and amplified to incorporate 
biotin-labelled nucleotides.  Biological triplicates of the RNA samples from cells in which GPX4 
expression was reduced by siRNAs and the corresponding control were hybridised onto individual 
arrays within the HumanHT-12 v4 Expression BeadChip (Illumina). Signals of the hybridized-labeled 
sample were developed with Streptavidin-Cy3 and scanned with BeadChip. The intensity value for each 
probe and gene expression data from the scan images was calculated. 
 
3.4.2 Data analysis  
The microarray raw data was supplied electronically and was deposited in GEO (accession GSE40287). 
Using RankProd analysis (Hong et al., 2006) and visualisation in Genespring GX11 (Agilent) on a 
quality filtered subset of microarray probes, genes for which expression was up-regulated or down-
regulated by a factor of 1.2 fold or greater under conditions of GPX4 knockdown were identified 
(Appendices A1 and A2). 795 genes showed a 1.2 fold or greater change in gene expression with p-
value of <0.05.  
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After identification of genes whose expression was reduced or increased, confirmation of changes in 
biological pathway (s) was deemed necessary. Ingenuity Pathway analysis (IPA) tool was utilised to 
investigate changes in biological pathways resulting from GPX4 knock-down. The observed 795 genes 
were mapped into IPA to generate both pathways and networks. Network eligible molecules were 
generated from the input microarray data by IPA on the basis of their expression and/or their interaction 
with other molecules in the Ingenuity Knowledge Base (IKB). In addition, pathway eligible molecules 
were selected from the microarray dataset by IPA due to their expression values and/or due to having at 
least one functional annotation or disease association in the IKB. The network eligible molecules then 
served as “seeds” for generating networks that were overlaid onto available networks to maximize their 
connectivity with each other relative to all molecules to which they are connected within the IKB.   
Ingenuity Pathway analysis (IPA) of this dataset showed that the major canonical pathways most 
significantly affected by GPX4 knock-down were oxidative phosphorylation, ubiquinone biosynthesis 
and mitochondrial dysfunction, and the top two toxicological lists were mitochondrial dysfunction and 
oxidative stress (Table 6).  Visualisation of these pathways in a network showed clearly that 
differentially expressed genes were clustered as those coding for components of mitochondrial 
complexes I, IV and V (Figure 13); importantly, apoptosis-inducing factor (AIF), a key node in the 
network, was also differentially expressed.  Microarray hybridization and data analysis was carried out 
with both 20 and 40 nM GPX4 siRNA(1) and negative control siRNA. Changes in gene expression and 
pathway analysis were the same with both concentrations of siRNA. 
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CANONICAL PATHWAYS (Already 
established pathway in IPA) 
TOTAL GENES GENES THAT 
CHANGED 
FOLD CHANGE P VALUE 
OXIDATIVE PHOSPHORYLATION 166 28 1.2-1.7 5.26E-12 
UBIQUINONE BIOSYNTHESIS 119 15 1.3-1.7 1.08E-08 
MITOCHONDRIAL DYSFUNCTION 172 23 1.3-2.2 1.15E-08 
COAGULATION SYSTEMS 37 9 1.3-2.3 7.65E-06 
GLYCOSAMINOGLYCAN 
DEGRADATION 
72 7 1.3-2.0 3.6E-04 
ARYL HYDROCARBON RECEPTOR 
SIGNALING 
157 15 1.2-1.6 4.43E-04 
LPS/IL-1 MEDIATED INHIBITION OF 
RXR FUNCTION 
208 18 1.2-1.6 8026E-04 
PURINE METABOLISM 440 25 1.2-1.7 1.07E-04 
Table 6. Pathway analysis of the transcriptomic data after GPx4 knock-down. 
Table show the canonical pathways and toxicological pathway list found to be most significantly 
affected by IPA analysis of the microarray data after GPX4 knock-down. Core Analysis in Ingenuity 
Pathway Analysis (IPA) was used to analyse affected pathways of the microarray dataset from the 
GPX4 knock-down experiment. Ingenuity Pathway Analysis (IPA) highlighted changes in pathways 
associated with mitochondrial function including oxidative phosphorylation and ubiquinone 
biosynthesis and oxidative stress.  
TOX LIST TOTAL GENES GENES THAT 
CHANGED 
FOLD CHANGE P VALUE 
MITOCHONDRIA 
DYSFUNCTION 
125 20 1.3-2.2 1.39E-07 
OXIDATIVE STRESS 57 9 1.3-2.4 4.4E-04 
LPS/IL-1 MEDIATED 
INHIBITION OF RXR 
FUNCTION 
187 18 1.2-1.6 6.05E-04 
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Figure 13. Network analysis of the transcriptomic data. 
 Network analysis of the transcriptomic data showing changes in genes encoding complex I, IV and V 
of the mitochondrial electron transport chain following GPX4 knock-down. Both pathway and 
network analysis of the transcriptomic data indicated alterations in expression of genes encoding 
components of mitochondria electron chain complexes I, V and IV. The largest circle within the 
inner mitochondrial membrane is complex I of the mitochondrial electron transport chain, followed 
by the two highlighted complex IV and V respectively. Up-regulated genes are highlighted in green 
and down-regulated genes highlighted in red.  
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3.4.3 Validation of transcriptomic data 
To validate the microarray results, quantitative real-time polymerase chain reaction (qRT-PCR) assays 
were carried out. Remnants of the same RNA extracted from Caco-2 cells treated with GPX4-siRNA 
and scrambled negative control siRNA that was used for the microarray experiment and from a 
subsequent knockdown were utilised. Validation of the microarray data using qRT-PCR was necessary 
to confirm that some of the observed changes in gene expression in the microarray data were not by 
chance and could be reproduced using another technique. qRT-PCR amplifies a gene of interest (target 
gene) specifically in a given sample and monitors the amplification progress through the utilization of 
fluorescence technology (Valasek & Repa, 2005). 
Since GPX4 knock-down had major effects on expression of components of complexes I, IV and V, 
validation of the microarray data by real-time PCR was focussed on specific target genes that code for 
components of these complexes. The genes selected were: Cytochrome C oxidase copper chaperone 
(COX17), a component of mitochondrial complex IV, which was up-regulated according to the 
microarray data; NADH dehydrogenase (ubiquinone) 1 alpha subcomplex 6 (NDUFB6) a component of 
complex I and also up-regulated on the microarray; NADH dehydrogenase (ubiquinone) 1 alpha 
subcomplex 10 (NDUFA10), a component of complex I that was down-regulated according to the 
microarray data; AIF and Bcl2 associated X protein (BAX), which were  down-regulated and up-
regulated respectively on the microarray. ATP synthase, H
+
 transporting mitochondrial FO complex, 
subunit E (ATP5I), a component of complex V that was up-regulated according to the microarray data 
89 
 
was investigated with RT-PCR. There was however, enormous difficulty in getting the ATP5I primers to 
amplify hence, the expression of this gene could not be investigated. As shown in (Figure 14) real-time 
qRTPCR showed that GPX4 knock-down caused significant down-regulation of NDUFA10, and up-
regulation of NDUFB6 and COX17, in concordance with the microarray data. Similarly, real-time 
qRTPCR also confirmed that GPX4 knock-down led to decreased AIF mRNA expression and increased 
BAX expression as found by microarray analysis.  GAPDH was used as house-keeping genes to 
normalize the target genes. Although the fold change observed for the up-regulated genes assessed by 
qRTPCR was higher than that of the microarray experiment and the change in down-regulated genes 
lower than that of the microarray overall, but the direction of change obtained with the two techniques 
was the same, so validating the microarray data. 
 
Figure 14. Confirmation of GPX4 knock-down transcriptomic data by quantitative RT-PCR.  
RNA was isolated from Caco-2 cells treated with 20 nM GPX4-siRNA(1) or a  scrambled  negative 
control siRNA and  target gene expression measure by quantitative RTPCR. Expression was 
calculated relative to GAPDH and β-actin as the housekeeping control and then as a percentage of 
the mean value for cells treated with the negative control siRNA. Results confirmed the changes in 
gene expression observed with the transcriptomic data. Values shown are mean ± s.e.m. for n=6. 
Groups were compared using a Mann-Whitney U test, * p<0.05, ** p<0.01 
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3.5 Investigation of mitochondrial complex I and IV protein expression following 
GPX4 knock-down 
To investigate if GPX4 knock-down alters the protein expression of complex I and IV of the 
mitochondrial electron transport chain, Western blotting  was used to analyse levels of major markers of 
complex 1 (NADH dehydrogenase (ubiquinone) 1 beta subcomplex 8; NDUFB8) and complex IV 
function (cytochrome c oxidase subunit II; COX2).  Seventy two hours after transfection, cells treated 
with 20 nM GPX4-siRNA(1) were found to have a statistically significantly higher protein expression of 
both NDUFB8 and COX2 (~150% and 75%) respectively compared to cells treated with the negative 
control siRNA (Figure 15).   
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Figure 15. Expression of markers of mitochondrial complexes I and IV after GPX4 knock-down.  
Total protein was extracted from Caco-2 cells treated with GPX4-siRNA (1) or the scrambled negative 
control for 72 h.  Expression of NDUFB8 (mitochondrial complex I indicator) and COX2 
(mitochondria complex IV indicator) were measured by western blotting. Protein expression was 
calculated relative to B-Actin and then as a percentage of the mean value for cells treated with the 
scrambled control siRNA. Western panels = 2 wells, values shown are mean ± S.D of n=6. Groups 
were compared using a Mann-Whitney U test, * p<0.05, ** p<0.01 
 
 
92 
 
3.6 Effects of a second GPX4-specific siRNA on mitochondrial protein expression 
As a control, to exclude non-specific off-target effects of the siRNA treatment, measurement of the two 
mitochondrial components NDUFB8 and COX2 was repeated in cells treated with a second GPX4- 
siRNA. As shown in Figure 16A-B, semi-quantitative RTPCR and Western blotting showed that 
treatment with this second siRNA for 72 h led to a ~50% decrease in GPX4 mRNA a ~60% decrease in 
GPx4 protein expression. This GPX4 knock-down was accompanied by a 30% increase in NDUFB8 
protein expression and a 50% increase in COX2 protein Figure 16C.  These results confirm that GPX4 
knock-down with a second siRNA affects expression of components of mitochondrial complexes I and 
IV, as observed with the first siRNA, indicating that the effects are due to knock-down of GPX4 and not 
due to off-target effects. 
A 
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Figure 16. Expression of GPx4 mRNA and protein and markers of mitochondrial complexes I and IV 
after GPX4 knock-down with siRNA (2).   
Total RNA and protein was extracted from Caco-2 cells treated with GPX4-siRNA (2) or the 
scrambled negative control. (A) Percentage expression of GPX4 mRNA following 48 h cell treatment 
with the second GPX4-siRNA and scrambled negative control mRNA levels were calculated relative 
to GAPDH as the housekeeping control. (B) Percentage expression of GPx4 protein following 72 h 
treatment with the second GPX4-siRNA and scrambled negative control. (C) Percentage expression 
of NDUFB8 and COX2 protein after 72 hours treatment with GPX4-siRNA (2). Protein levels were 
calculated relative to β-actin as the housekeeping control and then as a percentage of the mean value 
for cells treated with the negative control siRNA. PCR and western panels = 2 wells, values shown are 
mean ± S.D of n=6. Groups were compared using a Mann-Whitney U test, * p<0.05, ** p<0.01. 
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3.6 Discussion 
Several selenoproteins such as GPX1 and GPX4, which use glutathione as a substrate, and thioredoxin 
reductase, which controls the redox state of thioredoxin, are thought to have roles in regulating cellular 
redox state and intracellular ROS levels. These proteins are often viewed as antioxidants, but their 
contributions to redox regulation are not fully understood. In order to explore the role of GPX4 in gut 
epithelial cell, GPX4 mRNA and protein expression was knocked-down in Caco-2 cell line and a global 
gene expression analysis was carried out to study downstream effects.  
Previous studies have investigated functions of GPX4 using transgenic mouse model (Seiler et al, 2008) 
and cell lines overexpressing an additional mouse or human allele (Imai et al, 2006; Barriere et al., 
2004). These studies have suggested roles for GPX4 in regulation of apoptotic and inflammatory 
pathways. Gene knock-down approaches using antisense or siRNA approaches provide alternative tools 
to investigate GPX4 functions. There are only a few studies in this field using antisense methods to 
inhibit GPX4 mRNA expression and these reported different results. Studies on epidermal carcinoma 
A431 cells reduced GPX4 expression by 20% in one study (Chen et al., 2000) and 10% in a second 
study (Chen et al., 2003). Another group used an antisense approach, but in the P4 (MCF-7) cell line, 
and achieved inhibition of mitochondrial GPX4 mRNA and protein by 25% approximately (Zhao et al., 
2003).  Another study on NIH3T3 cells transfected with either PU6-m3 control vector or PU6-M3 
vectors containing four different sets of GPX4-siRNA achieved 50-80% reduction of GPX4 mRNA and 
protein (Yoo et al., 2010). 
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The use of small interfering RNA (siRNA) has become a technique of choice for lowering gene 
expression. This method essentially uses a synthesized exogenous small dicer strand RNA (dsRNA) 
which recognizes and recruits the enzyme complex to a target mRNA. siRNA is ideal for study of 
dynamic cellular processes because it produces a rapid inhibition of expression in 2-4 days. This 
compares with long term knock down which takes a longer time and is achieved by stable transfection 
using a specific short RNA sequence in a vector (e.g. small-hairpin shRNA). In this study, a pre-
designed siRNA specific to GPX4 and a negative control siRNA (-ve control siRNA) designed by 
mismatching and scrambling the siRNA sequence was used to knock-down the expression of GPX4 
gene in Caco-2 cells. The siRNA matches a 21nt target in exon 4 and optimal prediction was achieved 
according to various algorithms (Reynolds et al., 2004; Ui-Tei et al., 2006). Additional considerations 
were applied in order to achieve efficient transfection;  (a) cell culture medium used  during transfection 
contained only half the concentration of foetal calf serum so as  to minimize the interferon response 
which could easily occur as a result of interaction between serum and siRNA (according to Ambion user 
manual), (b) antibiotic was not added to the medium during transfection (according to Ambion user 
manual), (c) medium was changed 24 h after transfection to minimize cytotoxicity that can be caused by 
the lipofectamine or the remaining siRNA (as per Ambion user manual).  
As judged by semi-quantitative PCR GPX4 expression was lower following 48 h after transfection with 
the GPX4-siRNA(1) compared with cells transfected with the negative control siRNA. To compensate 
for any variation in loading and RT efficiency GPX4 mRNA levels were normalised by calculating the 
ratio of GPX4/GAPDH mRNA levels and was further normalized as a mean percentage of the scrambled 
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control for change in expression. siRNA reduced GPX4 mRNA  by approximately 50-60 % for 20 and 
40 nM respectively.  The important effect of any siRNA is on the target protein level and in the present 
work GPx4 protein level was assessed by western blotting 72 h after transfection (protein level is 
expected to be knocked-down later than the mRNA). Also to compensate for variation in loading GPx4 
protein levels were normalised by calculating the ratio of GPx4/β-actin protein levels and further 
normalized as a mean percentage of the scrambled control for change in expression. Overall the data 
indicate knock-down of GPX4 at both mRNA (2 days) and protein levels (3 days) in agreement with 
previous findings that siRNA function efficiently 1-3 days post-transfection (Ui-Tei et al., 2006). 
The work described in this chapter was a hypothesis-generating genome-wide experiment which aimed 
to investigate whether reduction in levels of GPx4 protein is sufficient to bring about some 
consequential effect on a range of biological pathways. Such approaches would detect changes in gene 
expression as a result of changing the level of GPX4 expression through all active mechanisms – not 
only effect on gene expression but also downstream effects on different biological pathways. For 
example, multiple cellular substrates undergo GPX4-mediated ROS or apoptosis induction, including 
transcription factors and co-regulators that are required for gene expression.  
These findings were novel and provide the first transcriptomic evidence to associate reduced GPX4 
expression with dysfunctional mitochondria, particularly in relation to alteration in the mitochondrial 
oxidative phosphorylation and biosynthesis of ubiquinone in gut epithelial cell.  Further investigation 
into the effects of these altered biological pathways through biological network analysis revealed 
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changes in mitochondrial electron transport complexes I, IV and V and its components. The mRNA 
expression of most of the genes within these complexes were up-regulated except for NDUFA10 which 
was down-regulated. Validation of the microarray experiment using qRT-PCR confirmed the same 
pattern of change in gene expression in the selected genes as observed in the microarray data.  
Using  protein extracted from the GPx4 knock-down experiment using siRNA(1), expression levels of 
protein encoding components of the mitochondrial electron transport chain complex I and IV were 
assessed by Western blotting. Depletion of GPX4 resulted in a significant reduction in protein 
expression of protein encoding the complex I and IV of the mitochondrial electron transport chain. 
NDUFB8 and COX2 are strong functional indicators of mitochondrial electron transport chain complex 
I and IV respectively (Funk & Schnellmann, 2012; Matsumoto et al., 2012).  To confirm that these 
findings with the first siRNA were not by chance, a second siRNA specific to GPX4 was utilized. 
Treatment with this second siRNA led to efficient GPX4 knock-down and this was accompanied by 
increases in NDUFB8 and COX2 components of mitochondrial complexes I and IV of electron transport 
chain. Protein expression levels of NDUFB8 and COX2 were increased by ~40% and 50% respectively 
following GPX4 knock-down with a second siRNA (Figure 16C), indicating that the previous findings 
with the first siRNA were not by chance.  
Interaction with allosteric effectors allows the rapid regulation of OXOPHOS activity to occur. Non-
catalytic binding sites for ADP and ATP in various enzymes and or proteins (Wierenga et al. 1986; 
Rajagopalan et al. 1999; Robblee et al. 2005; Inoue and Shingyoji 2007), including ATP synthase 
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(Walker et al. 1982), have been identified. The regulatory ability of enzyme activity to bind ADP or 
ATP to the same site depending on ATP/ADP ratio has been shown for complex IV (COX) subunits. 
Mammalian OXOPHOS comprises of five enzyme complexes of multiple subunits. Complex I (NADH 
dehydrogenase) comprises of 45 subunits, 4 subunits in complex II (succinate dehydrogenase), 11 
subunits in complex III, 13 subunits in complex IV, and 17 subunits in complex V (ATP synthase) 
(Carroll et al. 2009; McKenzie et al. 2009). The complexes must be appropriately encoded, partly on 
mtDNA and partly by nuclear DNA (except for complex II). Complex formation requires multiple 
assembly factors and in case of defects, or alterations, may result in various mitochondrial diseases 
(Kadenbach 2012).  
Following ischemia and reperfusion, transgenic mice overexpressing mGPX4 showed reduced levels of 
lipid peroxide compared to the control group (Dabkowski et al., 2008). These mice also exhibited 
increased electron transport chain complex I, III, and IV activities in the heart compared with control 
mice following ischemia reperfusion. The same study showed that overexpression of mGPX4 increased 
complex I, III, IV activities in subsarcolemmal mitochondria and electron transport chain complex I and 
III activities in interfibrillar mitochondria. These results from Dabkowski suggested that overexpression 
of mitochondrial form of GPX4 protects cardiac contractile function and preserves electron transport 
chain complex activities following ischemia (Dabkowski et al., 2008). These findings complement the 
work described in this thesis in the sense that reduced GPX4 would result in the loss of function in 
living organisms, whereas, increased expression of GPX4 would lead to a gain in function. Since the 
Western blotting data indicate that GPX4 knock-down led to changes in expression of components of 
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complexes I and IV, findings that correlate with the observed changes in RNA expression of genes 
expressing components of these complexes, an investigation into mitochondrial integrity and function 
was carried out, as described in the next Chapter. 
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Chapter 4: Investigation of mitochondrial function and integrity following GPX4 
knock-down 
4.1 Introduction  
Deleterious Reactive oxygen species (ROS) modify biological molecules such as nucleic acids, proteins 
and lipids, and this can result in cell abnormalities (Droge, 2002; Rhaods et al., 2006). On other hand, it 
has been widely shown that ROS play vital roles in various signaling cascades that regulate the balance 
between biological processes such as cellular respiration, cell growth, differentiation and death (Brand 
& Nicholls et al., 2011). Alteration or imbalance in ROS regulation could cause damage in organelles 
such as the mitochondria (Laloi et al., 2004; Clifton et al., 2005). To maintain normal cell function, a 
precise balance between ROS generating processes and ROS degrading processes is crucial. Glutathione 
peroxidases (GPx) are family of selenium dependent enzymes known for their cellular protective 
function against ROS. At the expense of reduced glutathione, GPx reduces hydroperoxides to the 
corresponding alcohols. In particular, GPx4 scavenges lipophilic hydroperoxides and in mice, 
knockdown of this gene leads to abnormal embryonic development and lethal phenotypes in mice 
(Borchert et al., 2006).  
Energy is essential for biological processes and is mostly based on the synthesis of high energy 
adenosine triphosphate (ATP) by either glycolysis or oxidative phosphorylation (Jezek & Havata 2005). 
Adenosine diphosphate is converted to ATP through the reduction of nicotinamide adenine dinucleotide 
(NADH) as electron donor and oxygen as electron acceptor in the electron transport chain (Muller et al., 
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2004). However, oxidative metabolism is a potential hazard due to ROS and reactive nitrogen species 
(RNS) being formed as byproducts, particularly the superoxide anion and hydroxyl radical (OH˙) 
(Kowaltowski et al., 2009). ROS and RNS have the ability to remove electrons from other molecules 
and transform them into free radicals and the resulting free radicals are able to modify biological 
molecules and macromolecules such as polysaccharides ( Kaur & Halliwell, 1994), DNA (Richter et al., 
1988; LeDoux et al., 1999), RNA (Stadtman & Levine, 2000), proteins (Carney et al., 1991) and lipids 
(Rubbo et al., 1994) and can alter their function (Sweetlove et al., 2002; Winger et al., 2005).   
GPX4 is a unique glutathione peroxidase using phospholipid hydroperoxides as a substrate (Brigelius-
Flohe, 1999; Imai & Nakagawa 2003; Bellinger et al., 2009), and in Chapter 3 data is presented to 
indicate that knock-down of GPX4 expression leads to changes in expression of components of the 
mitochondrial electron transport chain complexes. Therefore, one possibility is that the changes in 
complexes I, IV, and V observed following GPX4 knock-down may be due to alterations in the 
mitochondrial membrane, changes in lipid peroxide status and mitochondrial damage as a result of 
increase in ROS. Such damages would also be expected to possibly lead to alterations in mitochondrial 
function. 
Measurement of mitochondrial respiration is an important tool for understanding regulation of cellular 
bioenergetics and provides an appropriate indication of the function of mitochondria (Schuh et al., 
2012). Hence, experiments were carried out to investigate mitochondrial respiration and parameters of 
mitochondrial membrane integrity following GPX4 knock-down in Caco-2 cells. There are different 
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approaches to investigate mitochondrial function and dysfunction particularly with respect to cellular 
respiration. Measurements of fluxes by oxygen electrode give information about mitochondrial ability to 
maintain stable cellular respiration and synthesize ATP (Fernyhough et al., 2010; Ferreira et al., 2010). 
Cell respiratory control has been shown to be the best approach for the study of cell respiration and this 
approach reports proton leak rate, coupling efficiency, maximum respiratory rate, respiratory control 
ratio, spare respiratory capacity and ATP synthesis while measurement of mitochondrial membrane 
potential provides additional useful information (Fernyhough et al., 2010; Brand & Nicholls, 2011). In 
the present experiments, respiration was measured using an oxygen electrode (Chapter 2, Section 2.10). 
In addition, other parameters of mitochondrial function were measured: ATP levels using a recombinant 
firefly luciferase assay (Chapter 2, Section 2.8), mitochondrial membrane potential using JC-1 (Chapter 
2, Section 2.9), lipid peroxide levels using thiobarbituric acid measurements (Chapter 2, Section 2.6), 
cellular ROS and mitochondria superoxide levels by carboxy-H2DCFDA and MitoSOX™ Red  
methods respectively (Chapter 2, Section 2.7 & 2.7.1 respectively).  These measurements were made to 
test the hypothesis that GPX4 knock-down led to mitochondrial oxidative stress. To address this, levels 
of both mitochondrial oxidative stress were measured after GPX4 knock-down. Finally, cell viability 
was assayed using CellTiter-Blue® array (Chapter 2, Section 2.5). 
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4.2.1 Impact of GPX4 knock-down on Lipid peroxides and ROS. 
Caco-2 cells were seeded and transfected after 24 h with either GPX4-siRNA or a scrambled negative 
control siRNA. Seventy two hours after transfection, cells were assayed specifically for lipid peroxides 
and mitochondrial superoxide, GPX4 knock-down with GPX4-siRNA(1) led to a two-fold increase in 
lipid peroxidation (Figure 17A) and a two-fold increase in mitochondrial superoxide (Figure 17B); the 
latter may reflect not only increased mitochondrial superoxide levels but also increased activity of other 
one-electron oxidants such as cytochrome c and H202 (Lowes & Galley, 2011). Treatment with a second 
GPX4-siRNA also showed increase mitochondrial ROS formation (Figure 18A), confirming that these 
effects are specifically due to knock-down of GPX4 and not due to off-target effects.   
 
4.2.2 Impact of GPX4 knock-down on mitochondrial membrane potential (ΔΨm) 
and ATP production 
Since both superoxide formation and mitochondrial membrane damage have been reported to impair 
oxidative phosphorylation (Hamanaka & Chandel, 2010) and ATP synthesis (Szeto et al., 2009), 
measurement of mitochondrial membrane potential and mitochondrial ATP levels were measured after 
GPX4 knock-down. GPX4 knock-down led to a significant reduction in mitochondrial membrane 
potential a marker of mitochondrial membrane damage by ~ 24% (Figure 19A), and a decrease in 
mitochondrial ATP by ~30% (Figure 19B).  compared with cells treated with the control siRNA 
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Overall, these results suggest that GPX4 protects mitochondria from oxidative damage and plays a 
crucial role in regulating and maintaining the oxidative phosphorylation system and ATP synthesis.  
 
4.2.3 Effects of GPX4 knock-down on mitochondrial respiration and cellular ROS 
To further explore the consequences of GPX4 knock-down on mitochondrial function, direct 
measurements of mitochondrial respiration were made in Caco-2 cells treated with either GPX4-
siRNA(1) or the scrambled negative control siRNA. Oxygen consumption was monitored following 
addition of metabolic inhibitors and the physiological respiratory control state, uncoupled respiratory 
capacity, and rotenone+antimycin A sensitive respiration and the uncoupling and respiratory ratios 
calculated.  As shown in Figure 20A, cells depleted of GPX4 did not show a statistically significant 
difference in electron transport capacity in routine respiratory state (Cr) compared to control cells. Cells 
treated with GPX4 siRNA(1) did not show a statistically significant difference in electron transport 
capacity related to non-phosphorylating respiration (Cro) compare to control cells. A change in electron 
transport capacity in relation to non-phosphorylating respiration would have been an indication of 
proton leak. There was also no statistically significant difference in total uncoupled electron transport 
capacity related to phosphorylation (Cru & CruRA). Although there was no statistical difference in flux 
ratios between these cells, it should be noted that small changes in cellular respiration may indicate 
biologically significant mitochondrial defects (Hutter et al., 2004).   
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 Following cell treatment with GPX4-siRNA (1), cellular ROS levels were assessed using carboxy-
H2DCFDA. As shown in (Figure 20B ), carboxy-H2DCFDA fluorescence showed no significance 
difference in cellular ROS between cell treated with GPX4-siRNA (1) and negative control siRNA, 
suggesting that GPX4 knock-down does not affect overall cellular ROS. 
 
4.2.4 Impact of GPX4 knock-down on cell Viability 
To investigate the possible effect of GPX4 knock-down on cell viability which could have  resulted from 
changes in lipid peroxide, ATP and mitochondrial membrane potential,  effects of GPX4 knock-down on 
cells viability was carried out. As shown in Figure 21, no difference in cell viability was observed in 
GPX4 knock-down cells compared to cells treated with scrambled negative control siRNA.  
 
4.2.5 Effects of GPx4 knock-down on mitochondrial superoxide and ΔΨm with 
GPX4-specific siRNA(2)  
Following treatment of cells with the second GPX4-siRNA, assessment of mitochondrial superoxide 
levels and mitochondrial membrane potential was carried out (Figure 18). Treatment with the second 
GPX4-siRNA showed a ~50% increase in mitochondrial superoxide formation and a ~30% decrease in 
mitochondrial membrane potential indicating, that these effects are due to knock-down of GPX4 and not 
off-target effects.   
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Figure 17. Assessment of lipid peroxide and superoxide level following GPX4 knock-down with 
GPX4-siRNA(1). 
 Caco-2 cells were treated with 20 nM of GPX4-siRNA (1) or a scrambled negative control siRNA. (A) 
Levels of lipid peroxidation and (B) mitochondrial superoxide were assessed following treatment.  
Cells treated with negative control siRNA were used as controls and their mean percentage values 
were used to calculate changes in siRNA treated cells. Values shown are mean ± s.e.m. n=6 for each 
assay and groups were compared using a Mann-Whitney U test, * p<0.05, ** p<0.01. 
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 Figure 18. Assessment of mitochondrial membrane integrity and oxidative stress following GPX4 knock-down 
with siRNA(2).  
Caco-2 cells were treated with 20 nM  of GPX4-siRNA (2) or a scrambled negative control siRNA. (A) Levels 
of mitochondrial superoxide and (B) mitochondrial membrane potential were assessed. (A) Mitosox 
fluorescence showed increase in ROS (superoxide) levels in cells treated with 20 nM GPX4-siRNA(2) 
compared with cells treated with a negative control siRNA. (B) Mitochondrial membrane potential (MMP) was 
lower in cells treated with 20 nM GPX4-siRNA(2) compared with cells treated with a negative control siRNA.  
Values shown are mean ± s.e.m. n=6 for each assay and groups were compared using a Mann-Whitney U test, 
* p<0.05, ** p<0.01 
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Figure 19. Assessment of mitochondrial membrane potential and mitochondrial ATP following GPX4 knock-
down with GPX4-siRNA(1).  
Caco-2 cells were treated with 20 nM of GPX4-siRNA (1) or negative control siRNA.  Mitochondrial 
membrane potential (A) and mitochondrial ATP (B) were assessed following treatment. (A) JC-1 fluorescence 
showed an approximate 30% decrease in cells treated with 20 nM  GPX4-siRNA compared with cells treated 
with a scrambled negative control siRNA. (B) ATP/ADP ratio were lower in cells treated with 20 nM GPX4-
siRNA compared with cells treated with  a scrambled  negative control siRNA.  Cells treated with negative 
control siRNA were used as controls and their mean percentage values were used to calculate changes in 
siRNA treated cells. Values shown are mean ± s.e.m. n=6 for each assay and groups were compared using a 
Mann-Whitney U test, * p<0.05, ** p<0.01 
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Figure 20. Assessment of mitochondrial respiration and overall cellular ROS following GPX4 knock-down 
with GPX4 siRNA(1).  
Caco-2 cells were treated with 20 nM of the GPX4-siRNA(1) or a scrambled negative control siRNA. (A) 
Investigation of functional capacity of the mitochondria after GPX4 knock-down. Cellular oxygen 
consumption was measured in a respirometer by measurement of resting respiration (Cr) successive addition 
of oligomycin (CrO), carbonyl cyanide p-(trifluoromethoxy) (FCCP) (Cru), rotenone and antimycin (CruRA) 
(inhibitors of mitochondrial complex V, uncoupler, and inhibitor of complex I and III respectively). (B) 
Cellular ROS were assessed following carboxy-H2DCFDA treatment. Mean percentage values for cells treated 
with negative control siRNA were used to calculate changes in siRNA treated cells. Values shown are mean ± 
s.e.m. with n=6 for cellular oxygen consumption measurements and n=6 for cellular ROS measurements. 
Group (A) were compared using One-way Anova, whereas ROS Groups were compared using a Mann-
Whitney U test, * p<0.05, ** p<0.01. 
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Figure 21. Assessment of cell viability following cell treatment with either GPX4-siRNA(1) or 
negative control siRNA. 
Cells were treated with either siRNA or with tert-butylhydroperoxide (tBooH) as a positive control. 
tBooH treatment caused a loss of cell viability. There was no difference in levels of viable and non-
viable cells between cells treated with GPX4-siRNA(1) and scrambled control group.  Cells treated 
with negative control siRNA were used as controls and their average mean percentage values were 
used to calculate changes in siRNA treated cells. Values shown are mean ± S.D for n=6 and groups 
were compared using a Mann-Whitney U test. 
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4.3 Discussion 
The antioxidant enzyme GPx4 has the ability to reduce complex lipid hydroperoxides in addition to 
hydrogen peroxide and other organic hydroperoxides (Latchoumycandane et al., 2012). As GPx4 is a 
ROS scavenger (Ufer & Wang, 2011), GPX4 depletion is likely to bring about increased levels of ROS 
in mammalian cells. Previous studies of transgenic GPX4+/- mice and fibroblast derived from such mice 
have shown impairments of responses to oxidative stress (Ran et al., 2003; Garry et al., 2008).Two 
studies have been carried out since the start of this work and suggested GPX4 depletion leads to 
increased ROS production, lipid peroxide production, coupled with reduced mitochondrial integrity and 
impairment in ATP production (Latchoumycandane et al., 2012; Yoo et al., 2012). Knock-down of 
GPX4 in Jurkat cells enhanced phospholipid peroxidation, increased TNFα-stimulated azelaoyl 
phosphatidylcholine (AZ-PC) formation and  increased apoptosis, resulting in mitochondrial damage 
(Latchoumycandane et al., 2012). Study of transgenic mice in which the GPX4 gene was ablated by 
tamoxifen administration showed that the mice exhibited increased mitochondrial damage, increased 
lipid peroxides (assessed by elevated 4-hydroxylnonenal (4-HNE), a strong indicator of lipid peroxide), 
decreased activity of the mitochondrial electron transport chain and reduced ATP synthesis, supporting 
the data in this thesis and highlighting the importance of GPx4 in the maintenance of mitochondrial 
integrity (Yoo et al., 2012). 
In another recently published study increased GPx4 activity in selenium supplemented rats was found to 
protect from elevated thiobarbituric acid formation, a byproduct formed from lipid peroxidation and 
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observed in selenium depleted rats with low GPX4 activity (Erkekoglu et al., 2012). In addition, 
decreased activity of GPX4 together with decreased level of other antioxidants such as SOD1 and GPx1 
resulted in enhanced levels of malondialdehyde (MDA) and oxidative stress in the hippocampus of 
immature rat brain subjected perinatally, to lead exposure, indicating that disruption of antioxidant 
balance, including that of GPX4, increases oxidative stress (Baranowska-Bosiacka et al., 2012). Knock-
down of GPX4 by siRNA increased VEGF and IL-8 expression resulting in increased linoleic acid 
peroxide (LOOH) in human HCC cell lines and these findings were further confirmed in a rat 
hepatocarcinogenesis model. Selenium treatment in these models increased GPX4 expression and 
reduced the expression of VEGF and AP-1 (Rohr-Udilova et al., 2012).  
Co-overexpression of superoxide dismutase 1 (SOD1) with GPX4 reduced oxidative damage in the 
retina and slowed the loss of cones in mice deficient of SOD1, whereas, increased expression of either 
SOD1 or SOD2  could not rescue these mice from oxidative damage and loss of cones led to Retinitis 
Pigmentosa (RP). The observations from this study suggest that over-expression of SOD must be 
combined with expression of a peroxide scavenging enzyme such as GPX4 to combat RP-induced 
oxidative damage and loss of cone cell function (Usui et al., 2011). Overall the studies outlined above 
indicate that GPX4 has an important role in controlling ROS level and limiting mitochondrial damage 
and the findings described in this thesis (from the GPX4 knock-down in human gut epithelial cell line 
(Caco-2)) strongly support the hypothesis that GPx4 has a vital role in protecting cells from ROS and 
mitochondrial damage. 
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Mitochondria are the major source of energy in all eukaryotic cells, producing ATP through oxidative 
phosphorylation and the citric acid cycle. Mitochondria play a role in the modulation of apoptosis 
through the release of several cell death-inducing molecules (Lenaz et al., 2002; Ravagnan et al., 2002). 
Many studies have been carried out to elucidate the behaviour and function of mitochondria in most cell 
lines.  Mitochondrial membrane potential is a key indicator of cellular viability due to its reflection of 
the pumping of hydrogen ions across the inner membrane during the process of electron transport and 
oxidative phosphorylation which is the driving force behind ATP synthesis. The lipophilic 
mitochondrial probe JC-1 can be utilized to estimate changes in membrane potential (ΔΨm).  JC-1 is a 
sensitive probe widely used in different cell lines for assessment of ΔΨm and has been used in to 
investigate ΔΨm in mouse (Wilding et al., 2011) and human female germ cells (Van Blerkom et al., 
2002).  
Following GPX4 knock-down, JC-1 was used to assess ΔΨm in both siRNA treated cells and control 
cells. GPX4-siRNA treated cells exhibited a significant reduction in ΔΨm compared to cells treated with 
scrambled control siRNA and this result was confirmed with a second GPX4-siRNA. Majority of 
mitochondrial functions such as ATP synthesis and lipid biogenesis depend on the stability and 
maintenance of ΔΨm (Voisine et al., 1999). A study comparing wild type mice and transgenic mice 
overexpressing GPX4 showed a significant decline in mitochondrial ATP synthesis in livers of wild type 
mice after exposure to diquat compare to the transgenic mice. The same study observed reduced ΔΨm in 
wild type mice following diquat treatment, however ΔΨm was attenuated in mice overexpressing GPX4 
suggesting that decreased ATP production under oxidative stress is primarily due to reduced ΔΨm and 
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that overexpression of GPX4 maintains ΔΨm under oxidative stress (Liang et al., 2007). The same 
group also showed that transgenic mice overexpressing GPX4 exhibited reduced levels of liver damage 
and lipid peroxidation induced by diquat concomitant with reduced apoptosis, increased caspase-3 
activation and reduced cytochrome c release from mitochondrial (Liang et al., 2004).  
Investigation of lipid peroxide levels was carried out in both siRNA treated cells and cells treated with 
scrambled control siRNA and the data showed increased lipid peroxidation in siRNA treated cells 
compared with the corresponding controls.  Lipid hydroperoxides are primarily produced when lipids 
are damaged by 1-electron oxidants, such as the tyrosyl radical and nitrogen radical. Advanced products 
of oxidation such as alkanes, aldehydes and isoprostanes can be generated through peroxidation of lipid 
(Moore & Roberts, 1998).  During the peroxidation of unsaturated fatty acids or tissue lipids, 
malonaldehyde is produced which reacts with thiobarbituric acid to produce a pink colour that can be 
measured colorimetrically (Niehaus & Samuelsson, 1968). Malonaldehyde forms through peroxidation 
of arachidonic acid and is often considered the most accurate way to measure oxidative stress in vivo 
and in vitro, and has been used extensively as a biomarker of lipid peroxidation a risk factor for various 
kinds of diseases (Janero, 1990). Formation of malonaldehyde observed in cells treated with GPX4-
siRNA was higher than in control cells, suggesting that reduced expression of GPX4 exposes cells to 
increase levels of oxidative damage. The increases in lipid peroxidation and ROS are consistent with 
earlier observations that over-expression of GPX4 leads to lower levels of mitochondrial cardiolipin 
peroxidation (Liang et al., 2004). As previously discussed, transgenic mice overexpressing the GPX4 
gene were protected from oxidative damage induced by lipid peroxide (Liang et al., 2007). The study 
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described in this thesis showed the importance of GPX4 in protecting human gut epithelial cells from 
lipid peroxide induced-oxidative damage. This strongly supports the findings of Liang and Colleagues.  
Considering the observed changes in lipid peroxide and ATP synthesis, investigations of levels of 
mitochondrial superoxide formation were also carried out. Increase in mitochondrial ROS has been 
previously shown to be one of the contributors to mitochondrial oxidative damage, mitochondria DNA 
damage and reduced mitochondria integrity either through alterations of the mitochondrial electron 
transport efficiency, mitochondrial oxidative phosphorylation or mitochondrial ATP synthesis (Liang et 
al., 2007; Tissier et al., 2012; Zhi et al., 2012). To assess mitochondrial superoxide formation, Caco-2 
cells were treated with MitoSOX following either siRNA or negative control siRNA treatment. 
MitoSOX has been widely used to study the presence of superoxide in vitro and in vivo. A significant 
increase in superoxide formation was observed in siRNA treated cells compared to control cells. 
Embryonic fibroblasts lacking the DJ-1 gene exhibited increased mitochondrial damage, reduced 
mitochondrial ATP production, elevated mitochondrial permeability transition pore and reduced ΔΨm 
associated with increased mitochondrial ROS (Giaime et al., 2012), consistent with increased 
superoxide level leading to mitochondrial damage. 
Investigation into cellular oxygen consumption activities was carried out in intact Caco-2 cells treated 
with siRNA and scrambled control siRNA. To my knowledge, this is the first study of cellular oxygen 
consumption following GPX4 knock-down in a human gut epithelial cell line. Mitochondrial functional 
performance was assessed following GPX4 knock-down by measuring oxygen utilization using complex 
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specific substrates.  Cells depleted of GPX4 did not show a statistically significant difference in electron 
transport capacity in routine respiratory state (Cr) compared to control cells. Compared with control 
cells, cells treated with GPX4 siRNA(1) did not show a statistically significant difference in electron 
transport capacity related to non-phosphorylating respiration (Cro). There was also no statistically 
significant difference in total uncoupled electron transport capacity related to phosphorylation (Cru & 
CruRA) between siRNA treated cells and control cells. The intracellular ROS level was measured using 
5-(and-6)-carboxy-2′,7′-dichlorodihydrofluorescein diacetate (carboxy-H2DCFDA), a cell membrane 
permeability indicator  that only fluoresces when acetate groups are abolished by intracellular esterases 
and oxidation takes place in the cell. Carboxy-H2DCFDA is converted to the fluorescent form DCF 
irreversibly when oxidized by various kinds of reactive oxygen species (Shimizu et al., 2004) and has 
been widely used as a general oxidative stress detector (Hansen-Hagge et al., 2008; Naha et al., 2010; 
Dickie et al., 2012; Kimura et al., 2012; Yang et al., 2012;).  As shown in Figure 20B, no change in 
intracellular ROS was observed in GPX4-siRNA treated cells compared with the control group and this 
finding suggests that although GPX4 is known to protect cells from oxidative damage, there may be 
other compensatory factors such as other antioxidants e.g. GPX1 and Catalase that can limit any 
increase in oxidative stress when GPX4 activity is compromised. This finding also suggests that GPX4 
knock-down alone is not enough to bring about changes in overall intracellular ROS.  
Changes in membrane permeability and increases reactive oxygen species have been associated with 
either loss or reduced cell viability (Chen et al., 2012; Fatemi et al., 2012; Kim et al., 2012). 
Considering the observed changes in ΔΨm, lipid peroxide and superoxide following GPX4 knock-down 
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in Caco-2 cells, cell viability was investigated in order to assess the effects of the observed changes in 
cell growth and stability. As shown in Figure 21, there was no difference in cell viability between Caco-
2 cells treated with GPX4-siRNA and negative control siRNA. This observation suggests that GPX4-
siRNA treatment for 72 h does not have any obvious impact on cell viability.  
Overall, the data described in this Chapter indicates that reduced expression of GPX4 alters 
mitochondrial integrity through altered levels of mitochondrial ROS, lipid peroxide, ΔΨm and ATP,  but 
not cellular ROS, and that the observed changes do not interfere with cell viability. GPX4 knock-down 
led to changes in protein expression of components of complex I and IV of the mitochondrial electron 
transport chain complexes. These findings correlate with the observed changes in genes expressing 
components of these complexes, increased lipid peroxide and mitochondrial superoxide, decreased ΔΨm 
and ATP synthesis, reflecting changes in mitochondrial metabolism. Overall, the data indicate that 
GPX4 knock down altered the functions of Complex I and IV and resulted in increased mitochondrial 
ROS production and reduced mitochondrial function and integrity. Considering the observed changes in 
mitochondrial function and integrity, it appears that GPX4 knock-down also alters mitochondria stability 
either through increased production of lipid peroxides or through multiple mechanisms. As described in 
Chapter 3, GPX4 knock-down led to change in mRNA expression of components of mitochondrial 
electron transport complexes I, IV and V and changes in protein expression of components of complex I 
and IV. The microarray data indicated AIF mRNA expression to be altered and network analysis 
indicated this as a key regulatory component. Since AIF has been reported to be a regulator of 
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expression of complex I and IV, further work was carried out to investigate AIF protein expression 
following GPX4 knock-down, as described in the next Chapter. 
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Chapter 5: Investigation of the impact of GPX4 knock-down on AIF expression 
5.1 Introduction 
 Microarray data from the GPX4 knock-down experiment indicated a change in expression of AIF 
(Figure 15). Inducible inactivation of GPX4 in mice resulted in 12/15-lipoxygenase-derived lipid 
peroxidation and activation of AIF (Seiler et al., 2008). AIF is thought both to be part of a mitochondrial 
apoptotic signalling and to play a role in oxidative phosphorylation by modulating the structure and 
function of complex I of the respiratory chain (Vahsen et al., 2004; Joza et al., 2009).  The observed 
effects of knock-down on mitochondrial complex I and IV function were followed by measuring levels 
of the AIF protein. AIF has been reported to regulate complex I and IV activity but also to change 
expression and activity itself following oxidative stress or activation of apoptosis (Daugas et al., 2000; 
Vahsen et al., 2004; Joza et al., 2009;).  As discussed in Chapter 4, GPX4 knock-down resulted in 
altered levels of mitochondrial ROS and lipid peroxide levels, and therefore time-course experiments 
were also carried out to explore the relationship between ROS and AIF levels following GPX4 knock-
down.   
Pro-apoptotic signal molecules induce mitochondrial outer membrane permeability thereby activating 
the release of mitochondrial proteins (Natarajan & Becker, 2012). AIF is a flavoprotein, which is 
confined to the mitochondrial intermembrane space of healthy cells (Natarajan & Becker, 2012). AIF 
has been shown to translocate via the cytosol to the nucleus upon apoptotic signaling and in the nucleus 
it binds to DNA and induces caspase-independent DNA fragmentation (Natarajan & Becker, 2012; 
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Wang et al., 2012). AIF has been shown to have oxidoreductase activity and interact electrostatically 
with double-stranded DNA (Joza et al., 2001). In this chapter, Western blotting was used to assess AIF 
protein levels after GPX4 knock-down and a time course experiment carried out to investigate the 
relationship between changes in AIF, NDUFB8 and COX2. 
 
5.2 Impact of GPX4 knock-down on AIF protein expression 
To study AIF protein expression, Caco-2 cells seeded 24 hours previously at 3.5 x 10
5
 cells/well in a six 
well plate were transiently transfected with either 20 nM GPX4-siRNA(1) or  GPX4-siRNA(2) or 
negative control siRNA. Seventy two hours following transfection, cells were lysed, total cell lysate 
extracted and AIF protein assayed by Western blotting using anti-AIF antibody. As shown in Figure 
22A-B, densitometry analysis of the protein band showed that treatment with GPX4-siRNA (1) led to 
~100% increase in levels of AIF protein and 40% increase following treatment with GPX4-siRNA(2).   
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Figure 22. Expression of AIF protein following GPX4 knock-down. 
 Caco-2 cells were treated with 20 nM of (A) GPX4-siRNA(1) and (B) GPX4-siRNA(2) and scrambled 
negative control siRNA. Total protein was extracted following knock-down and AIF protein 
expression assayed by Western blotting and intensity of the protein bands carried out by densitometry. 
Protein level was calculated relative to β-actin, and further calculated as a percentage of the mean 
value for cells treated with the negative control siRNA. Western panels = 2 wells, values shown are 
mean ± s.e.m. for n=6. A statistically significant increase in AIF protein expression was observed in 
cells depleted of GPX4 compared to control cells. Groups were compared using a Mann-Whitney U 
test, * p<0.05, ** p<0.01 
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In further experiments, after knock-down with GPX4-siRNA(1) cells were harvested and cytosolic and 
mitochondrial fraction prepared. After Western blotting, densitometry analysis of the protein bands was 
carried out and the results showed that GPX4 knock-down led to an increase in AIF levels in both 
fractions with the mitochondria fraction showing ~ 58% increase and cytosolic fraction ~38% increase, 
as shown in Figure 23. 
 
Figure 23. Expression of AIF in mitochondrial and cytosolic fractions following GPX4 knock-down 
with siRNA(1). 
 Caco-2 cells were treated with 20 nM of GPX4-siRNA(1) or a scrambled negative control siRNA for 
72 h. Mitochondrial and cytosolic fractions prepared following knock-down and AIF protein 
expression assessed by Western blotting. AIF levels were calculated relative to β-actin for cytosolic 
fractions and in the case of isolated mitochondria succinate dehydrogenase (SDH) was used as the 
housekeeping control. Protein expression was then calculated as a percentage of the mean value for 
cells treated with the negative control siRNA. Western panels = 2 well, values shown are mean ± 
s.e.m. for n=4  A statistically significant increase in AIF protein expression was observed in both 
fractions in cells depleted of GPX4 compared to control cells. Groups were compared using a Mann-
Whitney U test, * p<0.05, ** p<0.01 
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5.3 A time-Course study to investigate the impact of GPX4 knock-down on 
NDUFB8, COX2 and AIF protein expression and on ΔΨm, lipid peroxide and ROS. 
To further explore the roles of ROS and AIF in the sequence of events in the mitochondria following 
GPX4 knock-down, a time-course experiment was carried out in which  GPx4, AIF, NDUBF8 and 
COX2 levels were measured by Western blotting using Caco-2 protein extracts; levels of  lipid peroxide, 
ΔΨm and mitochondrial superoxide were also assessed. Caco-2 cells were treated with either GPX4-
siRNA(1) or negative control siRNA for 24, 36, 48, 60 or 72 h. Cells were lysed and protein extracted 
from total cell lysate was then used to assess protein expression levels of GPx4, AIF, NDUFB8 and 
COX2. GPx4 protein at the different time points was monitored by Western blotting. As shown in 
Figure 24A, GPx4 protein expression was significantly reduced at the different time points investigated. 
Following confirmation of GPx4 knock-down at protein level, the extracted protein samples from the 
knock-down experiment were used to monitor the protein levels of AIF, NDUFB8 and COX2 by 
Western blotting using anti-AIF, NDUFB8 and COX2 antibodies. As shown in Figure 24B, the time-
course data showed a 80% increase in level of AIF by 24 h after addition of GPX4-siRNA but levels of 
NDUFB8 and COX2 did not increase until later at 36 h.  
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Figure 24. A time-course assessment of GPx4, NDUFB8, COX2 and AIF protein following GPX4 
knock-down with siRNA(1).  
Caco-2 cells were treated with 20 nM of GPX4-siRNA(1) or a scrambled negative control siRNA. 
Total protein was extracted 24, 36, 48, 60 and 72 h after knock-down. (A) Expression of GPx4 protein 
expression at different time points following GPx4 knock-down by Western blotting using anti-GPx4 
antibody. (B) Expression of AIF, NDUFB8 and COX2 proteins at 24, 36, 48, 60 and 72 h following 
GPX4 knock-down. Data shown in figure 24B are from protein extracted 24 h following GPx4 knock-
down. Protein expression levels were calculated relative to β-actin as the control and then as a 
percentage of the mean value for cells treated with the negative control siRNA. Western panels = 1 
well for each protein, values shown are mean ± s.e.m. for n=4 for each protein. Groups were 
compared using a Mann-Whitney U test, * p<0.05, ** p<0.01. 
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Previous experiments described in Chapter 4 showed changes in ΔΨm, lipid peroxide and mitochondrial 
superoxide following GPX4 knock-down at 72 h. Investigations of earlier events would help to 
understand the sequence of events particularly in relation to changes in these parameters. To investigate 
the sequence of events in relation to mitochondrial integrity following GPX4 knock-down, a time-course 
assessment of ΔΨm, lipid peroxide and superoxide production was carried out in Caco-2 cells treated 
with either GPX4-siRNA(1) or the scrambled negative control siRNA. Briefly, cells were seeded in a six 
well plate and transfected 24 hours later with either GPX4-siRNA(1) or negative control siRNA for 24 
and 36 h respectively. The time-course data showed that ΔΨm had decreased by ~56% at 24 h and~ 
68% at 36 h after addition of GPX4-siRNA (Figure 25A) levels of lipid peroxide had increased by ~30% 
at 24 h and ~37% at 36 h (Figure 25B) and mitochondrial superoxide levels had increased by ~124% at 
24 h and ~125% at 36 (Figure 25C) after GPX4-siRNA(1) treatment.  
A 
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Figure 25. Time-course of mitochondrial integrity, oxidative stress following GPX4 knock-down with 
siRNA(1) 
Caco-2 cells were subcultured and 42 h later transfected with GPX4-siRNA(1) and scrambled 
negative control siRNA. Twenty four and 36 h following transfection cells were harvested and 
assayed for mitochondrial membrane potential, lipid peroxides and superoxide.  (A) Assessment of 
Mitochondrial membrane potential at 24 and 36 h after treatment with either GPX4-siRNA(1 )or 
negative control siRNA. (B) Levels of lipid peroxide were investigated using thiobabituric acid. (C) 
Assessment of mitochondrial superoxide levels were assayed using MitoSOX 24 and 36 h after 
treatment with GPX4-siRNA(1) and scrambled negative control siRNA. For all assays cells treated 
with negative control siRNA were used as controls and their mean percentage values were used to 
calculate changes in siRNA treated cells. Values shown are mean ± s.e.m. n=6. Groups were 
compared using a Mann-Whitney U test, * p<0.05, ** p<0.01. 
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5.3 Discussion 
The microarray data from the GPX4 knock-down experiment in Caco-2 cells showed altered expression 
of AIF mRNA as a central component of a mitochondrial network (Figure 17). Altered expression of 
AIF protein was also observed after GPX4-siRNA(1) treatment  and was further confirmed by the 
second GPX4-siRNA Figure 22B. The change in AIF mRNA (down-regulated) and protein (up-
regulated) did not complement each other however, both results were consistent throughout the study. 
The human AIF is a flavoprotein encoding a 67 kDa polypeptide with 613 residues (Sevrioukova, 2009; 
Sevrioukova, 2011). Flavoproteins are known to catalyse  various reactions through the utilization of 
flavin mononucleotide or flavin adenine dinucleotide as cofactors (Joza et al., 2009). The 
oxidoreductase properties of AIF have been associated with oxidative insult, redox homeostasis and 
different cellular process such as apoptosis (Ye et al., 2002). AIF changes intracellular location by 
translocating from the inner mitochondria membrane space to the nucleus upon exposure to apoptotic 
stimuli. AIF plays a very important role in the enhancement of mitochondrial bioenergetics and complex 
I activity/assembly in the maintenance of cellular redox homeostasis (Sevrioukova, 2009).  
After AIF translocation from the mitochondria to the nucleus, a chromatin degradation complex with 
other proteins such as cyclophilin A is formed. The translocation is usually triggered by oxidative stress, 
thereby suggesting the possibility of AIF as a redox sensor in the mitochondria (Sevrioukova, 2011). It 
has also been reported that AIF generates superoxide and plays a significant role in mitochondrial 
function (Miramar et al., 2001).  
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Previous studies have implicated AIF deficiency or low expression of AIF in reduced oxidative 
phosphorylation. Although, AIF itself is not a component of mitochondrial complex I, it has been linked 
strongly with mitochondrial complex I activity as loss of AIF in the mitochondria usually increases 
oxidative stress (Klein et al., 2002; Vahsen et al., 2004; Pospisilik et al., 2007; Koene et al., 2011). A 
study in the early mouse embryo after inactivation of AIF showed impaired activity of mitochondrial 
complex I and increased apoptosis (Brown et al., 2006), suggesting that altered expression of AIF 
results in impaired mitochondrial bioenergetics including respiration and energy metabolism. A study of 
Harlequin mice deficient in AIF also implicated AIF involvement in mitochondrial respiratory activity 
(Klein et al., 2002).  Harlequin mice exhibit significant reduction in AIF mRNA expression (~80%-
90%) compared to wild type mice and have been considered as an appropriate model for the evaluation 
of the physiological role of AIF in the mitochondria, including complex I function and oxidative 
phosphorylation (Klein et al., 2002; Culmsee et al., 2005). Harlequin mice exhibit approximately 50% 
reduced oxidative phosphorylation and complex I function, increased oxidative stress in brain, heart and 
cerebellum, and elevated levels of lipid peroxides and mitochondrial damage (Joza et al., 2001; Klein et 
al., 2002). Additionally, the mice are highly resistant to polyADP-ribose polymerase (PARP) induced 
cell death (Klein et al., 2002) and T cells extracted from Harlequin mice exhibited increased sensitivity 
to Fas-ligand induced apoptosis compared with wild type mice (Joza et al., 2001; Joza et al., 2009).  
Although AIF has been described as an antioxidant enzyme due to the observation of increased levels of 
oxidative stress in Harlequin mice, in vitro knock-down of AIF has not yet provided substantial 
evidence to back up the hypothesis that AIF functions as an antioxidant enzyme (Apostolova et al., 
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2006; Krantic et al., 2007). Cells deficient in AIF exhibited increased loss of cell tumorigenicity as a 
result of loss of complex I activity. Increased oxidative stress has been shown to induce depolarization 
of mitochondrial membrane potential in cultured NRK-52E cells, resulting in activation and increased 
secretion of AIF (Kim et al., 2012). A study investigating the function of GPx4 in photoreceptor cells 
showed that there was a severe degeneration of rods and cones in GPx4 knock-out cells, and nuclear 
translocation of AIF and increased apoptosis (Ueta., et al., 2012).  
Increased levels of AIF protein in both mitochondrial and cytosolic extracts were observed following 
GPX4 knock-down. As discussed previously, AIF translocation involves its migration from the 
mitochondria to the cytosol and further to the nucleus. Observation of AIF in the cytosol was a strong 
indication that AIF indeed translocated from the intermembrane space of the mitochondrial into the 
cytosol and possibly to the nucleus. The presence of AIF in the cytosol of cells treated with GPX4 
siRNA may have been as a result of increased oxidative stress. 
The time-course experiment showed increased level of AIF protein at 24 h after knock-down before 
changes in levels of NDUFB8 and COX2. Also the time course experiment showed decreased ΔΨm at 
24 and 36 h and increased lipid peroxide and mitochondrial superoxide at these time points. These 
observations were a clear indication that knock-down of GPX4 did not cause changes in NDUFB8 and 
COX2 expression which then had secondary effect on superoxide and ΔΨm. Knock-down either 
resulted in changes in the mitochondrial redox state, which then altered AIF expression or altered 
expression of AIF first. Altered AIF expression may have changed the mitochondrial redox state 
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including levels of lipid peroxide, mitochondrial superoxide levels and ΔΨm, resulting in changes in 
mitochondrial complexes I and IV. 
To summarize, the difference  in  the pattern of  AIF expression at mRNA (down-regulated) and protein 
(up-regulated), is difficult to understand. However, the observed increase in AIF prior to that of 
NDUFB8 is consistent with AIF being a key factor in the regulation of the genes encoding components 
of complex 1 in response to GPX4 knock-down. Taken together these data suggest that following GPX4 
knock-down, mitochondrial membrane damage and decreased membrane potential causes changes in 
AIF protein which lead to alterations in expression of complex 1 components. These findings linking 
lower GPX4 expression and changes in expression of components of respiratory complex I and AIF 
strongly suggest that GPX4 plays an important role in mitochondria function. These findings are 
complementary to the earlier observation that lower GPX4 expression leads to altered 12/15 
lipoxygenase activity and AIF-mediated cell death (Seiler et al., 2008; Conrad, M., 2009). The study 
described in this thesis also support earlier observation that absence of GPX4 affects angiogenesis in 
murine embryonic fibroblasts through the increase of 12/15 lipooxygenase activity (an enzyme that 
promotes apoptosis). This finding suggests that GPX4 controls 12/15-LOX activity, which is an 
important regulator of tumor angiogenesis (Schneider et al., 2010). 
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Chapter 6: Investigating the effect of Mitoquinone (MitoQ10) on Caco-2 cells 
following GPX4 knock down. 
6.1 Introduction  
Mitoquinone (MitoQ) is one of the several antioxidants that can be targeted to mitochondria by their 
conjugation to the triphenylphosphonium (TPP) moiety (Asin-Cayuela et al., 2004) (see Figure 25). As 
lipid peroxidation is important in many forms of mitochondrial oxidative damage, and because the 
alkylTPP conjugates strongly associate with the mitochondrial inner membrane (Asin-Cayuela et al., 
2004; Green et al., 2004), the effect of an antioxidant that acts against lipid peroxidation, particularly the 
targeted version of ubiquinol MitoQ10 was further investigated. MitoQ10, when absorbed, accumulates at 
a 5-10 fold higher concentration in the plasma membrane and 100-500 fold higher concentration in the 
mitochondrial membrane (Jauslin et al., 2003). As reported in the preceding chapters, mitochondrial 
superoxide formation seems to be one of the contributors to mitochondrial dysfunction following GPX4 
knock-down in Caco-2 cells; Indeed, results showed changes in ubiquinone biosynthesis pathway, 
protein expression of components of mitochondrial complex I and IV, AIF and changes in levels of lipid 
peroxide, ΔΨm, and mitochondrial ATP.  I hypothesized that MitoQ10 would interfere with the effects 
of GPX4 knock-down, particularly changes in lipid peroxides, since it blocks lipid peroxidation. 
Additionally, MitoQ10 was selected for this study because it is directly targeted to the mitochondria 
(Asin-Cayuela et al., 2004), where it is proposed the initiating events or effects of GPX4 knock-down 
occurred. 
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Figure 26. Structure of Mitoquinone and scheme illustrating its uptake into plasma membranes and 
mitochondrial membranes.  
Mitoquinone accumulates 5 to 10-fold within the cell driven by the plasma membrane potential (ΔΨp) 
and then further accumulates (100 to 500-fold) within the mitochondria driven by the mitochondrial 
membrane potential (ΔΨm). In the mitochondrial matrix MitoQ10 is reduced to the active antioxidant 
form ubiquinol by the respiratory chain; this prevents lipid peroxidation. Antioxidant activity 
produces the ubiquinone form, which is then recycled back to ubiquinol by the respiratory chain 
(Taken from Doughan & Dikalov, 2007). 
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6.1.2 Effect of MitoQ10 on GPX4 mRNA expression in Caco-2 cells. 
Experiments were carried out to ascertain if MitoQ10 treatment has any effect on GPX4 status in Caco-2 
cells. Cells were seeded at 3.5 x 10
5 
per well and 24 h later were treated with  either 1 µM MitoQ10 or 
decyltriphenylphosphonium bromide (DTPP) (a control compound), which has a similar chemical 
structure to MitoQ10, but without the antioxidant ubiquinol moiety. Seventy two hours following 
treatment, cells were lysed and total RNA extracted. The RNA was reverse transcribed to cDNA and 
subjected to RT-PCR using primers specific to GPX4 and GAPDH. As shown in Figure 27, MitoQ10 
treatment did not change the mRNA expression of GPX4.  
 
Figure 27. Confirmation of GPX4 mRNA status following MitoQ10 and DTPP treatment. 
 RNA extracted from duplicate culture of Caco-2 cells treated with either MitoQ10 or DTTP, reverse 
transcribed and PCR carried out using primers specific for GPX4 to assess GPX4 mRNA level or 
GAPDH to assess the level of this housekeeping control. By visual observation, there was no 
difference in GPX4 mRNA expression following either treatments suggesting that the antioxidant 
activity of MitoQ does not alter GPX4 mRNA status. 
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6.1.3 Confirmation of GPx4 knock-down at protein level following treatment with 
GPX4-siRNA (1) and MitoQ10. 
In a second experiment cells were seeded and transfected 24 h later with either GPX4-siRNA or 
negative control siRNA plus 1 µM MitoQ10 concentration. Seventy two hours following treatment, cells 
were lysed and total protein extracted from cell lysate and GPx4 protein assessed by Western blotting 
using anti-GPx4 antibody. Densitometry analysis of the protein bands showed approximately 70% 
reduction in GPx4 protein in cells treated with GPX4-siRNA(1) plus MitoQ10 indicating that MitoQ10 
does not have any impact on the ability of the GPX4-siRNA to knock-down GPx4 protein.   
 
Figure 28. Confirmation of GPX4 knock-down at protein level following siRNA treatment in presence of 
MitoQ10.  
Caco-2 cells were treated for 72 h with GPX4-specific siRNA or scrambled negative control in the presence of 
1 µM MitoQ10 concentration, protein was extracted and GPx4 levels assessed by Western blotting. Protein 
bands were measured by densitometry and GPx4 expression was compared to β-Actin as the control and as a 
percentage of the mean value for cells treated with the scrambled control siRNA.  Western panels = 2 wells, 
values shown are mean ± S.D  for n=4. Groups were compared using a Mann-Whitney U test, * p<0.05, ** 
p<0.01. 
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6.1.4 Effect of MitoQ10 treatment on NDUFB8, COX2 and AIF protein expression 
following GPX4 knock-down in Cacco-2 cells. 
As discussed in Chapters 4, 5 and 6 of this thesis, GPX4 knock-down resulted in changes in protein 
expression of functional markers of complex I and IV of the mitochondrial electron transport chain and 
AIF. I hypothesized that MitoQ10 treatment abrogates the effects of GPX4-siRNA treatment on these 
proteins in Caco-2 cells. Caco-2 cells were treated with either GPX4-siRNA or negative control siRNA 
with or without 1 µM MitoQ10 concentration for 72 h. Total protein was extracted from cell lysates and 
NDUFB8 (Figure 29A), COX2 (Figure 29B) and AIF (Figure 29C) measured by Western blotting using 
antibodies specific to each protein. In the presence of MitoQ10, knock-down of GPX4 has no significant 
effect on NDUFB8 and COX expression. Indeed, MitoQ10 treatment completely abolished the changes 
previously observed in NDUFB8 and COX2 after GPX4 knock-down. AIF protein following MitoQ10 
treatment and GPX4 knock-down remained up-regulated as previously observed in the absence of 
MitoQ10 treatment. 
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Figure 29. Investigation of the impact of MitoQ10 treatment on the effect of GPX4 knock-down on 
mitochondrial complex I and IV functional indicators and on AIF 
Cells were treated with GPX4-specific siRNA(1) or scrambled negative control in the presence of 
MitoQ for 72 h. Total cell protein was subjected to Western blotting for analysis of NDUFB8(A), 
COX2 (B) and AIF (C) (A) Protein expression of NDUFB8 following GPX4 knock-down plus 
MitoQ10 treatment.  (B) Protein expression of COX2 following GPX4 knock-down plus MitoQ10 
treatment. (C) Protein expression of AIF following GPX4 knock-down plus MitoQ10. Protein 
expression levels were calculated relative to β-actin as the housekeeping control and as a percentage 
of the mean value for cells treated with the negative control siRNA. (Western panels = 2 wells), values 
shown are mean ± S.D. n=4 for each protein. Groups were compared using a Mann-Whitney U test, * 
p<0.05, ** p<0.01. 
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As previously shown in Chapter 5 of this thesis, GPX4 knock-down resulted in significant increase in 
mitochondrial superoxide production and lipid peroxide levels, and reduced mitochondrial membrane 
potential. To test the effect of MitoQ10 on these parameters following  GPX4 knock-down, cells were 
seeded in a 96 well plate  at 1 x 10
6
/well and 24 h later transfected with GPX4-siRNA(1) or negative 
control siRNA plus either MitoQ10 or DTPP at 24, 48, and 72 h. Following treatments, cells were 
washed with PBS and assayed for lipid peroxidation using thiobarbituric acid, superoxide using 
MitoSOX and mitochondrial membrane potential using JC-1. As shown in Figure 30, MitoQ10 treatment 
following GPX4-siRNA(1) treatment decreased superoxide and lipid peroxide levels, suggesting that 
MitoQ provided significant protection against oxidative stress (lipid peroxide production, mitochondrial 
superoxide production). Level of lipid peroxides were three fold higher in cells treated with GPX4-
siRNA(1) compared with cells treated with both GPX4-siRNA and MitoQ10 at  three different time 
points (Figure 30A). Cells treated with DTPP also showed high levels of lipid peroxide (Figure 30A). 
Additionally, significant reduction of mitochondria superoxide was achieved following treatment with 
both GPX4-siRNA(1) and MitoQ10 at all three time points, compared to cells treated with GPX4-siRNA 
only (Figure 30B). Mitochondrial membrane potential was higher in cells treated with the GPX4-siRNA 
and MitoQ10 compared to cells treated with siRNA alone (Figure 30C). 
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Figure 30. Effects of MitoQ10 on mitochondrial integrity and oxidative stress following GPX4 knock-
down with siRNA(1).  
Caco-2 cells were treated with 20 nM GPX4-siRNA and either1µM MitoQ10, 1µM of DecylTPP (at 24, 
48, and 72 h) (A) Assessment of lipid peroxide in cells depleted of GPX4 and treated with MitoQ10 and 
in control cells. (B) Assessment of mitochondria superoxide in cells treated with GPX4-siRNA plus 
MitoQ10 and in control cells. (C) Assessment of Mitochondrial membrane potential in cells treated 
with GPX4-siRNA plus MitoQ10 and in control cells. Cells treated with negative control siRNA were 
used as controls and their mean percentage values were used to calculate changes in siRNA treated 
cells. Values shown are mean ± S.D for n=6 for each assay and groups were compared using a 
Mann-Whitney U test, (comparing cells treated with GPX4-siRNA and cells treated with GPX4-
siRNA and MitoQ10)* p<0.05, ** p<0.01. 
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6.2 Discussion 
Mitochondria are a major site of reactive oxygen species (ROS) generation within cells, and there is 
increasing evidence that mitochondrial oxidative stress contributes to a wide range of pathologies, 
including cardiovascular disease, neurodegeneration and aging (James et al., 2005). Production of ROS 
by the mitochondrial respiratory chain (complex I through complex III) occurs under normal 
physiological conditions and is as a result of 1-electron reduction of O2 to superoxide (O2
-
) by the 
respiratory chain, which goes on to produce a range of damaging ROS. Production of  ROS lead to 
nonspecific modification of mitochondrial proteins, lipids, and nucleic acids, thereby altering 
mitochondrial function (Koopman et al., 2005). Mitochondrial DNA is particularly susceptible to 
modification by ROS, and this damage can rapidly lead to functional changes in the cell, because it 
encodes 13 essential polypeptide components of the mitochondrial respiratory chain (Kelso et al., 2000; 
Koopman et al., 2005; Jing et al., 2011). Mitochondria are normally protected from oxidative damage 
by a multilayer network of mitochondrial antioxidant systems and these includes the mitochondrial 
matrix enzyme manganese superoxide dismutase, which converts the O2
-
 anion to hydrogen peroxide, 
glutathione peroxidase 4, and peroxiredoxins 3 and 5, which readily convert hydrogen peroxide to water 
and ultimately prevent mitochondrial oxidative damage such as lipid peroxidation (Ross et al., 2005; 
James et al.,2007; Murphy, 2008; Smith et al., 2008; Graham et al., 2009). Modification of these 
antioxidant enzymes resulting from the knockout of manganese superoxide dismutase or glutathione 
peroxidase 4 gene can significantly influence mitochondrial activity and ROS production (Zhang et al., 
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2009; García-Fernández et al., 2012). Changes in the mitochondrial antioxidant system may result in a 
modification of mitochondrial integrity by mitochondria-derived ROS production through increased 
oxidative stress, which could have confounding effects on mitochondrial membrane potential and ATP 
production.  
 A recently developed mitochondria-targeted ubiquinone, MitoQ10, can have important effects on 
determination of mitochondrial membrane potential and is composed of a lipophilic 
triphenylphosphonium cation covalently attached to a ubiquinol antioxidant (Nierobisz et al., 2011). 
Lipophilic cations can easily move through phospholipid bilayers without requiring a specific uptake 
mechanism; therefore, the triphenylphosphonium cation concentrates MitoQ10 several hundred-fold 
within the mitochondria. Driven by the large mitochondrial membrane potential MitoQ10 is reduced by 
the respiratory chain to its active ubiquinol form, which is particularly effective in preventing lipid 
peroxidation and mitochondrial damage (Smith et al., 2003; Murphy, 2008). Since MitoQ10 has been 
used in a large range of cell and mitochondrial models (Murphy & Smith, 2010) and has been described 
as an effective antioxidant against lipid peroxidation (Adlam et al., 2005; Koopman et al., 2005;  
Murphy, 2008) and is  membrane potential dependent (Murphy, 2008), I then hypothesized that cell 
treatment with MitoQ10 following GPX4 knock-down may (1) abolish the levels or lipid peroxide and 
ROS observed previously in siRNA only treated cells and (2) may also retrieve the mitochondrial 
membrane potential. Experiments described in this Chapter studied whether MitoQ10 could ameliorate 
effect of GPX4 knock-down. 
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GPX4 mRNA status was assessed following cell treatment with MitoQ10 or a control compound DTPP. 
As shown in Figure 27, GPX4 mRNA level was similar following either MitoQ10 or DTPP treatment 
suggesting that MitoQ10 antioxidant activity does not have impact on GPX4 mRNA expression in Caco-
2 cells and can be used as an appropriate compound for further investigation. As also shown in Figure 
28, a significant level of GPX4 knock-down at protein level was achieved in the presence of MitoQ10 
indicating that MitoQ10 does not affect GPX4-siRNA efficiency.  
Protein levels of NDUFB8, COX2 and AIF were also measured following siRNA and MitoQ10 
treatment. Effects of MitoQ10 was assessed by comparing MitoQ10 with the control compound 
decyltriphenylphosphonium (decylTPP). This is composed of the lipophilic triphenylphosphonium 
cation and aliphatic 10-carbon chain but lacks the ubiquinone moiety and thereby controls for any non-
specific effects attributed to the accumulation of liphophilic cations within mitochondria. There was no 
difference in protein expression between cells treated with siRNA plus MitoQ10 for NDUFB8 (Figure 
29A) and COX2 (Figure 29B) compared to the scrambled control siRNA group as observed in the 
treatment with only GPX4-siRNA(1). However, AIF protein expression still remained significantly 
increased (Figure 29C) in knock-down cells treated with MitoQ10 compared to cells treated with the 
negative control siRNA. 
In addition, MitoQ10 protected cells from GPX4 knock-down induced lipid peroxide and superoxide, and 
was able to protect mitochondrial membrane potential. MitoQ10 is orally bio-available and has been 
shown to accumulate extensively in rat tissues after administration in the drinking water and to protect 
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against tissue damage (Adlam et al., 2005). MitoQ10 has been shown to be effective against 
mitochondrial oxidative damage in vivo and in rodent models of sepsis and reperfusion injury (Lowes et 
al., 2008; Supinski et al., 2009; Mukhopadhyay et al., 2012). Cardiovascular diseases such as 
atherosclerosis had been associated with increased lipid peroxide, combined supplementation of 
selenium and Coenzyme Q10 resulted to significant reduction of cardiovascular mortality among 
Swedish citizens aged 70-88 (Alehagen et al., 2012). MitoQ10 protected rat kidney from cold storage 
injury induced superoxide production, completely prevented mitochondrial dysfunction and 
significantly improved cell viability in these rats, whereas, these protective effects were not observed in 
rats treated with DTPP (Mitchell et al., 2010). The protective mechanism observed following MitoQ10 
treatment appeared to be attributed to the accumulation of ubiquinol within the mitochondria, because 
the control substance, decylTPP (DTPP) had no beneficial action. DTPP was used as a control 
compound because it is known to be taken up in a very similar way to MitoQ10 in cells in vitro however 
lacks the ubiquinol antioxidant moiety as MitoQ10.  
In conclusion, the experiments described in this chapter suggest that MitoQ10 in the presence of siRNA 
increased mitochondrial membrane potential, reduced mitochondrial superoxide and lipid peroxide. 
Under the same conditions, MitoQ10 prevented increased NDUFB8, COX2 but maintained increase in 
AIF protein expression. This suggests that increased mitochondrial superoxide is not important for 
increase in AIF protein expression to occur following GPX4 knock-down, but increase in superoxide are 
required for increase NDUFB8 and COX2 protein expression. 
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Chapter 7: Effect of GPX4 knock-down on apoptosis signaling in Caco-2 cells. 
7.1 Introduction. 
Apoptosis, also known as programmed cell death, comprises blebbing of the plasma membrane and 
fragmentation of DNA (Souza et al., 2012). Cells lose all attachments from the substratum and shrivel 
during apoptosis.  The mechanism of apoptosis involves the release of cytochrome c from the 
mitochondria into the cytoplasm and activation of a range of other apoptogenic proteins (Souza et al., 
2012). Caspases are key enzymes that drive apoptosis and activation of one or more of the Caspases has 
been widely recognized as an indicator of apoptosis. Activation of other apoptogenic proteins such as 
Bax, Bak or AIF is also considered as an indication of apoptosis (MacKenzie & Clark 2012).  
Following GPX4 knock-down in Caco-2 cells, the whole genome microarray study described in Chapter 
3 indicated changes in mRNA expression of Bax and AIF. It has also been described in Chapter 5 that 
there were changes in AIF protein level following GPX4 knock-down. Absence of GPX4 has been 
suggested to affect angiogenesis in murine embryonic fibroblasts through the increased activity of 12/15 
lipooxygenase, an enzyme that promotes apoptosis, and is an important regulator of tumor angiogenesis 
(Schneider et al., 2010). Liang and colleagues demonstrated that the cytosolic GPX4 protected mice 
from diquat-induced apoptosis (Liang et al., 2009) and reduced GPX4 expression has been found to 
increase life-span through increased sensitivity to apoptosis (Ran et al., 2007).  
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There are two different mechanisms by which apoptosis can occur: the extrinsic apoptotic pathway and 
the intrinsic mitochondrial-dependent pathway. The extrinsic pathway involves the initiation of 
extracellular death ligands such as Fas ligand (Fasl) through their binding to their corresponding 
receptors. The extrinsic apoptotic pathway involves activation of Caspase 3 and 7 (known as effector 
caspases) which leads to a breakdown in cellular components and DNA fragmentation (Zou et al., 1997; 
Park et al., 2007; Fadeel et al., 2008). Contrary to the extrinsic pathway, the intrinsic pathway (also 
known as the mitochondrial or AIF-mediated pathway) is regulated by Bcl-2, Bcl-xl, Bax and Bak (Xu 
et al., 2010). These proteins regulate the permeabilization of the outer membrane of the mitochondria, 
either positively or negatively, to promote the release of cytochrome c and other apoptotic molecules 
such as AIF, Smac/DIABLO and Caspase-9 (Fadeel et al., 2008). This results in degradation of cellular 
components and cell death (Fadeel et al., 2008). Both pathways have been shown to participate in cell 
apoptosis (Xu et al., 2010). Since microarray analysis following GPX4 knock-down in Caco-2 cells had 
shown effects on the expression of AIF and BAX mRNA levels and since evidence in the literature has 
implicated GPX4 in apoptosis (Liang et al., 2009), a detailed study into the possible link between GPX4 
expression and apoptosis in human intestinal cells was carried out. Activation of apoptosis was assessed 
by measurement of DNA fragmentation, Caspase-3,-7,-9 protein level and activity, Bax and Bcl-2 
protein levels, and levels of phosphatidylserine using Annexin V labeling (an indicator of early stage of 
apoptosis). 
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7.2 Results 
7.2.1 DNA fragmentation. 
Formation of nucleosomal units as a result of nuclear DNA degradation (DNA fragmentation) is one of 
the hallmarks of apoptotic cell death. Degradation of nuclear DNA occurs in response to different 
apoptotic stimuli and activation of different apoptogenic proteins in different cell types (Nagata, 2000). 
Formation of DNA into internucleosomal fragments (fragmented DNA) can be visually observed by the 
fragments of roughly 180-500 base pairs (Gavrieli et al., 1992). To investigate the effect of GPX4 
knock-down on end stage apoptosis, Caco-2 cells were treated with either GPX4 siRNA or negative 
control siRNA and DNA fragmentation assayed as previously described in (Chapter 2 Section 2.11-
2.11.1) Cells treated with negative control siRNA did not show any evidence of fragmented nuclear 
DNA as the DNA remained intact without fragments (Figure 31-NCSIRNA). GPX4-siRNA treated cells 
showed increased level of fragmented DNA (Figure 31-SIRNA) with nuclear DNA fragments of as low 
as ~200bp. This result is consistent with knock-down of GPX4 leading to apoptosis. 
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Figure 31. Assessment of DNA fragmentation following treatment with either GPX4-siRNA(1) or 
scrambled negative control siRNA. 
 Caco-2 cells were seeded and 24 h later treated with either GPX4-siRNA(SIRNA) or negative control 
siRNA (NCSIRNA). Seventy two hours following transfection, cells were lysed, nuclear DNA 
extracted and subjected to electrophoresis along a DNA ladder of 100-1-13bp markers.  
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7.2.2 Impact of GPX4 knock-down on Caspase -3 and-9 protein levels 
Caspases play a crucial role in apoptosis and have been shown to play important roles in cell 
differentiation, survival, proliferation, homeostasis and NFkB activation in different cell types (Sztiller-
Sikorska et al., 2009). Since caspases have been implicated in both intrinsic and extrinsic pathways of 
apoptosis, an investigation of the level of caspase-3 and -9 proteins expression after GPX4 knock-down 
was carried out.   
Caco-2 cells were seeded and 24 h later transfected with either GPX4-siRNA(1) or negative control 
siRNA. Seventy two hours following transfection cells were washed with cold PBS,  lysed and total cell 
lysate used for protein extraction as described in Chapter 2 Section 2.4-2.4.6. Following protein 
extraction, caspase-3 and -9 proteins were assessed by Western blotting using specific antibodies. 
Caspases are zymogens (inactive enzymes precursors) and only become active in the presence of an 
apoptotic stimulus. Initiator caspases such as caspase-9 cleave the pro-forms of effector caspases such as 
caspase-3 thereby activating them and caspase-3 then triggers apoptosis by cleaving other protein 
substrates such as  caspase-7 and carbamoyltransferase-dihydroorotase (CAD) within cell. A cleaved 
caspase-3 can be detected by SDS gel electrophoresis as a ~17-19kDa size protein migrating below the 
32 kDa full size protein.  As shown in (Figure 31A), there was no cleaved caspase-3 in cells treated with 
either GPX4-siRNA(1) or negative control siRNA suggesting that caspase-3 was not activated following 
GPX4 knock-down. Western blotting with an anti-caspase-9 antibody however showed both a full-size 
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pro-caspase-9 and a cleaved caspase-9 (Figure 32B) following treatment with GPX4-siRNA(1), 
suggesting that GPX4 knock-down leads to Caspase 9 activation. 
A 
 
 
B 
 
 
Figure 32. Expression of Caspase-3 and Caspase-9 following GPX4 knock-down. 
Caco-2 cells were treated with either GPX4-siRNA (SIRNA)  or scrambled negative control siRNA 
(NCSIRNA) for 72 h. Cell protein was extracted and caspase 3(A) and caspase-9 (B) assayed by 
Western blotting. Protein expression was compared to β-actin as a loading control. Note the lower 
molecular weight caspase-9 band after GPX4-siRNA treatment. (Western panels = 2 wells). 
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7.2.3 Caspase 3/7 enzymatic activity following GPX4 knock-down 
Since no change in cleavage for caspase-3 (an effector caspase for caspase-dependent apoptotic 
pathway) was observed by Western blotting following GPX4 knock-down, caspase 3/7 enzymatic 
activities were measured to verify change in activities of these caspases. Following treatment with 
GPX4 siRNA(1) or scrambled negative control siRNA, luminescence-based measurement of caspase 
activity was carried out at 30, 60, 90 and 120 minutes using Caspase-Glo® 3/7 assay as described in 
Chapter 2, Section 2.11.2. As shown in Figure 33 there was no statistically significant difference in 
caspase3/7 activity between cells treated with GPX4-siRNA(1) and negative control siRNA, suggesting 
that neither caspase-3 nor -7 played a role in the apoptosis following GPX4 knock-down. These 
observations suggest that apoptosis may possibly be through the alternative  intrinsic pathway involving 
AIF-mediated caspase-9 activation.  
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Figure 33. enzymatic activity of caspase-3/7 following treatment with GPX4-siRNA(1) or scrambled 
negative control siRNA.  
Caco-2 cells were treated with either GPX4-siRNA or scrambled negative control siRNA and then 
measurement of caspase 3/7 enzyme activities was carried out at different time points. Caspase 3/7 
enzyme activity of the GPX4-siRNA treatment group was expressed relative to the level of the control 
siRNA group, n=4 for each group. Values shown are mean ± S.D. Groups were compared using a 
Mann-Whitney U test, * p<0.05, ** p<.0.01 
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7.2.4 Impact of GPX4 knock-down on Bax and Bcl-2 protein levels 
To test whether GPX4 knock-down leads to apoptosis through the intrinsic pathway via AIF and 
caspase-9 activation, measurement of Bax and Bcl-2, markers of the intrinsic pathway of apoptosis, was 
carried out. Following cell treatment with either GPX4-siRNA(1) or negative control siRNA, Western 
blotting with an anti-Bax and Bcl-2 antibody was used to assess Bax and Bcl-2 protein levels. Bax 
protein level was increased by 50% (Figure 34A) in GPX4-siRNA(1) treated cells compared with 
control cells, whereas Bcl-2 protein was decreased by 25% (Figure 34B) in GPX4-siRNA(1) treated 
cells. The observed down-regulation of Bcl-2 protein expression and higher levels of Bax following 
GPX4 siRNA(1) treatment is consistent with increased activation of apoptosis. 
A 
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Figure 34. Bax and Bcl-2 protein expression following Caco-2 cell treatment with either GPX4-
siRNA(1) or  scrambled negative control siRNA. 
Caco-2 cells were treated with GPX4-siRNA (1) or scrambled negative control siRNA for 72 h. Total 
protein was isolated and Western blotting carried out using anti-Bax (A) and anti-Bcl-2 (B). A 
significant increase in Bax expression, and a reduction in Bcl-2 were observed following siRNA 
treatment  compared to cells treated with negative control siRNA. Protein bands were measured by 
densitometry, Bax and Bcl-2 expression normalized to β-Actin as a control and then levels expressed 
as a percentage of the mean value for cells treated with the scrambled control siRNA. Western panel 
=3 wells for BAX and 2 wells for Bcl-2, values shown are mean ± S.D  for n=6 Groups were 
compared using a Mann-Whitney U test, * p<0.05, ** p<.0.01 
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Since Bax has been strongly linked with apoptosis, further investigation of Bax involvement in GPX4 
knock-down-induced apoptosis was carried out. Caco-2 cells were seeded and 24 h later transfected with 
either GPX4 siRNA(1) or negative control siRNA. Seventy two hours following treatment, cells were 
washed with PBS, lysed and mitochondrial and cytosolic fractions isolated. Bax protein expression was 
assessed by Western blotting and, as shown in Figure 35, Bax protein was present both in the 
mitochondrial and cytosol fractions of cells treated with GPX4-siRNA(1) and negative control siRNA. 
Densitometryc analysis of the protein bands showed a statistically significant increase of Bax protein in 
mitochondria fraction of siRNA(1) treated cells compare with control cells. The increased level of Bax 
protein in the mitochondrial extract of cells treated with GPX4-siRNA(1) indicates translocation of  Bax 
from the cytosol into the mitochondria.  
 Results described in this Chapter have shown GPX4 knock-down to lead to activation of caspase-9, 
changes in level of Bax and Bcl-2 protein and DNA fragmentation (marker of end stage apoptosis), all 
of which point towards activation of the intrinsic apoptotic pathway.  
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Figure 35. Bax protein levels in mitochondrial and cytosolic fractions expression following treatment 
with either GPX4 siRNA(1) or scrambled negative control siRNA.  
Following treatment of Caco-2 cells with either GPX4-siRNA(1) or scrambled negative control siRNA 
for 72 h, mitochondrial and cytosolic fractions were isolated. Using anti-Bax antibody, Bax protein 
was expressed by Western blotting. Bax protein was present in both mitochondrial and cytosolic 
fractions in both groups. Protein bands were measured by densitometry, cytosolic Bax expression was 
normalized to β-Actin as the control whereas mitochondrial Bax expression was normalized to SDH 
as the control and then as a percentage of the mean value for cells treated with the scrambled control 
siRNA. Western panel = 2 wells, values shown are mean ± S.D for  n=4. Groups were compared using 
a Mann-Whitney U test, * p<0.05, ** p<0.01 
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7.2 Flow Cytometric analysis of apoptosis in Caco-2 cells. 
Results from previous sections of this chapter have implicated GPX4 in apoptosis through activation of 
caspase-9, Bax and Bcl-2 and DNA fragmentation. This section aimed to confirm early stage apoptosis 
through the release of phosphatidylserine (PS) using Annexin V staining and flow cytometry. In 
addition, since in Chapter 6 MitoQ10 was shown to influence response of various mitochondrial 
parameters to GPX4 knock-down, the effect of MitoQ10 on apoptosis after GPX4 knock-down was also 
assessed using Annexin V staining. As described in Chapter  2, section 2.11.3 Caco-2 cells were sub-
cultured and left to grow for 24 h before addition of either GPX4-siRNA(1) or negative control siRNA 
and MitoQ10. Seventy two hours following treatment, cells were washed with PBS, harvested and 
stained with either Annexin V, propidium iodide PI or a combination of Annexin V and PI. Following 
staining, cells apoptisis were analyzed by flow cytometry.  
As shown in Figure 36A and Figure 36B,  following cell treatment with either negative control siRNA 
or both negative control siRNA and MitoQ10, the number of cells undergoing apoptosis appeared low. 
However, following cell treatment with GPX4-siRNA(1) there was a noticeable increase in the number 
of apoptotic cells (Figure 36C) compared to negative control siRNA treated cells. Quantification of the 
data (Table 7) confirmed that after GPX4-siRNA(1) treatment, there was a greater mean population of 
apoptotic cells compared to cells treated with the control siRNA however, this difference was not 
statistically significant. Overall these data suggest that there may be translocation of phosphatidylserine 
from the inner to the outer plasma membrane in GPX4-siRNA(1) treated cells, providing further 
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evidence that GPX4 knock-down leads to activation of apoptosis. Additionally, cells treated with GPX4-
siRNA(1) plus MitoQ10 did not show a statistically significant difference in apoptosis compared to cells 
treated with the GPX4-siRNA only (Figure 36D). This result suggests that lipid peroxidation as a result 
of GPX4 knock-down could be one of the causes of changes in DNA fragmentation, caspase 9, Bax and 
Bcl-2 protein expression, since MitoQ10 has previously been shown in (Chapter 6, Figure 30) to block 
lipid peroxidation following GPX4 knock-down.   
 
Figure 36. Flow cytometric assessment of apoptosis in Caco-2 cells following GPX4 knockdown. 
  Caco-2 cells were stained with Annexin V to detect apoptotic cells or PI to detect dead (necrotic) 
cells. Highlighted in green are vibrant cells (i.e. live cells) and highlighted in pink are apoptotic cells. 
(A) Cells treated with the GPX4 negative control siRNA for 72 h (B) Cells treated with a GPX4 
negative control siRNA and MitoQ10 for 72 h (C) Cells treated with GPX4-siRNA for 72 h and (D) 
Cells treated with GPX4-siRNA and MitoQ10 for 72 h.       
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SAMPLE -ve control siRNA (A)  -ve control +MQ10 (B) GPX4-siRNA 1 (C) GPX4-siRNA 1+MQ10  (D) 
GROUP ANNEXIN ANNEXIN  ANNEXIN  ANNEXIN  
%APOPTOSIS 
P-Value 
1 ± 0.3  
 
0.9 ± 0.12  
0.6 
3 ± 0.7  
0.3 
0.9 ± 0.1  
0.6 
 
Table 7. Quantification of flow cytometric data to assess apoptosis in Caco-2 cells following GPX4 
knockdown.  
The percentage of apoptotic cells was calculated from the Annexin V staining. All groups were 
compared to the percentage of the mean value of cells treated with the negative control siRNA, n=6 
for each group. Values shown are mean ± S.D. Groups were compared using Mann-Whiney U test. 
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7.3 Discussion 
Changes in expression of  AIF and BAX mRNA from the microarray data after GPX4 knock-down led to 
further investigation of whether GPX4 knock-down led to cell apoptosis. As shown in Figure 30, 
fragmented DNA was observed in siRNA(1) treated cells but not in cells treated with negative control 
siRNA. DNA from siRNA treated cells migrated towards a position suggesting fragments of 100-200bp, 
which is a typical indication of DNA fragmentation in apoptotic cells (Hotchkiss & Nicholson, 2006).  
Generally known as phospholipid-binding protein, Annexin V has a strong binding affinity for 
phosphatidylserine, a negatively charged phospholipid, known to be localized in the cytosol leaflet of 
the plasma membrane lipid bilayer, but redistributed from the inner to the outer leaflet in the early phase 
of apoptosis (Lee et al., 2012). Following Annexin V staining, 3% apoptosis was detected in cells 
treated with GPX4-siRNA(1) compared to cells treated with the negative control siRNA which, showed 
a 1%  apoptosis (Figure 36) although quantification failed to show a statistically significant effect.  
Apoptosis can occur through intrinsic (also known as mitochondria or AIF-mediated) pathway or 
extrinsic pathway which involves activation of caspase 3, 7 and 8. To further investigate the mechanism 
through which the observed DNA fragmentation occurred, caspase-3 and -9 protein expression,  caspase 
3/7 activities and Bax and Bcl-2 protein expression were investigated. As shown in Figure 31, there was 
no activation or cleavage of caspase-3 protein in cells treated with either GPX4-siRNA(1) or negative 
control siRNA treated cells. Cleavage to produce a product of approximately 19 kDa would have 
suggested an activation of pro-caspase-3 which would indicate a caspase-dependent extrinsic pathway 
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route leading to apoptosis. Increased Caspase 3 and 7 activities have previously been implicated in 
apoptosis, particularly in the caspase-dependent cell death pathway (Thati et al., 2007). Following 
GPX4 knock-down, there was no difference in caspase 3/7 activity in cells treated with siRNA and 
scrambled control cells (Figure 34) suggesting that the apoptosis observed in the GPX4 knock-down is 
independent of caspase-3. 
 A further study was carried out to explore the protein level of caspase-9 (an initiator caspase linked to 
mitochondrial death pathway) in cells treated with GPX4-siRNA(1) or negative control siRNA. An 
increase in cleavage of caspase-9 was observed in cells depleted of GPX4 expression (Figure 32) but not 
in cells treated with negative control siRNA. This result suggests that the apoptosis observed from the 
knock-down study may have been through the activation of caspase-9 rather than caspase-3. 
The microarray analysis showed GPX4 knock-down to alter Bax mRNA level. Furthermore, a 
significant increase in Bax protein was observed in cells treated with GPX4 siRNA(1) compared to 
negative control siRNA  treated cells and this observation was consistent with changes observed from 
increase in pro-apoptotic Bax mRNA (Appendix A1). Increased in Bax expression has been widely 
linked to increased apoptosis (Ekegren et al., 1999; Ismail et al., 2005; Xiao & Zhang, 2008). Generally, 
Bax is sequestered in the cytosol and is translocated from the cytosol into the mitochondria during 
apoptosis (Putcha et al., 1999; Bedner et al., 2000; Jia et al., 2001). Translocation of Bax into the 
mitochondria targets the intermembrane of the mitochondria contact sites and releases cytochrome c 
(Gao et al., 2001; De Giorgi et al., 2002) which then allows Bax to assemble and package itself within 
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the mitochondria. Cytochrome c release from the mitochondria cleaves and activates Caspase-9, which 
sequentially leads to the apoptosis process (Putcha et al., 1999; Gao et al., 2001; Jia et al., 2001). 
A study in Hela cells following Xanthorrhizol (an anti-inflammatory compound that can induce 
apoptosis) treatment showed increased apoptosis through up-regulation of Bax protein (Ismail et al., 
2005). Another study in prenatal fetal brain following exposure to cocaine reported increased Bax 
protein expression alongside decreased Bcl-2 protein and increased Caspase-9 activity. A study in spinal 
motor neurons reported increased apoptosis through increased Bax protein expression (Ekegren et al., 
1999). In the present work, increased Bax protein was also observed in the isolated mitochondria of cells 
treated with GPX4-siRNA(1) (Figure 35).  
Down-regulation of anti-apoptotic protein Bcl-2 expression (Figure 33B) was observed in cells treated 
with GPX4-siRNA(1). Bcl-2 is a crucial regulator of the apoptotic process and an anti-apoptotic protein. 
Zhang et al., (1999), reported that down-regulation of Bcl-2 mRNA through the use of antisense 
resulted in increased sensitivity of human gastric adenocarcinoma cell line to phototoxic treatment. A 
study in human prostate cancer PC3 cells following a delivery of adenoviral ribozyme resulted in down-
regulation of Bcl-2 protein expression and increased induction of apoptosis (Dorai et al., 1997a,b;  
Dorai et al., 1999). Down-regulation of Bcl-2 has been reported as a classical indicator of apoptosis 
owing to the fact that Bcl-2 function is mainly to inhibit the activation of pro-apoptotic enzymes such as 
caspases (Cory & Adams, 2002).  
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These observations suggest that depletion of GPX4 expression may have acted as an apoptotic stimulus 
which inhibited expression of anti-apoptotic proteins such as Bcl-2 and activated the expression of pro-
apoptotic proteins such as Caspase-9. Bax activation and translocation from the cytosol to the 
mitochondria, may also have led to a direct activation of intrinsic apoptotic pathway thereby releasing 
AIF from the mitochondrial inter-membrane space to the cytosol. These results are consistent with 
several studies which suggest that altered GPX4 leads to effects on apoptosis. For example, 
overexpression of GPX4 protected lung fibroblasts from phosphatidylcholine hydroperoxide (PCOOH)-
induced loss of mitochondrial membrane potential and blocked apoptosis induced by different apoptotic 
agents (Garry et al., 2008).  During the  course of the present work, it was reported that knock-down of 
GPX4 with siRNA in Jurkat cells led to enhanced phospholipid peroxidation, increased TNFα-
stimulated Az-PC formation and apoptosis (Latchoumycandane et al., 2012). Furthermore, ablation of 
GPX4 with tamoxifen administration increased apoptosis in adult mice (Yoo et al., 2012). Previously, 
Ran et al (2007), reported that reduced GPX4 expression increases life-span in mice through increase 
sensitivity to apoptosis. Overexpression of GPX4 in apolipoprotein E-deficient (APoE(-/-)) mice  
reduced atherosclerotic lesions in aortic tree and aortic sinus suggesting that GPX4 inhibits the 
development of atherosclerosis by decreasing lipid peroxidation and inhibits the sensitivity of vascular 
cells to oxidized lipids (Guo et al., 2008). 
Flow cytometry using annexin V antibody showed a non-statistically significant difference in the 
number of apoptotic cells after GPX4 knock-down compared to control cells.  Additionally, in the 
presence of MitoQ10 there was also no statistical difference in the the number of apoptotic cells 
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compared to cells treated with GPX4-siRNA only (Figure 36D). Although MitoQ10 treatment did not 
show any statistical difference between the two groups, previous studies have implicated MitoQ10 in 
modulating apoptosis (Wani et al., 2011). MitoQ10 suppressed DNA fragmentation, cytochrome c 
release and caspase-3 activation against dichlorvos-induced oxidative stress and cell death in rat brain, 
and MitoQ10 enhanced the activities of MnSOD and glutathione (Wani et al., 2011). MitoQ10 has also 
been reported to protect pancreatic B-cells against apoptosis and promoted their cell survival and 
enhanced insulin secretion (Lim et al., 2011). Human fetal liver cells were protected from HOC1-
induced cell death by MitoQ10 (Whiteman et al., 2008). An investigation of the mechanism (s) through 
which cells undergo damage was carried out in cardiomyocyte-like cell line (H9C2) exposed to 
stimulated ischemia-reperfusion (I/R). This exposure resulted in apoptosis and these cells were found to 
exhibit increased level of Bax expression. MitoQ10 treatment inhibited further ROS production, 
protected these cells from apoptosis and enhanced Bcl-2 and Bcl-xl expression (Neuzil et al., 2007). 
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Chapter 8. Final Discussion  
Selenium and selenoproteins have been studied widely in relation to their role in cell physiology and 
health including  antioxidant protection, cancer risk, thyroid hormone metabolism, immune function,  
inflammation, ER-stress and protein folding, (Sep15 and SelS) (Labunskyy et al., 2009, Shchedrina et 
al., 2010)  and calcium homeostasis (SelN) (Arbogast & Ferreiro, 2010). With regard to intestinal 
disease, previous studies have implicated Se in protecting the gastrointestinal tract from carcinogenesis 
and inflammation ( Duffield-Lillico et al., 2002, Karp & Koch, 2006). Se intake has been widely linked 
with reduced risk of colon cancer (Russo et al., 1997, Fairweather-Tait et al, 2011; Rayman, 2012; 
Meplan & Hesketh, 2012) and has been used to control  effects of inflammatory bowel disease 
(Halliwell et al., 2000). Furthermore, the antioxidant effect of Se is exerted through selenium-dependent 
enzymes such as the family of GPx, and double knock-out mice of GPx1-/- and GPx2-/-  showed 
increased vulnerability to colitis and colon cancer (Esworthy et al., 2003).  
Previous work with knock-out mice has shown that GPX4   is essential for normal development (Yant et 
al., 2003). In addition to its essential function in sperm viability and proposed functions in detoxifying 
lipid hydroperoxides, recent findings suggest a role linked to eicosanoid metabolism and apoptosis 
(Brigelius, 1999; Imai & Nakagawa, 2003; Seiler et al., 2008; Bellinger et al., 2009; Conrad, 2009). 
Low GPX4 expression has been found to lead to higher levels of 12/15 lipoxygenase-derived lipid 
hydroperoxides and increased AIF-induced apoptosis (Seiler et al., 2008; Conrad, 2009; Conrad et al., 
2010). The present findings complement and extend this earlier work by linking GPX4 and AIF to the 
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mitochondrial respiratory complexes in addition to apoptosis. Interestingly, a common genetic 
polymorphism has been found in the GPX4 gene in a region corresponding to the 3’untranslated region 
(rs713041) (Villette et al, 2002) and this variant has not only been shown to have functional 
consequences in reporter gene assays and effects on lymphocyte selenoprotein activity (Bernamo et al., 
2007; Pagmantidis et al., 2008) but has also been reported to affect susceptibility to CRC risk (Bernamo 
et al., 2007; Pagmantidis et al., 2008).  These results suggest that changes in GPX4 activity as a result of 
this variant, possibly in combination with low Se intake, will affect mitochondrial function and 
apoptosis.  
The first aim of the work described in this thesis was to use a gene microarray approach to study the 
function of GPX4 in intestinal epithelial cells using siRNA to knock-down GPX4 expression. In order to 
carry out this study, two different siRNA specific to GPX4 were designed using published methods 
(Reynolds et al., 2004, Ui-Tei et al., 2004) and commercially synthesized as described in Chapter 2, 
(Section 2.2). Caco-2 cells were used as an appropriate model for this study because they are derived 
from the human intestinal epithelium where majority of redox process occur. Caco-2 cells are relatively 
stable model to work with and many studies of antioxidant function (including that of selenoproteins) 
have been carried out in Caco-2 cell. Recent studies include investigation of the metabolism of linoleic 
acid (Lengler et al., 2012), glucose uptake (Zheng et al 2012), epigenetic effects of isothiocyanates 
(Barrera et al., 2012) and GPX4 induction during enterocytic cell differentiation (Speckmann et al., 
2011) was carried ou in Caco-2 cells. 
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Confirmation of GPX4 knock-down at both mRNA and protein was determined by PCR and Western 
blotting respectively. Results obtained following densitometry analysis of mRNA and protein band 
showed that expression levels of GPx4 both at mRNA and protein were reduced and statistical analysis 
indicated that the changes were significant.  
Following confirmation of GPX4 knock-down at 72 h, mRNA was isolated and used to study the effects 
of GPx4 knock-down on global gene expression in Caco-2 cells. The microarray data showed changes in 
mRNA expression of 795 genes including subunit genes of mitochondrial complexes I, V and IV, and 
genes involve in apoptosis (Appendix A1 and A2). 
Pathway analysis of the genes whose expression changed as a result of GPX4 knock-down was carried 
out. Ingenuity Pathway Analysis (IPA) showed that the major canonical pathways affected were 
mitochondrial pathways including oxidative phosphorylation pathway, ubiquinone pathway and 
mitochondrial dysfunctional pathway. Toxicology list analysis with IPA also showed increased in 
oxidative stress in cells treated with GPX4-siRNA (Table 6). Network analysis with IPA showed that 
the major effect of knock-down of GPX4 in the intestinal epithelial Caco-2 cell line was changes in 
mitochondrial complexes I, IV and V and their subunits (Figure 13) and also altered mRNA expression 
of AIF, a key regulator of mitochondrial complex I and IV electron transport chain complexes. 
Real-time RT-PCR and Western blotting measurements confirmed that knock-down of GPX4 led to 
changes in the respiratory chain complexes (Figure 14 and 15) respectively. Furthermore, although no 
statistically significant changes in cellular in respiration and cellular ROS were observed in cells treated 
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with GPX4-siRNA (Figure 20), the changes in gene expression were accompanied by increased 
mitochondrial ROS levels, increased lipid peroxidation, loss of mitochondrial membrane potential and 
lower ATP levels (Figures 19). Mice over-expressing GPX4 show changes in response to the oxidant 
diquat, with lower cardiolipin peroxidation and lower loss of mitochondrial membrane potential and 
increased apoptosis (Liang et al., 2007; Liang et al., 2009). The present data extend these earlier studies 
not only by showing that GPX4 knock-down has complementary effects on mitochondrial lipid 
peroxidation and membrane potential, but by also showing that GPX4 knock-down alters expression of 
components of complexes I, IV and V and, mitochondrial integrity and AIF expression. 
Additionally, Caco-2 cells were treated with a mitochondria-targeting antioxidant Mitoquinone 10 
(MitoQ10) following the observation that GPX4 knock-down altered mitochondrial ubiquinone 
biosynthesis pathway. The objective was to investigate if MitoQ10 would modulate some of the effects 
of GPX4 knock-down. Indeed MitoQ10 repressed the changes in lipid peroxide, ROS, and elevated 
mitochondrial membrane potential in cells treated with GPX4-siRNA (Figure 30) and prevented the 
change in protein expression observed in NDUFB8 and COX2 but not the changes in AIF (Figure 29). 
These observations suggest that GPX4 knock-down may cause the oxidation of ubiquinone (Q10), and 
preliminary data obtained using mass spectrometry to measure Q10 suggests that knock-down of GPX4 
results in lower Q10 level (data not shown). 
MitoQ has recently been used as a therapeutic intervention for ROS and mitochondrial oxidative 
damage induced pathologies. Combined supplementation of selenium and Coenzyme Q10 resulted in 
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significant reduction of cardiovascular mortality among Swedish citizens aged 70-88 (Alehagen et al., 
2012), supplementation of Coenzyme Q10 reduced oxidative stress and increased antioxidant enzyme 
activity in patient with coronary activity diseases (Lee et al., 2012). In addition supplementation of  
soluble MQ10 improves intracellular distribution and promotes mitochondrial respiration in T67 and 
H9c2 cell lines (Bergamini et al., 2012).  
This is the first transcriptomic study of effects of changes in GPX4 expression and the results emphasise 
a major role for GPX4 in AIF/mitochondrial pathways. Indeed the present results suggest that AIF plays 
a key role in the regulation of the mitochondrial oxidative phosphorylation system following GPX4 
knock-down. First, pathway analysis of the present transcriptomic analysis highlights changes in AIF as 
being a potential central regulator of the expression changes in complexes 1, 1V and V. Secondly, 
confirmation of mRNA data by Western blotting shows changes in NDUFB8, COX2 and AIF levels 
following GPX4 knock-down. However the contradiction between change in AIF mRNA and protein 
has been difficult to understand and this allows room for future investigation. The time course 
experiment shows that the increased AIF protein expression is an early event, occurring before 
alterations in NDUFB8 expression (Figure 24). This is consistent with recent studies suggesting that 
AIF regulates activity of complex I (Daugas et al., 2000; Joza et al., 2009; Hangen et al., 2010).  
The findings of this study following GPX4 knock-down in human gut epithelial cell suggest that the 
function of GPX4 is not only restricted to protecting cells against oxidative stress such as 
hydroperoxides, but can also play a role in either maintaining or regulating functional mitochondria and 
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protecting cell from apoptosis. Reduced GPX4 expression also resulted in DNA fragmentation (Figure 
32), activation of cleaved caspase-9 protein (Figure 33) and changes in protein expressions of Bax and 
Bcl-2 (Figure 35). Western blotting showed increased expression of Bax in the mitochondria fraction of 
siRNA treated cells (Figure 36), which support reports that Bax dimerization as a result of apoptosis 
stimulus leads to Bax translocation from the cytosol into the mitochondria. These observations strongly 
suggest GPX4 involvement in apoptosis. Also a translocation of AIF from the mitochondria into the 
cytosol was observed in isolated cytosol following siRNA treatment. 
Age-related mitochondrial DNA mutations lead to changes in colonic cell apoptosis (Nooteboom et al., 
2010), suggesting that changes in mitochondrial oxidative function as a result of altered GPX4 activity 
may influence colonic cell proliferation. However, further studies are needed to define whether this is 
the case, how such effects are related to overall gut epithelial cell function, and whether they influence 
risk of colorectal cancer.  
During the course of the study described in this thesis, a whole genome gene expression and pathway 
study in fibroblasts of a homogenous group of patients deficient in mitochondrial complex I with defect 
in one of the nuclear encoded structural subunits, showed increased expression of oxidative stress 
pathway and decreased selenium metabolism and selenoprotein pathway (Voets et al., 2011). This 
observation by Voets and colleagues implicated low selenium and selenoproteins in mitochondrial 
complex I deficiency. A second study in mice photoreceptor cells lacking GPX4 showed significant 
decrease in mitochondrial biomass, elevation of cell death associated with the translocation of AIF (also 
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an important regulator of mitochondrial electron transport chain complexes I and IV), suggesting the 
critical role of GPX4 in AIF-mediated cell death (Ueta et al., 2012). Thirdly, a study on GPX4 ablated 
mouse (GPX4(f/f)) with a flanked GPX4 exon 2-4 at loxP sites, and further cross-bred with a tamoxifen 
(tam)-inducible Cre transgenic mouse (R26CreER mice), showed a significant reduction (75-85%) of 
GPX4 levels in brain, liver, lung and kidney tissue of adult GPX4 mice. These mice died within 2 weeks 
of treatment, but prior to death, exhibited increased mitochondrial damage, increased levels of 4-
hydroxynonenal levels, decreased activities of mitochondrial electron transport chains complexes I and 
IV, decreased ATP synthesis in the liver and increased apoptosis (Yoo et al., 2012). Fourthly, siRNA 
knock-down of GPx4 in Jurkat cells has been found to lead to increased phospholipid hydroperoxides 
and TNFα-stimulated Az-PC formation, mitochondrial damage and apoptosis (Latchoumycandane et al., 
2012). 
This study has reported that in undifferentiated Caco-2 gut epithelial cells changes in GPX4 activity lead 
to altered expression of 795 genes of which some are involved in mitochondrial metabolism and some in 
apoptosis. Interestingly, it has recently been observed that GPX4 expression is increased during Caco-2 
cell differentiation and that there is higher expression in upper villus enterocytes which are fully 
differentiated (Speckmann et al., 2011). AIF has played a central role in the entire study of this project 
namely; in the microarray and time course experiment suggesting that the AIF-related protective role of 
GPX4 may be particularly important in differentiated enterocytes. Future work should involve 
investigating the role of GPx4 in other intestinal cell lines and in differentiated Caco-2.  
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In this study, the siRNA used were expected to knock-down both the cytosolic and mitochondria forms 
of GPx4, and it was not possible to distinguish between the extent of knock-down of the two forms.  
However, in control cells expression of mGPx4 was barely detectable by RTPCR and much lower than 
expression of cGPx4. Thus, the observed effect of the siRNA on mitochondrial parameters suggests that 
cGPx4 is also important in maintaining mitochondria function. Various studies on GPx4 such as 
Barriere et al. (2004), Ran et al., (2004), Ran et al., (2006), Liang et al., (2007), Garry et al., (2008), 
Guo et al., (2008), Ufer et al., (2008), and Rubio et al., (2012) have overexpressed both isoforms of 
GPx4 (mitochondria GPx4 (mGPx4) and cytosolic GPx4 (cGPx4). On the other hand,  Dabkowski et al., 
(2008), investigated overexpressed GPx4 solely in the mitochondrion (mGPx4). Interestingly, none of 
these studies was conclusive on the effects of two GPx4 isoforms for mitochondrial function and this 
presents an opportunity for further study of the relative importance of cGPx4 and mGPx4. 
In conclusion, I hypothesise that in Caco-2 gut epithelial cells GPX4 protects mitochondria from 
oxidative damage and plays a crucial role in regulating and maintaining the redox state, a functional 
oxidative phosphorylation system and ATP synthesis possibly through AIF (Figure 37). The Mito10 
experiment showed that the antioxidant lessened the effects of GPX4 knock-down on mitochondrial 
membrane potential, mitochondrial superoxide and mitochondrial Complex I and IV but not AIF. This 
suggests that GPX4 knock-down alters lipid peroxide and changes CoQ10 levels, which in turn affects 
mitochondrial membrane potential and Complex I and IV (Figure 37). This is also compatible with the 
time-course data showing GPX4 knock-down affecting lipid peroxide, mitochondrial membrane 
potential before expression of complex I and IV. However, GPX4 knock-down also affects AIF and I 
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suggest that this may be a result of change in mitochondrial ROS or a result of changes in regulation of 
complex I and IV.  
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Figure 37. A hypothetical model of the role of GPX4 in Caco-2 cells  
The hypothetical model is based on the findings described in this thesis and observed increase (↑) and 
decrease (↓) are indicated. In the model, oxidized lipids and ROS increase as a result of reduced 
GPX4 expression,  and their changes are proposed to have two sets of consequences. First, activation 
of mitochondrial apoptogenic proteins such as AIF, Caspase-9 and Bax. Activation of Bax inhibits 
anti-apoptotic Bcl-2 expression and induction of DNA fragmentation. Second, increased lipid 
peroxides following GPX4 knock-down also affect ubiquinone (CoQ) biosynthesis which in turn 
affects mitochondrial membrane potential (ΔΨm) and mitochondria complex I and IV. 
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Appendix A1 : List of genes of which expression were up-regulated 
 
FOLD 
CHANGE 
PROBE 
ID 
REGULATI
ON SYMBOL ENTREZ GENE NAME 
P.VAL
UE 
RP/SU
M PFP 
1.395  10347 UP  ABCA7  ATP-binding cassette, sub-family A (ABC1), member 7 
1.00E-
04 6.8987 
9.00E-
04 
1.276  22985 UP  ACIN1  apoptotic chromatin condensation inducer 1 
1.00E-
04 17.2908 
9.00E-
04 
1.231  123 UP  ADFP  adipose differentiation-related protein 
1.00E-
04 18.0271 
9.00E-
04 
1.303  11047 UP  ADRM1  adhesion regulating molecule 1 
1.00E-
04 50.6873 
9.00E-
04 
1.216  10598 UP  AHSA1  AHA1, activator of heat shock 90kDa protein ATPase homolog 1 (yeast) 
1.00E-
04 56.39 
9.00E-
04 
1.379  23600 UP  AMACR  alpha-methylacyl-CoA racemase 
1.00E-
04 73.4084 
8.00E-
04 
1.718  336 UP  APOA2  apolipoprotein A-II 
1.00E-
04 75.2338 0.0011 
1.307  381 UP  ARF5  ADP-ribosylation factor 5 
1.00E-
04 80.7635 0.001 
1.292  402 UP  ARL2  ADP-ribosylation factor-like 2 
1.00E-
04 80.9704 0.001 
1.305  10124 UP  ARL4A  ADP-ribosylation factor-like 4A 
1.00E-
04 91.5363 0.001 
1.217  10094 UP  ARPC3  actin related protein 2/3 complex, subunit 3, 21kDa 
1.00E-
04 97.2508 0.0011 
1.506  430 UP  ASCL2  achaete-scute complex homolog 2 (Drosophila) 
1.00E-
04 97.6242 0.0011 
1.573  467 UP  ATF3  activating transcription factor 3 
1.00E-
04 
101.870
6 0.0012 
1.23  64422 UP  ATG3  ATG3 autophagy related 3 homolog (S. cerevisiae) 
1.00E-
04 
104.995
5 0.0012 
1.339  475 UP  ATOX1  ATX1 antioxidant protein 1 homolog (yeast) 
1.00E-
04 
106.346
1 0.0012 
1.582  516 UP  ATP5G1  ATP synthase, H+ transporting, mitochondrial F0 complex, subunit C1 (subunit 9) 
1.00E-
04 
110.668
5 0.0012 
1.498  517 UP  ATP5G2  ATP synthase, H+ transporting, mitochondrial F0 complex, subunit C2 (subunit 9) 
1.00E-
04 
111.996
9 0.0012 
1.336  10476 UP 
 ATP5H (includes 
EG:10476)  ATP synthase, H+ transporting, mitochondrial F0 complex, subunit d 
1.00E-
04 
127.854
9 0.0012 
1.717  521 UP  ATP5I  ATP synthase, H+ transporting, mitochondrial F0 complex, subunit E 
1.00E-
04 
128.294
6 0.0012 
1.385  522 UP  ATP5J  ATP synthase, H+ transporting, mitochondrial F0 complex, subunit F6 
1.00E-
04 
148.087
5 0.0012 
1.472  9551 UP  ATP5J2  ATP synthase, H+ transporting, mitochondrial F0 complex, subunit F2 
1.00E-
04 
167.059
2 0.0012 
1.39  10632 UP  ATP5L  ATP synthase, H+ transporting, mitochondrial F0 complex, subunit G 
1.00E-
04 
167.114
4 0.0012 
1.489  8313 UP  AXIN2  axin 2 
1.00E-
04 
170.781
2 0.0012 
1.623  25805 UP  BAMBI  BMP and activin membrane-bound inhibitor homolog (Xenopus laevis) 
1.00E-
04 
180.361
4 0.0014 
1.497  8815 UP  BANF1  barrier to autointegration factor 1 
1.00E-
04 
183.230
8 0.0014 
1.387  581 UP  BAX  BCL2-associated X protein 
1.00E-
04 
190.229
1 0.0014 
1.226  56647 UP  BCCIP  BRCA2 and CDKN1A interacting protein 
1.00E-
04 
191.065
2 0.0014 
1.207  633 UP  BGN  biglycan 
1.00E-
04 
197.330
6 0.0014 
1.265  8553 UP  BHLHE40  basic helix-loop-helix family, member e40 
1.00E-
04 
201.165
7 0.0014 
1.317  652 UP  BMP4  bone morphogenetic protein 4 
1.00E-
04 
202.241
1 0.0014 
1.769  552900 UP  BOLA2  bolA homolog 2 (E. coli) 
1.00E-
04 
218.848
1 0.0013 
1.596  388962 UP  BOLA3  bolA homolog 3 (E. coli) 
1.00E-
04 
220.953
9 0.0014 
1.212  9577 UP  BRE  brain and reproductive organ-expressed (TNFRSF1A modulator) 
1.00E-
04 
231.680
2 0.0015 
1.394  25798 UP  BRI3  brain protein I3 
1.00E-
04 233.448 0.0016 
1.293  684 UP  BST2  bone marrow stromal cell antigen 2 
1.00E-
04 
240.558
1 0.0017 
1.288  84154 UP  BXDC1  brix domain containing 1 
1.00E-
04 
242.287
2 0.0017 
1.549  746 UP  C11ORF10  chromosome 11 open reading frame 10 
1.00E-
04 
245.836
5 0.0017 
1.379  79081 UP  C11ORF48  chromosome 11 open reading frame 48 
1.00E-
04 
246.293
2 0.0019 
1.449  28984 UP  C13ORF15  chromosome 13 open reading frame 15 
1.00E-
04 
248.015
6 0.0023 
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1.635  81892 UP  C14ORF156  chromosome 14 open reading frame 156 
1.00E-
04 256.738 0.0023 
1.404  145853 UP  C15ORF61  chromosome 15 open reading frame 61 
1.00E-
04 257.405 0.0023 
1.338  55009 UP  C19ORF24  chromosome 19 open reading frame 24 
1.00E-
04 
258.933
4 0.0022 
1.377  163183 UP  C19ORF46  chromosome 19 open reading frame 46 
1.00E-
04 
260.657
2 0.0023 
1.397  125988 UP  C19ORF70  chromosome 19 open reading frame 70 
1.00E-
04 262.423 0.0024 
1.269  708 UP  C1QBP  complement component 1, q subcomponent binding protein 
1.00E-
04 
262.881
1 0.0026 
1.272  84319 UP  C3ORF26  chromosome 3 open reading frame 26 
1.00E-
04 
266.404
5 0.0026 
1.425  114915 UP  C5ORF26  chromosome 5 open reading frame 26 
1.00E-
04 
277.720
7 0.0026 
1.284  84300 UP  C6ORF125  chromosome 6 open reading frame 125 
1.00E-
04 
279.464
9 0.0026 
1.39  387103 UP  C6ORF173  chromosome 6 open reading frame 173 
1.00E-
04 286.775 0.0026 
1.291  84310 UP  C7ORF50  chromosome 7 open reading frame 50 
1.00E-
04 
290.464
4 0.0025 
1.318  401466 UP  C8ORF59  chromosome 8 open reading frame 59 
1.00E-
04 
297.344
1 0.0025 
1.366  375757 UP  C9ORF119  chromosome 9 open reading frame 119 
1.00E-
04 
298.437
5 0.0029 
1.24  55450 UP  CAMK2N1  calcium/calmodulin-dependent protein kinase II inhibitor 1 
1.00E-
04 306.86 0.0031 
1.255  826 UP  CAPNS1  calpain, small subunit 1 
1.00E-
04 
306.879
3 0.0031 
1.29  865 UP  CBFB  core-binding factor, beta subunit 
1.00E-
04 
313.269
1 0.0032 
1.321  131076 UP  CCDC58  coiled-coil domain containing 58 
1.00E-
04 
313.657
3 0.0031 
1.272  29080 UP  CCDC59  coiled-coil domain containing 59 
1.00E-
04 
327.441
9 0.0032 
1.385  51372 UP  CCDC72  coiled-coil domain containing 72 
1.00E-
04 
331.386
1 0.0032 
1.292  79080 UP  CCDC86  coiled-coil domain containing 86 
1.00E-
04 
332.570
6 0.0032 
1.203  898 UP  CCNE1  cyclin E1 
1.00E-
04 
337.426
9 0.0038 
1.232  908 UP  CCT6A  chaperonin containing TCP1, subunit 6A (zeta 1) 
1.00E-
04 
343.788
4 0.0039 
1.279  993 UP  CDC25A  cell division cycle 25 homolog A (S. pombe) 
1.00E-
04 
343.901
3 0.004 
1.22  1027 UP  CDKN1B  cyclin-dependent kinase inhibitor 1B (p27, Kip1) 
1.00E-
04 
345.817
4 0.004 
1.214  634 UP  CEACAM1  carcinoembryonic antigen-related cell adhesion molecule 1 (biliary glycoprotein) 
1.00E-
04 
347.191
1 0.0041 
1.365  4680 UP 
 CEACAM6 (includes 
EG:4680) 
 carcinoembryonic antigen-related cell adhesion molecule 6 (non-specific cross reacting 
antigen) 
1.00E-
04 
347.333
9 0.004 
1.427  400916 UP  CHCHD10  coiled-coil-helix-coiled-coil-helix domain containing 10 
1.00E-
04 
362.671
9 0.0043 
1.464  55847 UP  CISD1  CDGSH iron sulfur domain 1 
1.00E-
04 
382.131
2 0.005 
1.425  51192 UP  CKLF  chemokine-like factor 
1.00E-
04 
383.865
5 0.005 
1.364  1163 UP  CKS1B  CDC28 protein kinase regulatory subunit 1B 
1.00E-
04 386.128 0.0054 
1.696  1281 UP  COL3A1  collagen, type III, alpha 1 
1.00E-
04 
388.159
9 0.0054 
1.372  51241 UP  COX16  COX16 cytochrome c oxidase assembly homolog (S. cerevisiae) 
2.00E-
04 
388.767
8 0.0054 
1.508  10063 UP  COX17  COX17 cytochrome c oxidase assembly homolog (S. cerevisiae) 
2.00E-
04 389.922 0.0058 
1.243  9377 UP  COX5A  cytochrome c oxidase subunit Va 
2.00E-
04 
392.793
3 0.0061 
1.354  1337 UP  COX6A1  cytochrome c oxidase subunit VIa polypeptide 1 
2.00E-
04 
399.926
3 0.0062 
1.392  1340 UP  COX6B1  cytochrome c oxidase subunit Vib polypeptide 1 (ubiquitous) 
2.00E-
04 
400.702
2 0.0062 
1.403  1347 UP  COX7A2  cytochrome c oxidase subunit VIIa polypeptide 2 (liver) 
2.00E-
04 
403.270
7 0.0062 
1.506  1351 UP  COX8A  cytochrome c oxidase subunit 8A (ubiquitous) 
2.00E-
04 
404.419
1 0.0062 
1.465  1382 UP  CRABP2  cellular retinoic acid binding protein 2 
2.00E-
04 
408.434
4 0.0066 
1.364  92359 UP  CRB3  crumbs homolog 3 (Drosophila) 
2.00E-
04 
409.110
6 0.0067 
1.741  1469 UP  CST1  cystatin SN 
2.00E-
04 
413.752
5 0.0069 
1.4  1476 UP  CSTB  cystatin B (stefin B) 
2.00E-
04 
423.855
1 0.0071 
1.314  1622 UP  DBI  diazepam binding inhibitor (GABA receptor modulator, acyl-Coenzyme A binding protein) 
2.00E-
04 
431.304
7 0.007 
1.251  84259 UP  DCUN1D5  DCN1, defective in cullin neddylation 1, domain containing 5 (S. cerevisiae) 
2.00E-
04 
433.779
9 0.0071 
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1.406  1649 UP  DDIT3  DNA-damage-inducible transcript 3 
2.00E-
04 
434.388
8 0.0071 
1.374  1652 UP  DDT  D-dopachrome tautomerase 
2.00E-
04 435.857 0.0072 
1.274  9188 UP  DDX21  DEAD (Asp-Glu-Ala-Asp) box polypeptide 21 
2.00E-
04 
438.413
6 0.0072 
1.326  1716 UP  DGUOK  deoxyguanosine kinase 
2.00E-
04 
439.784
5 0.0072 
1.205  54505 UP  DHX29  DEAH (Asp-Glu-Ala-His) box polypeptide 29 
2.00E-
04 
442.752
7 0.0072 
1.236  1660 UP  DHX9  DEAH (Asp-Glu-Ala-His) box polypeptide 9 
2.00E-
04 
444.470
9 0.0073 
1.202  1736 UP  DKC1  dyskeratosis congenita 1, dyskerin 
2.00E-
04 
446.457
3 0.0073 
1.331  22943 UP  DKK1  dickkopf homolog 1 (Xenopus laevis) 
2.00E-
04 
449.481
3 0.0073 
1.327  84661 UP  DPY30  dpy-30 homolog (C. elegans) 
2.00E-
04 
450.233
2 0.0073 
1.328  8655 UP  DYNLL1  dynein, light chain, LC8-type 1 
2.00E-
04 
451.625
6 0.0073 
1.381  83658 UP  DYNLRB1  dynein, light chain, roadblock-type 1 
2.00E-
04 
456.678
5 0.0074 
1.213  10969 UP  EBNA1BP2  EBNA1 binding protein 2 
2.00E-
04 
459.488
5 0.0074 
1.42  9718 UP  ECE2  endothelin converting enzyme 2 
2.00E-
04 
460.718
8 0.0073 
1.343  8721 UP  EDF1  endothelial differentiation-related factor 1 
2.00E-
04 
462.909
8 0.0073 
1.291  1933 UP  EEF1B2  eukaryotic translation elongation factor 1 beta 2 
2.00E-
04 
464.091
2 0.0074 
1.204  1948 UP  EFNB2  ephrin-B2 
2.00E-
04 
464.364
9 0.0075 
1.419  1958 UP  EGR1  early growth response 1 
2.00E-
04 
465.949
2 0.0079 
1.231  1981 UP  EIF4G1  eukaryotic translation initiation factor 4 gamma, 1 
3.00E-
04 
469.470
1 0.0079 
1.21  1982 UP  EIF4G2  eukaryotic translation initiation factor 4 gamma, 2 
3.00E-
04 
473.615
5 0.0081 
1.288  1983 UP  EIF5  eukaryotic translation initiation factor 5 
3.00E-
04 
473.911
6 0.0082 
1.282  3692 UP  EIF6  eukaryotic translation initiation factor 6 
3.00E-
04 478.562 0.0082 
1.386  10436 UP  EMG1  EMG1 nucleolar protein homolog (S. cerevisiae) 
3.00E-
04 
489.274
4 0.0082 
1.329  2077 UP  ERF  Ets2 repressor factor 
3.00E-
04 
493.693
5 0.0082 
1.207  10961 UP  ERP29  endoplasmic reticulum protein 29 
3.00E-
04 
495.401
1 0.0084 
1.28  2114 UP  ETS2  v-ets erythroblastosis virus E26 oncogene homolog 2 (avian) 
3.00E-
04 
504.394
3 0.0083 
1.298  51013 UP  EXOSC1  exosome component 1 
3.00E-
04 
512.503
7 0.0085 
1.38  26071 UP  FAM127B  family with sequence similarity 127, member B 
3.00E-
04 513.111 0.0086 
1.367  2197 UP  FAU  Finkel-Biskis-Reilly murine sarcoma virus (FBR-MuSV) ubiquitously expressed 
3.00E-
04 
513.205
6 0.0085 
1.39  51024 UP  FIS1  fission 1 (mitochondrial outer membrane) homolog (S. cerevisiae) 
3.00E-
04 
517.046
3 0.0085 
1.211  51303 UP  FKBP11  FK506 binding protein 11, 19 kDa 
3.00E-
04 
519.009
1 0.0085 
1.358  2280 UP  FKBP1A  FK506 binding protein 1A, 12kDa 
3.00E-
04 521.866 0.0084 
1.289  2288 UP  FKBP4  FK506 binding protein 4, 59kDa 
3.00E-
04 
522.285
2 0.0084 
1.264  8087 UP  FXR1  fragile X mental retardation, autosomal homolog 1 
3.00E-
04 
529.243
1 0.0086 
1.899  51083 UP  GAL  galanin prepropeptide 
3.00E-
04 
529.844
9 0.0086 
1.387  54433 UP  GAR1  GAR1 ribonucleoprotein homolog (yeast) 
3.00E-
04 
533.067
3 0.009 
1.275  54552 UP 
 GNL3L (includes 
EG:54552)  guanine nucleotide binding protein-like 3 (nucleolar)-like 
3.00E-
04 
537.272
4 0.009 
1.239  2821 UP  GPI  glucose phosphate isomerase 
3.00E-
04 
538.502
2 0.009 
1.997  2876 UP  GPX1  glutathione peroxidase 1 
3.00E-
04 
552.162
7 0.009 
1.37  404672 UP  GTF2H5  general transcription factor IIH, polypeptide 5 
3.00E-
04 
557.994
6 0.0089 
1.214  2971 UP  GTF3A  general transcription factor IIIA 
3.00E-
04 
558.077
6 0.009 
1.372  10542 UP  HBXIP  hepatitis B virus x interacting protein 
3.00E-
04 
558.492
4 0.009 
1.523  650646 UP  HCG 2033311  ribosomal protein S26 pseudogene 15 
3.00E-
04 
558.958
3 0.009 
1.291  3094 UP  HINT1  histidine triad nucleotide binding protein 1 
3.00E-
04 563.006 0.0091 
1.38  85236 UP  HIST1H2BK  histone cluster 1, H2bk 
3.00E-
04 
565.563
4 0.0091 
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1.453  8364 UP  HIST1H4C  histone cluster 1, H4c 
3.00E-
04 
571.863
2 0.0095 
1.21  81502 UP  HM13  histocompatibility (minor) 13 
3.00E-
04 
573.972
4 0.0095 
1.322  3159 UP  HMGA1  high mobility group AT-hook 1 
3.00E-
04 
576.008
2 0.0095 
1.259  3182 UP  HNRNPAB  heterogeneous nuclear ribonucleoprotein A/B 
4.00E-
04 577.062 0.0096 
1.493  3218 UP  HOXB8  homeobox B8 
4.00E-
04 
577.150
9 0.0096 
1.294  3320 UP  HSP90AA1  heat shock protein 90kDa alpha (cytosolic), class A member 1 
4.00E-
04 
586.163
3 0.0095 
1.328  51504 UP  HSPC152  hypothetical protein HSPC152 
4.00E-
04 
586.779
6 0.0096 
1.429  3336 UP  HSPE1  heat shock 10kDa protein 1 (chaperonin 10) 
4.00E-
04 
594.747
1 0.0096 
1.613  3397 UP  ID1  inhibitor of DNA binding 1, dominant negative helix-loop-helix protein 
4.00E-
04 
597.307
1 0.0097 
1.596  3399 UP  ID3  inhibitor of DNA binding 3, dominant negative helix-loop-helix protein 
4.00E-
04 
603.002
5 0.0102 
1.411  2537 UP  IFI6  interferon, alpha-inducible protein 6 
4.00E-
04 
604.108
8 0.0101 
1.371  3481 UP  IGF2  insulin-like growth factor 2 (somatomedin A) 
4.00E-
04 605.96 0.0103 
1.892  3484 UP  IGFBP1  insulin-like growth factor binding protein 1 
4.00E-
04 
610.807
5 0.0105 
1.328  3487 UP  IGFBP4  insulin-like growth factor binding protein 4 
4.00E-
04 
617.092
2 0.0106 
1.619  147920 UP  IGFL2  IGF-like family member 2 
4.00E-
04 
623.013
7 0.0106 
1.276  79711 UP  IPO4  importin 4 
4.00E-
04 
623.744
2 0.0106 
1.387  10265 UP  IRX5  iroquois homeobox 5 
4.00E-
04 
624.080
3 0.0105 
1.496  3725 UP  JUN  jun oncogene 
4.00E-
04 
624.668
7 0.0111 
1.292  23277 UP  KIAA0664  KIAA0664 
4.00E-
04 
629.497
2 0.0112 
1.304  200185 UP  KRTCAP2  keratinocyte associated protein 2 
4.00E-
04 
630.104
6 0.0117 
1.386  8270 UP  LAGE3  L antigen family, member 3 
4.00E-
04 
634.554
5 0.0117 
1.254  3936 UP  LCP1  lymphocyte cytosolic protein 1 (L-plastin) 
4.00E-
04 
637.680
2 0.012 
1.503  51176 UP  LEF1  lymphoid enhancer-binding factor 1 
4.00E-
04 
638.315
5 0.0128 
1.34  3955 UP  LFNG  LFNG O-fucosylpeptide 3-beta-N-acetylglucosaminyltransferase 
4.00E-
04 
641.109
5 0.0134 
1.383  56891 UP  LGALS14  lectin, galactoside-binding, soluble, 14 
4.00E-
04 
645.667
1 0.0138 
1.264  3957 UP  LGALS2  lectin, galactoside-binding, soluble, 2 
4.00E-
04 646.369 0.0142 
1.227  389421 UP  LIN28B  lin-28 homolog B (C. elegans) 
4.00E-
04 
647.197
7 0.0144 
1.341  127295 UP  LOC127295  ribosomal protein L36 pseudogene 5 
4.00E-
04 
648.888
4 0.0149 
1.233  283412 UP  LOC283412  ribosomal protein L29 pseudogene 12 
5.00E-
04 
649.701
4 0.015 
1.415  441377 UP  LOC441377  ribosomal protein S26 pseudogene 35 
5.00E-
04 
650.829
3 0.0151 
1.339  644844 UP  LOC644844  hypothetical protein LOC644844 
5.00E-
04 
652.381
7 0.0151 
1.679  644934 UP  LOC644934  ribosomal protein S26 pseudogene 50 
5.00E-
04 
652.483
5 0.0151 
1.251  652595 UP  LOC652595  similar to U2 small nuclear ribonucleoprotein A (U2 snRNP-A) 
5.00E-
04 
652.510
3 0.0151 
1.202  9361 UP  LONP1  lon peptidase 1, mitochondrial 
5.00E-
04 
656.976
7 0.0155 
1.431  27258 UP  LSM3  LSM3 homolog, U6 small nuclear RNA associated (S. cerevisiae) 
5.00E-
04 
657.335
2 0.0159 
1.26  23658 UP  LSM5  LSM5 homolog, U6 small nuclear RNA associated (S. cerevisiae) 
5.00E-
04 
660.392
6 0.0159 
1.443  51690 UP  LSM7  LSM7 homolog, U6 small nuclear RNA associated (S. cerevisiae) 
5.00E-
04 
663.836
5 0.0162 
1.203  4074 UP  M6PR  mannose-6-phosphate receptor (cation dependent) 
5.00E-
04 
664.618
1 0.0161 
1.346  51025 UP  MAGMAS 
 mitochondria-associated protein involved in granulocyte-macrophage colony-stimulating 
factor signal transduction 
5.00E-
04 
668.693
4 0.0161 
1.398  4192 UP  MDK  midkine (neurite growth-promoting factor 2) 
5.00E-
04 
669.861
3 0.0161 
1.333  29081 UP  METTL5  methyltransferase like 5 
5.00E-
04 
673.549
6 0.0161 
1.565  4258 UP  MGST2  microsomal glutathione S-transferase 2 
5.00E-
04 
675.721
3 0.0162 
1.278  6182 UP  MRPL12  mitochondrial ribosomal protein L12 
5.00E-
04 678.208 0.0162 
1.319  29074 UP  MRPL18  mitochondrial ribosomal protein L18 
5.00E-
04 
680.721
8 0.0168 
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1.454  219927 UP  MRPL21  mitochondrial ribosomal protein L21 
5.00E-
04 
681.887
5 0.0167 
1.332  29093 UP  MRPL22  mitochondrial ribosomal protein L22 
5.00E-
04 
684.137
4 0.0167 
1.41  6150 UP  MRPL23  mitochondrial ribosomal protein L23 
5.00E-
04 
687.551
8 0.017 
1.41  51264 UP  MRPL27  mitochondrial ribosomal protein L27 
5.00E-
04 
687.646
3 0.0176 
1.469  9553 UP  MRPL33  mitochondrial ribosomal protein L33 
5.00E-
04 
691.243
1 0.018 
1.239  54148 UP  MRPL39  mitochondrial ribosomal protein L39 
6.00E-
04 
693.543
7 0.018 
1.301  51258 UP  MRPL51  mitochondrial ribosomal protein L51 
6.00E-
04 
694.428
3 0.018 
1.272  64960 UP  MRPS15  mitochondrial ribosomal protein S15 
6.00E-
04 
695.396
2 0.0183 
1.334  51373 UP  MRPS17  mitochondrial ribosomal protein S17 
6.00E-
04 696.687 0.0183 
1.567  51023 UP  MRPS18C  mitochondrial ribosomal protein S18C 
6.00E-
04 
697.126
4 0.0187 
1.298  64951 UP  MRPS24  mitochondrial ribosomal protein S24 
6.00E-
04 
697.595
9 0.0188 
1.23  10884 UP  MRPS30  mitochondrial ribosomal protein S30 
6.00E-
04 
700.988
8 0.0188 
1.309  51650 UP  MRPS33  mitochondrial ribosomal protein S33 
6.00E-
04 
701.280
4 0.0189 
1.289  4487 UP  MSX1  msh homeobox 1 
6.00E-
04 
702.923
2 0.0189 
1.434  4501 UP  MT1X  metallothionein 1X 
6.00E-
04 
706.898
2 0.0189 
1.244  91663 UP  MYADM  myeloid-associated differentiation marker 
6.00E-
04 
707.138
9 0.0191 
1.97  4608 UP  MYBPH  myosin binding protein H 
7.00E-
04 
707.548
6 0.019 
1.31  10627 UP  MYL12A  myosin, light chain 12A, regulatory, non-sarcomeric 
7.00E-
04 
708.796
5 0.0191 
1.297  10787 UP  NCKAP1  NCK-associated protein 1 
7.00E-
04 
708.834
8 0.0194 
1.472  126328 UP  NDUFA11  NADH dehydrogenase (ubiquinone) 1 alpha subcomplex, 11, 14.7kDa 
7.00E-
04 
710.101
1 0.0201 
1.366  55967 UP  NDUFA12  NADH dehydrogenase (ubiquinone) 1 alpha subcomplex, 12 
7.00E-
04 
710.757
5 0.0203 
1.596  4696 UP  NDUFA3  NADH dehydrogenase (ubiquinone) 1 alpha subcomplex, 3, 9kDa 
7.00E-
04 
712.679
6 0.0204 
1.321  4697 UP  NDUFA4  NADH dehydrogenase (ubiquinone) 1 alpha subcomplex, 4, 9kDa 
7.00E-
04 
712.814
4 0.0203 
1.254  4706 UP  NDUFAB1  NADH dehydrogenase (ubiquinone) 1, alpha/beta subcomplex, 1, 8kDa 
7.00E-
04 
713.376
1 0.0203 
1.435  91942 UP  NDUFAF2  NADH dehydrogenase (ubiquinone) 1 alpha subcomplex, assembly factor 2 
7.00E-
04 
719.419
5 0.0203 
1.397  29078 UP  NDUFAF4  NADH dehydrogenase (ubiquinone) 1 alpha subcomplex, assembly factor 4 
7.00E-
04 
720.961
2 0.0209 
1.404  4708 UP  NDUFB2  NADH dehydrogenase (ubiquinone) 1 beta subcomplex, 2, 8kDa 
7.00E-
04 
721.518
6 0.0209 
1.423  4709 UP  NDUFB3  NADH dehydrogenase (ubiquinone) 1 beta subcomplex, 3, 12kDa 
7.00E-
04 
722.252
4 0.0214 
1.625  4712 UP  NDUFB6  NADH dehydrogenase (ubiquinone) 1 beta subcomplex, 6, 17kDa 
7.00E-
04 
725.050
2 0.0225 
1.346  4713 UP  NDUFB7  NADH dehydrogenase (ubiquinone) 1 beta subcomplex, 7, 18kDa 
7.00E-
04 
726.259
8 0.0228 
1.392  4717 UP  NDUFC1  NADH dehydrogenase (ubiquinone) 1, subcomplex unknown, 1, 6kDa 
7.00E-
04 
727.504
9 0.0229 
1.347  4725 UP  NDUFS5  NADH dehydrogenase (ubiquinone) Fe-S protein 5, 15kDa (NADH-coenzyme Q reductase) 
7.00E-
04 
732.263
2 0.0229 
1.283  27247 UP  NFU1  NFU1 iron-sulfur cluster scaffold homolog (S. cerevisiae) 
8.00E-
04 
732.516
6 0.0229 
1.311  55651 UP  NHP2  NHP2 ribonucleoprotein homolog (yeast) 
8.00E-
04 
737.629
1 0.0228 
1.325  4809 UP  NHP2L1  NHP2 non-histone chromosome protein 2-like 1 (S. cerevisiae) 
8.00E-
04 
738.004
6 0.023 
1.966  85407 UP  NKD1  naked cuticle homolog 1 (Drosophila) 
8.00E-
04 
740.545
7 0.0232 
1.402  4830 UP  NME1  non-metastatic cells 1, protein (NM23A) expressed in 
8.00E-
04 
747.352
9 0.0233 
1.386  654364 UP  NME1-NME2  NME1-NME2 readthrough transcript 
8.00E-
04 
747.631
5 0.0234 
1.236  51406 UP  NOL7  nucleolar protein 7, 27kDa 
8.00E-
04 
747.792
3 0.0234 
1.291  55505 UP  NOP10  NOP10 ribonucleoprotein homolog (yeast) 
8.00E-
04 
748.190
6 0.0236 
1.367  4839 UP  NOP2  NOP2 nucleolar protein homolog (yeast) 
8.00E-
04 
756.283
8 0.0237 
1.507  10360 UP  NPM3  nucleophosmin/nucleoplasmin, 3 
8.00E-
04 757.903 0.0239 
1.407  54959 UP  ODAM  odontogenic, ameloblast asssociated 
8.00E-
04 
762.383
8 0.0238 
1.214  4953 UP  ODC1  ornithine decarboxylase 1 
8.00E-
04 
763.043
8 0.0239 
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1.261  5036 UP  PA2G4  proliferation-associated 2G4, 38kDa 
8.00E-
04 
767.595
3 0.0239 
1.287  8106 UP  PABPN1  poly(A) binding protein, nuclear 1 
8.00E-
04 
777.423
9 0.0242 
2.774  9506 UP  PAGE4  P antigen family, member 4 (prostate associated) 
9.00E-
04 
777.854
1 0.0244 
1.546  5092 UP  PCBD1 
 pterin-4 alpha-carbinolamine dehydratase/dimerization cofactor of hepatocyte nuclear factor 
1 alpha 
9.00E-
04 
785.857
8 0.0249 
1.459  9141 UP  PDCD5  programmed cell death 5 
9.00E-
04 
798.567
4 0.025 
1.319  5144 UP  PDE4D  phosphodiesterase 4D, cAMP-specific (phosphodiesterase E3 dunce homolog, Drosophila) 
9.00E-
04 
803.640
8 0.0249 
1.678  22822 UP  PHLDA1  pleckstrin homology-like domain, family A, member 1 
9.00E-
04 
806.115
1 0.0249 
1.315  84457 UP  PHYHIPL  phytanoyl-CoA 2-hydroxylase interacting protein-like 
9.00E-
04 
807.198
6 0.0252 
1.366  51227 UP  PIGP  phosphatidylinositol glycan anchor biosynthesis, class P 
9.00E-
04 
808.278
1 0.0251 
1.323  11145 UP  PLA2G16  phospholipase A2, group XVI 
9.00E-
04 
808.630
3 0.025 
1.428  5435 UP  POLR2F  polymerase (RNA) II (DNA directed) polypeptide F 
9.00E-
04 
809.862
6 0.0252 
1.326  51728 UP  POLR3K  polymerase (RNA) III (DNA directed) polypeptide K, 12.3 kDa 
9.00E-
04 
817.072
5 0.0253 
1.392  51371 UP  POMP  proteasome maturation protein 
9.00E-
04 
823.208
1 0.0256 
1.278  26472 UP  PPP1R14B  protein phosphatase 1, regulatory (inhibitor) subunit 14B 
9.00E-
04 
823.391
2 0.0259 
1.242  51029 UP  PPPDE1  PPPDE peptidase domain containing 1 
9.00E-
04 823.814 0.0259 
1.257  27166 UP  PRELID1  PRELI domain containing 1 
9.00E-
04 
827.495
5 0.0259 
1.401  29964 UP 
 PRICKLE4 (includes 
EG:29964)  prickle homolog 4 (Drosophila) 
9.00E-
04 
827.758
8 0.026 
1.285  27339 UP  PRPF19  PRP19/PSO4 pre-mRNA processing factor 19 homolog (S. cerevisiae) 
9.00E-
04 
827.867
9 0.0263 
1.688  11098 UP  PRSS23  protease, serine, 23 
9.00E-
04 
829.168
6 0.0264 
1.206  5687 UP  PSMA6  proteasome (prosome, macropain) subunit, alpha type, 6 
9.00E-
04 829.24 0.027 
1.404  5699 UP  PSMB10  proteasome (prosome, macropain) subunit, beta type, 10 
9.00E-
04 
832.204
1 0.0269 
1.33  8624 UP  PSMG1  proteasome (prosome, macropain) assembly chaperone 1 
9.00E-
04 
832.695
5 0.0277 
1.424  5805 UP  PTS  6-pyruvoyltetrahydropterin synthase 0.001 
839.530
7 0.0278 
1.292  29920 UP  PYCR2  pyrroline-5-carboxylate reductase family, member 2 0.001 
840.563
8 0.0278 
1.333  9584 UP  RBM39  RNA binding motif protein 39 0.001 
841.739
4 0.028 
1.307  9978 UP  RBX1 (includes EG:9978)  ring-box 1 0.001 
847.490
5 0.0283 
1.34  9986 UP  RCE1  RCE1 homolog, prenyl protein peptidase (S. cerevisiae) 0.001 
851.370
9 0.0286 
1.249  9104 UP  RGN  regucalcin (senescence marker protein-30) 0.001 
851.545
9 0.029 
1.346  440400 UP  RNASEK  ribonuclease, RNase K 0.001 
854.757
7 0.0305 
1.395  51255 UP  RNF181  ring finger protein 181 0.001 
856.213
5 0.0311 
1.339  140823 UP  ROMO1  reactive oxygen species modulator 1 0.001 
856.630
1 0.0311 
1.288  84268 UP  RPAIN  RPA interacting protein 0.001 
861.440
3 0.0319 
1.367  6136 UP 
 RPL12 (includes 
EG:6136)  ribosomal protein L12 0.001 
862.592
5 0.0322 
1.274  649821 UP  RPL14L  ribosomal protein L14 pseudogene 1 0.001 
866.016
2 0.0327 
1.437  6164 UP  RPL34  ribosomal protein L34 0.001 867.995 0.0333 
1.305  25873 UP 
 RPL36 (includes 
EG:25873)  ribosomal protein L36 0.001 
868.335
6 0.0333 
1.347  6166 UP  RPL36AL  ribosomal protein L36a-like 0.001 
870.907
2 0.0337 
1.315  6169 UP 
 RPL38 (includes 
EG:6169)  ribosomal protein L38 0.001 
874.416
3 0.034 
1.321  6128 UP  RPL6  ribosomal protein L6 0.0011 874.433 0.0342 
1.461  6176 UP  RPLP1  ribosomal protein, large, P1 0.0011 
875.576
7 0.0343 
1.303  79897 UP  RPP21  ribonuclease P/MRP 21kDa subunit 0.0011 
878.192
6 0.0343 
1.273  10799 UP  RPP40  ribonuclease P/MRP 40kDa subunit 0.0011 
882.856
6 0.0349 
1.299  6207 UP  RPS13  ribosomal protein S13 0.0011 
884.553
5 0.0348 
1.371  6210 UP  RPS15A  ribosomal protein S15a 0.0011 
885.997
6 0.0348 
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1.461  6227 UP  RPS21  ribosomal protein S21 0.0011 
886.588
9 0.0347 
1.372  6229 UP 
 RPS24 (includes 
EG:6229)  ribosomal protein S24 0.0011 
887.815
7 0.035 
1.651  6231 UP  RPS26  ribosomal protein S26 0.0011 
888.021
8 0.0358 
1.306  6232 UP  RPS27  ribosomal protein S27 0.0011 
894.813
9 0.0368 
1.32  51065 UP 
 RPS27L (includes 
EG:51065)  ribosomal protein S27-like 0.0011 
901.293
3 0.0368 
1.226  6234 UP  RPS28  ribosomal protein S28 0.0011 
902.717
9 0.0368 
1.284  6235 UP  RPS29  ribosomal protein S29 0.0011 
907.032
6 0.0371 
1.487  6201 UP  RPS7  ribosomal protein S7 0.0011 
909.452
9 0.0373 
1.339  6275 UP  S100A4  S100 calcium binding protein A4 0.0011 
914.304
7 0.0375 
1.31  389432 UP  SAMD5  sterile alpha motif domain containing 5 0.0012 
914.618
6 0.0378 
1.243  23478 UP  SEC11A  SEC11 homolog A (S. cerevisiae) 0.0012 914.668 0.0379 
1.293  10952 UP  SEC61B  Sec61 beta subunit 0.0012 
914.986
9 0.0378 
1.348  23480 UP  SEC61G  Sec61 gamma subunit 0.0012 
918.297
4 0.0382 
1.216  81929 UP  SEH1L  SEH1-like (S. cerevisiae) 0.0012 
919.673
5 0.0384 
1.388  58515 UP  SELK  selenoprotein K 0.0012 
922.103
9 0.0384 
1.281  728492 UP  SERF1B  small EDRK-rich factor 1B (centromeric) 0.0012 
923.352
8 0.0394 
1.296  871 UP  SERPINH1 
 serpin peptidase inhibitor, clade H (heat shock protein 47), member 1, (collagen binding 
protein 1) 0.0012 
923.893
4 0.0393 
1.328  51639 UP  SF3B14  splicing factor 3B, 14 kDa subunit 0.0012 
926.163
4 0.0395 
1.337  83443 UP  SF3B5  splicing factor 3b, subunit 5, 10kDa 0.0012 
927.693
8 0.0396 
1.2  119559 UP  SFXN4  sideroflexin 4 0.0012 
930.618
5 0.0402 
1.257  291 UP  SLC25A4  solute carrier family 25 (mitochondrial carrier; adenine nucleotide translocator), member 4 0.0012 
932.049
7 0.0402 
1.3  10237 UP  SLC35B1  solute carrier family 35, member B1 0.0012 
933.008
9 0.0409 
1.296  347734 UP  SLC35B2  solute carrier family 35, member B2 0.0012 935.596 0.0409 
1.33  8884 UP  SLC5A6  solute carrier family 5 (sodium-dependent vitamin transporter), member 6 0.0013 
936.734
3 0.0412 
1.373  387066 UP  SNHG5  small nucleolar RNA host gene 5 (non-protein coding) 0.0012 
939.456
8 0.0415 
1.286  79622 UP  SNRNP25  small nuclear ribonucleoprotein 25kDa (U11/U12) 0.0012 
944.184
3 0.0416 
1.429  6629 UP  SNRPB2  small nuclear ribonucleoprotein polypeptide B'' 0.0012 
944.192
9 0.0415 
1.607  6636 UP  SNRPF  small nuclear ribonucleoprotein polypeptide F 0.0012 
944.689
2 0.0416 
1.466  6637 UP  SNRPG  small nuclear ribonucleoprotein polypeptide G 0.0012 
946.335
7 0.0418 
1.563  389058 UP  SP5  Sp5 transcription factor 0.0012 
946.539
8 0.042 
1.301  28972 UP 
 SPCS1 (includes 
EG:28972)  signal peptidase complex subunit 1 homolog (S. cerevisiae) 0.0012 
950.100
5 0.0424 
1.344  6690 UP  SPINK1  serine peptidase inhibitor, Kazal type 1 0.0012 
950.155
3 0.0425 
1.292  6727 UP  SRP14  signal recognition particle 14kDa (homologous Alu RNA binding protein) 0.0011 
951.098
7 0.0425 
1.46  6728 UP  SRP19  signal recognition particle 19kDa 0.0012 
954.493
1 0.0426 
1.257  6734 UP  SRPR  signal recognition particle receptor (docking protein) 0.0012 
955.671
5 0.0427 
1.615  6742 UP  SSBP1  single-stranded DNA binding protein 1 0.0013 
957.265
3 0.043 
1.224  8148 UP  TAF15  TAF15 RNA polymerase II, TATA box binding protein (TBP)-associated factor, 68kDa 0.0013 
959.446
5 0.0429 
1.285  6876 UP  TAGLN  transgelin 0.0013 
960.042
9 0.0431 
1.309  6902 UP  TBCA  tubulin folding cofactor A 0.0013 
960.600
8 0.0431 
1.314  6921 UP  TCEB1  transcription elongation factor B (SIII), polypeptide 1 (15kDa, elongin C) 0.0013 
961.323
1 0.043 
1.331  6923 UP  TCEB2  transcription elongation factor B (SIII), polypeptide 2 (18kDa, elongin B) 0.0013 
965.253
6 0.0429 
1.203  6942 UP  TCF20  transcription factor 20 (AR1) 0.0013 
966.176
2 0.0433 
1.422  255758 UP  TCTEX1D2  Tctex1 domain containing 2 0.0013 
971.400
9 0.0432 
1.273  7035 UP  TFPI  tissue factor pathway inhibitor (lipoprotein-associated coagulation inhibitor) 0.0013 
971.692
1 0.0432 
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1.375  10189 UP  THOC4  THO complex 4 0.0014 
982.073
7 0.0439 
1.266  7064 UP  THOP1  thimet oligopeptidase 1 0.0014 
982.402
3 0.0439 
1.477  26519 UP  TIMM10  translocase of inner mitochondrial membrane 10 homolog (yeast) 0.0014 
985.867
6 0.0445 
1.405  10431 UP  TIMM23  translocase of inner mitochondrial membrane 23 homolog (yeast) 0.0014 
989.483
1 0.0454 
1.234  7082 UP  TJP1  tight junction protein 1 (zona occludens 1) 0.0014 
994.429
8 0.0454 
1.357  84233 UP  TMEM126A  transmembrane protein 126A 0.0014 
1004.92
81 0.0458 
1.212  55863 UP  TMEM126B  transmembrane protein 126B 0.0015 
1010.00
75 0.0461 
1.307  10430 UP  TMEM147  transmembrane protein 147 0.0015 
1010.18
76 0.0466 
1.252  51522 UP  TMEM14C  transmembrane protein 14C 0.0016 
1015.87
4 0.0467 
1.274  90809 UP  TMEM55B  transmembrane protein 55B 0.0017 
1019.59
82 0.0468 
1.352  83460 UP  TMEM93  transmembrane protein 93 0.0017 
1023.10
81 0.0468 
1.295  401505 UP 
 TOMM5 (includes 
EG:401505)  translocase of outer mitochondrial membrane 5 homolog (yeast) 0.0017 
1027.40
59 0.0478 
1.436  54543 UP  TOMM7  translocase of outer mitochondrial membrane 7 homolog (yeast) 0.0019 
1027.68
61 0.0478 
1.473  51693 UP  TRAPPC2L  trafficking protein particle complex 2-like 0.0023 
1028.31
68 0.0477 
1.36  7295 UP  TXN  thioredoxin 0.0023 
1030.31
55 0.0477 
1.238  11338 UP 
 U2AF2 (includes 
EG:11338)  U2 small nuclear RNA auxiliary factor 2 0.0023 
1030.92
18 0.0477 
1.366  59286 UP  UBL5  ubiquitin-like 5 0.0022 
1032.79
86 0.0476 
1.271  29979 UP  UBQLN1  ubiquilin 1 0.0023 
1034.85
16 0.0479 
1.279  7347 UP  UCHL3  ubiquitin carboxyl-terminal esterase L3 (ubiquitin thiolesterase) 0.0024 
1036.17
43 0.0479 
1.345  8409 UP  UXT  ubiquitously-expressed transcript 0.0025 
1037.28
1 0.0483 
1.224  114049 UP  WBSCR22  Williams Beuren syndrome chromosome region 22 0.0026 
1041.76
94 0.0487 
1.284  7529 UP  YWHAB 
 tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein, beta 
polypeptide 0.0025 
1042.06
79 0.0487 
1.291  55954 UP  ZMAT5  zinc finger, matrin type 5 0.0026 
1042.24
25 0.0492 
1.504  84858 UP  ZNF503  zinc finger protein 503 0.0026 
1042.67
96 0.0493 
1.306  30834 UP  ZNRD1  zinc ribbon domain containing 1 0.0026 
1044.71
99 0.0497 
 
Table 1. Analysis of genes affected by reduced GPX4 expression by (siRNA). Genes  with increased 
expression by 1.2 or greater (ranked) for 72 hours in response to GPX4 knock-down in Caco-2 cells 
by siRNA are listed. Genes identified through the in silico analysis as upregulated due to GPX4 
knock-down includes Human gene symbols and Entrez identifiers  
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Appendix A2: List of genes of which expression were down-regulated 
 
FOLD 
CHANGE 
PROB
E ID 
REGUL
ATION SYMBOL ENTREZ GENE NAME 
P.VA
LUE 
RP/S
UM PFP 
1.314 
 
29974 DOWN  A1CF  APOBEC1 complementation factor 
2.00E-
04 
5.706
8 0 
1.324 
 
10058 DOWN  ABCB6  ATP-binding cassette, sub-family B (MDR/TAP), member 6 
2.00E-
04 
13.66
85 0 
1.276  8714 DOWN  ABCC3  ATP-binding cassette, sub-family C (CFTR/MRP), member 3 
2.00E-
04 
15.85
02 0 
 1.347 
 
79575 DOWN  ABHD8  abhydrolase domain containing 8 
2.00E-
04 
17.29
48 0 
 1.404  26 DOWN  ABP1  amiloride binding protein 1 (amine oxidase (copper-containing)) 
2.00E-
04 
17.58
86 0 
 1.379  41 DOWN  ACCN2  amiloride-sensitive cation channel 2, neuronal 
2.00E-
04 
21.79
7 0 
 1.309 
 
11332 DOWN  ACOT7  acyl-CoA thioesterase 7 
2.00E-
04 
31.11
5 0 
 1.310  8309 DOWN  ACOX2  acyl-Coenzyme A oxidase 2, branched chain 
2.00E-
04 
39.05
91 0 
 1.310  6296 DOWN  ACSM3  acyl-CoA synthetase medium-chain family member 3 
3.00E-
04 
41.22
8 0 
 1.377  90 DOWN  ACVR1  activin A receptor, type I 
3.00E-
04 
43.02
22 0 
 1.303  91 DOWN  ACVR1B  activin A receptor, type IB 
5.00E-
04 
47.56
65 0 
 1.331  118 DOWN  ADD1  adducin 1 (alpha) 
5.00E-
04 
50.43
11 0 
 1.239  132 DOWN  ADK  adenosine kinase 
4.00E-
04 
52.73
82 0 
 1.885  174 DOWN  AFP  alpha-fetoprotein 
4.00E-
04 
65.45
13 0 
 1.289  9131 DOWN  AIFM1  apoptosis-inducing factor, mitochondrion-associated, 1 
4.00E-
04 
76.35
87 0 
 1.400  9465 DOWN  AKAP7  A kinase (PRKA) anchor protein 7 
6.00E-
04 
94.10
54 0 
 1.305  8644 DOWN  AKR1C3 
 aldo-keto reductase family 1, member C3 (3-alpha hydroxysteroid 
dehydrogenase, type II) 
6.00E-
04 
95.87
09 0 
 1.828  213 DOWN  ALB  albumin 
6.00E-
04 
103.2
966 
2.00
E-04 
 1.344  216 DOWN  ALDH1A1  aldehyde dehydrogenase 1 family, member A1 
5.00E-
04 
114.3
335 
2.00
E-04 
1.300 4329 DOWN ALDH6A1 aldehyde dehydrogenase 6 family, member A1 
6.00E-
04 
1155.
4874 
2.00
E-04 
 1.236  501 DOWN  ALDH7A1  aldehyde dehydrogenase 7 family, member A1 
7.00E-
04 
124.1
512 
2.00
E-04 
 1.278 
 
51321 DOWN  AMZ2  archaelysin family metallopeptidase 2 
6.00E-
04 
124.8
15 
2.00
E-04 
 1.492  8907 DOWN  AP1M1  adaptor-related protein complex 1, mu 1 subunit 
6.00E-
04 
126.9
185 
2.00
E-04 
 1.696  335 DOWN  APOA1  apolipoprotein A-I 
6.00E-
04 
136.1
924 
2.00
E-04 
 1.359  369 DOWN  ARAF  v-raf murine sarcoma 3611 viral oncogene homolog 
6.00E-
04 
138.2
483 
2.00
E-04 
 1.384 
 
64411 DOWN  ARAP3  ArfGAP with RhoGAP domain, ankyrin repeat and PH domain 3 
6.00E-
04 
140.1
404 
2.00
E-04 
 1.377 
 
55114 DOWN  ARHGAP17  Rho GTPase activating protein 17 
6.00E-
04 
147.4
309 
2.00
E-04 
 1.340  397 DOWN  ARHGDIB  Rho GDP dissociation inhibitor (GDI) beta 
8.00E-
04 
149.8
521 
3.00
E-04 
 1.366 
 
10550 DOWN  ARL6IP5  ADP-ribosylation-like factor 6 interacting protein 5 0.001 
150.7
32 
3.00
E-04 
 1.359 
 
10776 DOWN  ARPP19  cAMP-regulated phosphoprotein, 19kDa 
9.00E-
04 
151.9
979 
3.00
E-04 
 1.370 
 
84164 DOWN  ASCC2  activating signal cointegrator 1 complex subunit 2 
9.00E-
04 
155.2
893 
4.00
E-04 
 1.269  432 DOWN  ASGR1  asialoglycoprotein receptor 1 
9.00E-
04 
156.8
225 
4.00
E-04 
 1.581 
 
79170 DOWN  ATAD4  ATPase family, AAA domain containing 4 
0.001
4 
157.2
122 
4.00
E-04 
 1.285  476 DOWN  ATP1A1  ATPase, Na+/K+ transporting, alpha 1 polypeptide 
0.001
3 
175.6
125 
7.00
E-04 
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 1.212  481 DOWN  ATP1B1  ATPase, Na+/K+ transporting, beta 1 polypeptide 
0.001
4 
175.8
058 
7.00
E-04 
 1.379  509 DOWN  ATP5C1 
 ATP synthase, H+ transporting, mitochondrial F1 complex, gamma 
polypeptide 1 
0.001
4 
180.5
184 
7.00
E-04 
 1.329 
 
64734
0 DOWN  ATP5C2 
 ATP synthase, H+ transporting, mitochondrial F1 complex, gamma 
polypeptide 2 
0.001
5 
181.6
64 
7.00
E-04 
 1.235  537 DOWN  ATP6AP1  ATPase, H+ transporting, lysosomal accessory protein 1 
0.001
5 
183.3
768 
7.00
E-04 
 1.263 
 
15506
6 DOWN  ATP6V0E2  ATPase, H+ transporting V0 subunit e2 
0.001
5 
189.9
351 
9.00
E-04 
 1.375  558 DOWN  AXL  AXL receptor tyrosine kinase 
0.001
5 
195.1
795 
9.00
E-04 
 1.544  9334 DOWN  B4GALT5  UDP-Gal:betaGlcNAc beta 1,4- galactosyltransferase, polypeptide 5 
0.001
7 
198.2
168 
9.00
E-04 
 1.311 
 
11285 DOWN  B4GALT7 
 xylosylprotein beta 1,4-galactosyltransferase, polypeptide 7 
(galactosyltransferase I) 
0.001
6 
203.5
852 
9.00
E-04 
 1.398  593 DOWN  BCKDHA  branched chain keto acid dehydrogenase E1, alpha polypeptide 
0.001
6 
206.0
507 
9.00
E-04 
 1.376 
 
10295 DOWN  BCKDK  branched chain ketoacid dehydrogenase kinase 
0.001
6 
208.5
591 
9.00
E-04 
 1.238  274 DOWN  BIN1  bridging integrator 1 
0.001
6 
215.5
276 
9.00
E-04 
 1.289  8548 DOWN  BLZF1  basic leucine zipper nuclear factor 1 
0.001
7 
216.0
266 
9.00
E-04 
 1.244  738 DOWN  C11ORF2  chromosome 11 open reading frame2 
0.001
7 
217.3
378 
8.00
E-04 
 1.442 
 
79703 DOWN  C11ORF80  chromosome 11 open reading frame 80 
0.001
8 
221.5
212 
8.00
E-04 
 1.388 
 
79762 DOWN  C1ORF115  chromosome 1 open reading frame 115 
0.001
8 
221.6
028 
0.00
11 
 1.331 
 
25966 DOWN  C2CD2  C2 calcium-dependent domain containing 2 
0.001
8 
228.4
403 
0.00
1 
 1.292 
 
55845 DOWN  C3ORF10  chromosome 3 open reading frame 10 
0.001
8 
228.9
34 
0.00
1 
 1.489  725 DOWN  C4BPB  complement component 4 binding protein, beta 
0.001
9 
239.1
057 
0.00
1 
 1.349 
 
20189
5 DOWN  C4ORF34  chromosome 4 open reading frame 34 
0.001
9 
239.1
221 
0.00
11 
 1.308 
 
22192
7 DOWN  C7ORF27  chromosome 7 open reading frame 27 
0.001
9 
251.3
178 
0.00
11 
 1.397  784 DOWN  CACNB3  calcium channel, voltage-dependent, beta 3 subunit 0.002 
254.2
224 
0.00
12 
 1.405 
 
23705 DOWN  CADM1  cell adhesion molecule 1 0.002 
259.8
967 
0.00
12 
 1.281  808 DOWN  CALM3  calmodulin 3 (phosphorylase kinase, delta) 0.002 
262.5
064 
0.00
12 
 1.390  818 DOWN  CAMK2G  calcium/calmodulin-dependent protein kinase II gamma 
0.001
9 
263.5
209 
0.00
12 
 1.563  726 DOWN  CAPN5  calpain 5 
0.002
1 
264.1
178 
0.00
12 
 1.366  847 DOWN  CAT  catalase 
0.002
2 
277.8
732 
0.00
12 
 1.389  875 DOWN  CBS  cystathionine-beta-synthase 
0.002
2 
281.4
995 
0.00
12 
 1.299  896 DOWN  CCND3  cyclin D3 
0.002
2 
287.2
722 
0.00
12 
 1.422  900 DOWN  CCNG1  cyclin G1 
0.002
2 
289.2
514 
0.00
12 
 1.257 
 
10983 DOWN  CCNI  cyclin I 
0.002
2 
290.7
075 
0.00
12 
 1.376  7203 DOWN  CCT3  chaperonin containing TCP1, subunit 3 (gamma) 
0.002
3 
292.9
708 
0.00
12 
 1.296  928 DOWN  CD9  CD9 molecule 
0.002
3 
302.2
536 
0.00
12 
 1.223  4267 DOWN 
 CD99 (includes 
EG:4267)  CD99 molecule 
0.002
3 
303.9
589 
0.00
12 
 1.265 
 
14605
9 DOWN  CDAN1  congenital dyserythropoietic anemia, type I 
0.002
5 
314.5
203 
0.00
12 
 1.412  8555 DOWN  CDC14B  CDC14 cell division cycle 14 homolog B (S. cerevisiae) 
0.002
6 
317.1
492 
0.00
14 
 1.446  999 DOWN  CDH1  cadherin 1, type 1, E-cadherin (epithelial) 
0.002
8 
317.5
345 
0.00
14 
224 
 
 1.270  1015 DOWN  CDH17  cadherin 17, LI cadherin (liver-intestine) 
0.002
8 
321.3
004 
0.00
14 
 1.231 
 
91368 DOWN  CDKN2AIPNL  CDKN2A interacting protein N-terminal like 
0.002
8 
329.1
749 
0.00
14 
 1.373 
 
91368 DOWN  CDKN2AIPNL  CDKN2A interacting protein N-terminal like 
0.002
8 
339.4
503 
0.00
14 
 1.397 
 
91368 DOWN  CDKN2AIPNL  CDKN2A interacting protein N-terminal like 
0.003
1 
342.9
462 
0.00
14 
 1.313 
 
81620 DOWN  CDT1  chromatin licensing and DNA replication factor 1 
0.003
2 
350.5
827 
0.00
14 
 1.314 
 
13147
4 DOWN  CHCHD4  coiled-coil-helix-coiled-coil-helix domain containing 4 
0.003
2 
353.7
992 
0.00
13 
 1.208 
 
16601
2 DOWN  CHST13  carbohydrate (chondroitin 4) sulfotransferase 13 
0.003
3 
355.4
054 
0.00
13 
 1.298 
 
63924 DOWN  CIDEC  cell death-inducing DFFA-like effector c 
0.003
3 
356.9
938 
0.00
14 
 1.339 
 
23274 DOWN  CLEC16A  C-type lectin domain family 16, member A 
0.003
2 
365.1
194 
0.00
15 
 2.708 
 
29121 DOWN 
 CLEC2D (includes 
EG:29121)  C-type lectin domain family 2, member D 
0.003
3 
367.9
093 
0.00
15 
 1.486 
 
11946
7 DOWN  CLRN3  clarin 3 
0.003
3 
369.6
4 
0.00
16 
 1.257 
 
80790 DOWN  CMIP  c-Maf-inducing protein 
0.003
2 
373.8
272 
0.00
17 
 1.229  1266 DOWN  CNN3  calponin 3, acidic 
0.003
3 
375.6
908 
0.00
17 
 1.339 
 
55330 DOWN  CNO  cappuccino homolog (mouse) 
0.003
3 
384.5
502 
0.00
17 
 1.291 
 
80347 DOWN  COASY  Coenzyme A synthase 
0.003
3 
386.5
388 
0.00
19 
 1.582 
 
22837 DOWN  COBLL1  COBL-like 1 
0.003
5 
391.1
578 
0.00
23 
 1.297 
 
22796 DOWN  COG2  component of oligomeric golgi complex 2 
0.003
5 
394.5
228 
0.00
23 
 1.567  1303 DOWN  COL12A1  collagen, type XII, alpha 1 
0.003
5 
398.2
869 
0.00
23 
 1.366 
 
10087 DOWN  COL4A3BP  collagen, type IV, alpha 3 (Goodpasture antigen) binding protein 
0.003
6 
401.2
048 
0.00
22 
 1.223 
 
14995
1 DOWN  COMMD7  COMM domain containing 7 
0.003
6 
404.2
6 
0.00
23 
 1.343 
 
23603 DOWN  CORO1C  coronin, actin binding protein, 1C 
0.003
6 
406.2
356 
0.00
24 
 1.297 
 
54504 DOWN  CPVL  carboxypeptidase, vitellogenic-like 
0.003
6 
411.9
762 
0.00
26 
 1.353 
 
51747 DOWN  CROP  cisplatin resistance-associated overexpressed protein 
0.003
6 
416.0
53 
0.00
26 
 1.307  1429 DOWN  CRYZ  crystallin, zeta (quinone reductase) 
0.003
7 
422.2
502 
0.00
26 
 1.327  1438 DOWN 
 CSF2RA (includes 
EG:1438) 
 colony stimulating factor 2 receptor, alpha, low-affinity (granulocyte-
macrophage) 
0.003
7 
428.0
362 
0.00
26 
 1.267 
 
10106 DOWN  CTDSP2 
 CTD (carboxy-terminal domain, RNA polymerase II, polypeptide A) 
small phosphatase 2 
0.003
8 
430.4
944 
0.00
26 
 1.261  1495 DOWN  CTNNA1  catenin (cadherin-associated protein), alpha 1, 102kDa 
0.003
8 
431.7
868 
0.00
26 
 1.306  1508 DOWN  CTSB  cathepsin B 
0.004
4 
446.4
891 
0.00
25 
 1.218  1512 DOWN  CTSH  cathepsin H 
0.004
4 
447.5
745 
0.00
25 
 1.346  1515 DOWN  CTSL2  cathepsin L2 
0.004
5 
449.3
516 
0.00
29 
 1.434 
 
40409
3 DOWN  CUEDC1  CUE domain containing 1 
0.004
6 
456.1
893 
0.00
31 
 1.328 
 
26999 DOWN 
 CYFIP2 (includes 
EG:26999)  cytoplasmic FMR1 interacting protein 2 
0.004
8 
457.5
081 
0.00
31 
 1.296 
 
27071 DOWN  DAPP1  dual adaptor of phosphotyrosine and 3-phosphoinositides 
0.004
9 
464.4
514 
0.00
32 
 1.344 
 
79007 DOWN  DBNDD1  dysbindin (dystrobrevin binding protein 1) domain containing 1 
0.004
9 
466.4
678 
0.00
31 
 1.219  1642 DOWN  DDB1  damage-specific DNA binding protein 1, 127kDa 
0.004
9 
467.7
1 
0.00
32 
 1.564  1672 DOWN  DEFB1  defensin, beta 1 
0.005
2 
471.6
073 
0.00
32 
225 
 
 1.322  8560 DOWN  DEGS1  degenerative spermatocyte homolog 1, lipid desaturase (Drosophila) 
0.005
2 
471.9
604 
0.00
32 
 1.378  1687 DOWN  DFNA5  deafness, autosomal dominant 5 
0.005
3 
475.7
744 
0.00
38 
 1.541  8694 DOWN  DGAT1  diacylglycerol O-acyltransferase homolog 1 (mouse) 
0.005
2 
477.5
203 
0.00
39 
 1.236  1725 DOWN  DHPS  deoxyhypusine synthase 
0.005
2 
479.5
811 
0.00
4 
 1.346 
 
11581
7 DOWN  DHRS1  dehydrogenase/reductase (SDR family) member 1 
0.005
6 
484.2
411 
0.00
4 
 1.367 
 
84925 DOWN  DIRC2  disrupted in renal carcinoma 2 
0.005
8 
484.5
572 
0.00
41 
 1.246 
 
79962 DOWN  DNAJC22  DnaJ (Hsp40) homolog, subfamily C, member 22 
0.005
9 
487.0
292 
0.00
4 
 1.259 
 
79746 DOWN  ECHDC3  enoyl Coenzyme A hydratase domain containing 3 0.006 
493.4
745 
0.00
43 
 1.248  1892 DOWN  ECHS1  enoyl Coenzyme A hydratase, short chain, 1, mitochondrial 0.006 495.6 
0.00
43 
 1.581  1917 DOWN  EEF1A2  eukaryotic translation elongation factor 1 alpha 2 
0.006
1 
496.6
818 
0.00
5 
 1.327  1942 DOWN  EFNA1  ephrin-A1 
0.006
4 
499.7
438 
0.00
5 
 1.388  1949 DOWN  EFNB3  ephrin-B3 
0.006
4 
501.6
321 
0.00
5 
 1.309 
 
10938 DOWN  EHD1  EH-domain containing 1 
0.006
5 
507.3
827 
0.00
54 
 1.215 
 
51386 DOWN  EIF3L  eukaryotic translation initiation factor 3, subunit L 
0.007
2 
507.4
617 
0.00
54 
 1.294  2034 DOWN  EPAS1  endothelial PAS domain protein 1 
0.007
4 
510.7
8 
0.00
54 
 1.284 
 
29924 DOWN  EPN1  epsin 1 
0.007
6 
512.7
274 
0.00
58 
 1.393  2064 DOWN  ERBB2 
 v-erb-b2 erythroblastic leukemia viral oncogene homolog 2, 
neuro/glioblastoma derived oncogene homolog (avian) 
0.007
8 
513.6
842 
0.00
61 
 1.648 
 
12150
6 DOWN  ERP27  endoplasmic reticulum protein 27 
0.007
8 
518.9
779 
0.00
62 
 1.326  2122 DOWN  EVI1  ecotropic viral integration site 1 
0.007
9 
519.4
662 
0.00
62 
 2.163 
 
51466 DOWN  EVL  Enah/Vasp-like 
0.007
9 
524.4
771 
0.00
62 
 1.291  7430 DOWN  EZR  ezrin 
0.007
9 
525.0
101 
0.00
62 
 1.262  2159 DOWN  F10  coagulation factor X 
0.008
4 
526.2
134 
0.00
66 
 1.319 
 
50848 DOWN  F11R  F11 receptor 
0.008
4 
526.7
479 
0.00
67 
 1.360  2150 DOWN  F2RL1  coagulation factor II (thrombin) receptor-like 1 
0.009
2 
528.4
007 
0.00
69 
 1.336 
 
23197 DOWN  FAF2  Fas associated factor family member 2 
0.009
3 
530.1
463 
0.00
71 
 1.579 
 
83641 DOWN  FAM107B  family with sequence similarity 107, member B 
0.009
3 
530.3
444 
0.00
7 
 1.332 
 
63901 DOWN  FAM111A  family with sequence similarity 111, member A 
0.009
4 
536.0
104 
0.00
71 
 1.700 
 
33809
4 DOWN  FAM151A  family with sequence similarity 151, member A 
0.009
6 
536.8
854 
0.00
71 
 1.337 
 
28363
5 DOWN  FAM177A1  family with sequence similarity 177, member A1 
0.009
7 
538.9
095 
0.00
72 
 1.259  2192 DOWN  FBLN1  fibulin 1 
0.009
7 
542.2
597 
0.00
72 
 1.260  2222 DOWN  FDFT1  farnesyl-diphosphate farnesyltransferase 1 
0.010
1 
543.8
342 
0.00
72 
 2.348  2243 DOWN  FGA  fibrinogen alpha chain 
0.010
1 
552.2
205 
0.00
72 
 2.046  2244 DOWN  FGB  fibrinogen beta chain 0.01 
554.1
691 
0.00
73 
 1.521 
 
89846 DOWN  FGD3  FYVE, RhoGEF and PH domain containing 3 
0.010
1 
554.4
831 
0.00
73 
 1.296  2261 DOWN  FGFR3  fibroblast growth factor receptor 3 
0.010
2 
559.6
134 
0.00
73 
 2.018  2266 DOWN  FGG  fibrinogen gamma chain 
0.010
3 
560.9
484 
0.00
73 
 1.227  2271 DOWN  FH  fumarate hydratase 
0.010
2 
564.7
214 
0.00
73 
226 
 
 1.266  2218 DOWN  FKTN  fukutin 
0.010
6 
572.2
849 
0.00
74 
 1.419 
 
80164 DOWN  FLJ22184  hypothetical protein FLJ22184 
0.010
7 
575.2
287 
0.00
74 
 1.264 
 
28408
5 DOWN  FLJ40504  hypothetical protein FLJ40504 
0.010
7 
587.5
09 
0.00
74 
 1.237  2319 DOWN  FLOT2  flotillin 2 
0.010
9 
588.4
152 
0.00
74 
 1.327 
 
23048 DOWN  FNBP1  formin binding protein 1 
0.010
9 
588.9
121 
0.00
73 
 1.352  3169 DOWN  FOXA1  forkhead box A1 
0.010
9 
591.6
36 
0.00
73 
 1.501 
 
80144 DOWN  FRAS1  Fraser syndrome 1 
0.010
9 
593.2
276 
0.00
74 
 1.320 
 
10841 DOWN  FTCD  formiminotransferase cyclodeaminase 0.011 
604.4
483 
0.00
75 
 1.205 
 
53827 DOWN  FXYD5  FXYD domain containing ion transport regulator 5 
0.011
3 
606.4
85 
0.00
79 
 1.317  2584 DOWN  GALK1  galactokinase 1 
0.011
4 
611.1
03 
0.00
79 
 1.260  2592 DOWN  GALT  galactose-1-phosphate uridylyltransferase 
0.011
4 
611.5
248 
0.00
81 
 1.275  2621 DOWN  GAS6  growth arrest-specific 6 
0.011
5 
616.5
538 
0.00
82 
 1.297 
 
10985 DOWN  GCN1L1  GCN1 general control of amino-acid synthesis 1-like 1 (yeast) 
0.011
9 
617.4
511 
0.00
82 
 1.249 
 
10052 DOWN  GJC1  gap junction protein, gamma 1, 45kDa 0.012 
618.9
611 
0.00
82 
 1.220  2720 DOWN  GLB1  galactosidase, beta 1 
0.012
1 
621.0
534 
0.00
82 
 1.385 
 
15200
7 DOWN  GLIPR2  GLI pathogenesis-related 2 
0.012
1 
621.4
266 
0.00
84 
 1.402 
 
13215
8 DOWN  GLYCTK  glycerate kinase 
0.012
1 
628.8
998 
0.00
83 
 1.296 
 
51292 DOWN  GMPR2  guanosine monophosphate reductase 2 
0.012
4 
629.9
76 
0.00
85 
 1.533  2719 DOWN  GPC3  glypican 3 
0.012
3 
634.7
134 
0.00
86 
 1.585  2262 DOWN  GPC5  glypican 5 
0.012
7 
635.7
019 
0.00
85 
 1.328 
 
57211 DOWN  GPR126  G protein-coupled receptor 126 
0.012
7 
636.3
109 
0.00
85 
 1.328 
 
27239 DOWN  GPR162  G protein-coupled receptor 162 
0.012
8 
640.5
028 
0.00
85 
 2.175  2879 DOWN  GPX4  glutathione peroxidase 4 (phospholipid hydroperoxidase) 0.013 
650.7
664 
0.00
84 
 1.426  2888 DOWN  GRB14  growth factor receptor-bound protein 14 0.013 
651.7
823 
0.00
84 
 1.278  9380 DOWN  GRHPR  glyoxylate reductase/hydroxypyruvate reductase 0.013 
662.9
739 
0.00
84 
 1.436  2938 DOWN  GSTA1  glutathione S-transferase alpha 1 
0.012
9 
666.7
011 
0.00
86 
 1.445  2939 DOWN  GSTA2  glutathione S-transferase alpha 2 
0.013
3 
676.0
86 
0.00
86 
 1.294  2944 DOWN  GSTM1  glutathione S-transferase mu 1 
0.013
6 
678.5
655 
0.00
87 
 1.325  2946 DOWN  GSTM2  glutathione S-transferase mu 2 (muscle) 
0.013
9 
678.6
233 
0.00
9 
 1.447  2984 DOWN  GUCY2C  guanylate cyclase 2C (heat stable enterotoxin receptor) 
0.013
9 
680.4
539 
0.00
9 
 1.266  2990 DOWN  GUSB  glucuronidase, beta 0.014 
688.7
406 
0.00
9 
 1.278  8908 DOWN  GYG2  glycogenin 2 
0.013
9 
689.9
21 
0.00
9 
 1.369  9555 DOWN  H2AFY  H2A histone family, member Y 0.014 
697.2
437 
0.00
89 
 1.308  3033 DOWN  HADH  hydroxyacyl-Coenzyme A dehydrogenase 
0.014
1 
699.1
181 
0.00
9 
 1.408 
 
10866 DOWN  HCP5  HLA complex P5 
0.014
2 
699.6
822 
0.00
9 
 1.288 
 
51020 DOWN  HDDC2  HD domain containing 2 
0.014
4 
699.7
955 
0.00
9 
 1.372  8226 DOWN  HDHD1A  haloacid dehalogenase-like hydrolase domain containing 1A 
0.014
6 
703.8
159 
0.00
91 
227 
 
 1.388  9843 DOWN  HEPH  hephaestin 
0.014
7 
704.6
46 
0.00
91 
 1.265  3074 DOWN  HEXB  hexosaminidase B (beta polypeptide) 
0.014
7 
705.3
683 
0.00
91 
 1.346  3081 DOWN  HGD  homogentisate 1,2-dioxygenase (homogentisate oxidase) 
0.014
9 
705.9
495 
0.00
95 
 1.343  3156 DOWN  HMGCR  3-hydroxy-3-methylglutaryl-Coenzyme A reductase 
0.015
2 
713.4
526 
0.00
95 
 1.363  3157 DOWN  HMGCS1  3-hydroxy-3-methylglutaryl-Coenzyme A synthase 1 (soluble) 
0.015
1 
714.0
463 
0.00
95 
 1.524  3158 DOWN  HMGCS2  3-hydroxy-3-methylglutaryl-Coenzyme A synthase 2 (mitochondrial) 
0.015
2 
715.0
109 
0.00
95 
 1.364  3178 DOWN  HNRNPA1  heterogeneous nuclear ribonucleoprotein A1 
0.015
1 
715.1
446 
0.00
96 
 1.247  3281 DOWN  HSBP1  heat shock factor binding protein 1 
0.015
1 
715.7
917 
0.00
96 
 1.589  3294 DOWN  HSD17B2  hydroxysteroid (17-beta) dehydrogenase 2 
0.016
3 
717.9
537 
0.00
95 
 1.320  3283 DOWN  HSD3B1 
 hydroxy-delta-5-steroid dehydrogenase, 3 beta- and steroid delta-
isomerase 1 
0.016
3 
720.3
81 
0.00
96 
 1.251  3373 DOWN  HYAL1  hyaluronoglucosaminidase 1 
0.016
2 
720.7
417 
0.00
96 
 1.457  3398 DOWN  ID2  inhibitor of DNA binding 2, dominant negative helix-loop-helix protein 
0.016
2 
720.8
8 
0.00
97 
 1.213  3420 DOWN  IDH3B  isocitrate dehydrogenase 3 (NAD+) beta 
0.016
1 
720.9
761 
0.00
97 
 1.278 
 
83880 DOWN  IFP38  eukaryotic translation initiation factor 3, subunit F pseudogene 2 
0.016
1 
726.2
226 
0.01
02 
 1.290  3321 DOWN  IGSF3  immunoglobulin superfamily, member 3 
0.016
4 
727.3
493 
0.01
01 
 1.305  3588 DOWN  IL10RB  interleukin 10 receptor, beta 
0.016
5 
727.9
672 
0.01
03 
 1.367 
 
10994 DOWN  ILVBL  ilvB (bacterial acetolactate synthase)-like 
0.016
6 
730.6
025 
0.01
05 
 1.443 
 
64423 DOWN 
 INF2 (includes 
EG:64423)  inverted formin, FH2 and WH2 domain containing 
0.016
7 
732.4
673 
0.01
06 
 1.342 
 
55827 DOWN  IQWD1  IQ motif and WD repeats 1 
0.016
8 
733.4
964 
0.01
06 
 1.315 
 
51477 DOWN  ISYNA1  inositol-3-phosphate synthase 1 
0.016
7 
735.7
309 
0.01
06 
 1.266 
 
81618 DOWN  ITM2C  integral membrane protein 2C 
0.016
7 
738.1
265 
0.01
05 
 1.331  3710 DOWN  ITPR3  inositol 1,4,5-triphosphate receptor, type 3 
0.016
9 
742.8
336 
0.01
11 
 1.391 
 
38943
4 DOWN  IYD  iodotyrosine deiodinase 
0.016
9 
743.7
583 
0.01
12 
 1.354  9929 DOWN  JOSD1  Josephin domain containing 1 
0.017
3 
746.6
124 
0.01
17 
 1.262  9798 DOWN  KIAA0174  KIAA0174 
0.017
4 
753.2
532 
0.01
17 
 1.349 
 
23588 DOWN  KLHDC2  kelch domain containing 2 
0.017
3 
754.5
821 
0.01
2 
 1.792  3827 DOWN 
 KNG1 (includes 
EG:3827)  kininogen 1 
0.017
4 
759.1
518 
0.01
28 
 2.395  3875 DOWN  KRT18  keratin 18 
0.017
5 
759.1
567 
0.01
28 
 1.628 
 
28421
7 DOWN  LAMA1  laminin, alpha 1 0.018 
760.3
635 
0.01
34 
 1.462  3920 DOWN  LAMP2  lysosomal-associated membrane protein 2 
0.018
5 
762.5
715 
0.01
38 
 1.238 
 
51451 DOWN  LCMT1  leucine carboxyl methyltransferase 1 0.019 
766.4
197 
0.01
42 
 1.353 
 
64077 DOWN  LHPP  phospholysine phosphohistidine inorganic pyrophosphate phosphatase 0.019 
768.4
185 
0.01
44 
 1.209 
 
11025 DOWN 
 LILRB3 (includes 
EG:11025) 
 leukocyte immunoglobulin-like receptor, subfamily B (with TM and ITIM 
domains), member 3 0.019 
771.8
788 
0.01
49 
 1.591  3990 DOWN  LIPC  lipase, hepatic 
0.019
1 
773.7
104 
0.01
5 
 1.319  4000 DOWN  LMNA  lamin A/C 
0.019
6 
774.8
97 
0.01
51 
 1.457 
 
28573
3 DOWN  LOC285733  hypothetical LOC285733 
0.019
8 
775.6
527 
0.01
51 
 1.344 
 
40250
9 DOWN  LOC402509  similar to solute carrier family 29 (nucleoside transporters), member 4 
0.019
9 
775.6
567 
0.01
51 
228 
 
 1.360 
 
64293
4 DOWN  LOC642934  hypothetical LOC642934 
0.020
2 
776.0
3 
0.01
51 
 1.370 
 
64716
9 DOWN  LOC647169  similar to glutathione transferase 
0.020
2 
776.4
98 
0.01
55 
 1.215 
 
65323
2 DOWN  LOC653232  ribosomal protein L15 pseudogene 3 
0.020
2 
782.2
943 
0.01
59 
 1.269 
 
73216
5 DOWN  LOC729708  TPI1 pseudogene 
0.020
5 
785.1
755 
0.01
59 
 1.362 
 
73002
4 DOWN  LOC730024  hypothetical LOC730024 
0.020
5 
787.1
399 
0.01
59 
 1.467  4036 DOWN  LRP2  low density lipoprotein-related protein 2 
0.020
6 
788.5
231 
0.01
62 
 1.363 
 
11606
4 DOWN  LRRC58  leucine rich repeat containing 58 
0.020
6 
789.2
961 
0.01
61 
 1.353  4048 DOWN  LTA4H  leukotriene A4 hydrolase 
0.021
2 
789.5
84 
0.01
61 
 1.287  9500 DOWN  MAGED1  melanoma antigen family D, 1 
0.021
3 
791.8
799 
0.01
61 
 1.308 
 
63905 DOWN  MANBAL  mannosidase, beta A, lysosomal-like 
0.021
4 
794.5
857 
0.01
61 
 1.289  4082 DOWN 
 MARCKS 
(includes EG:4082)  myristoylated alanine-rich protein kinase C substrate 
0.021
5 
798.5
995 
0.01
62 
 1.218  9782 DOWN  MATR3  matrin 3 
0.021
5 
802.2
092 
0.01
62 
 1.276  9477 DOWN  MED20  mediator complex subunit 20 
0.021
7 
803.4
823 
0.01
68 
 1.332  4240 DOWN  MFGE8  milk fat globule-EGF factor 8 protein 
0.021
7 
804.2
626 
0.01
67 
 1.233 
 
11365
5 DOWN  MFSD3  major facilitator superfamily domain containing 3 
0.021
7 
805.9
867 
0.01
67 
 1.290  4320 DOWN  MMP11  matrix metallopeptidase 11 (stromelysin 3) 
0.021
7 
808.8
424 
0.01
67 
 1.325 
 
65258 DOWN  MPPE1  metallophosphoesterase 1 
0.021
6 
809.2
712 
0.01
7 
 1.351  9019 DOWN  MPZL1  myelin protein zero-like 1 
0.021
8 
809.6
909 
0.01
76 
 1.419 
 
12499
5 DOWN  MRPL10  mitochondrial ribosomal protein L10 
0.021
8 
811.1
064 
0.01
76 
 1.403 
 
64978 DOWN  MRPL38  mitochondrial ribosomal protein L38 0.022 
813.6
191 
0.01
8 
 1.311 
 
84311 DOWN  MRPL45  mitochondrial ribosomal protein L45 
0.021
9 
823.9
833 
0.01
8 
 1.332 
 
64419 DOWN  MTMR14  myotubularin related protein 14 
0.022
1 
825.0
695 
0.01
8 
 1.362 
 
10608 DOWN  MXD4  MAX dimerization protein 4 
0.022
2 
825.3
799 
0.01
83 
 1.373 
 
54820 DOWN  NDE1  nudE nuclear distribution gene E homolog 1 (A. nidulans) 
0.022
1 
825.5
161 
0.01
83 
 1.336 
 
10397 DOWN  NDRG1  N-myc downstream regulated 1 
0.022
5 
825.8
505 
0.01
87 
 1.305  4705 DOWN 
 NDUFA10 
(includes EG:4705)  NADH dehydrogenase (ubiquinone) 1 alpha subcomplex, 10, 42kDa 
0.022
5 
826.5
292 
0.01
88 
 1.367 
 
10783 DOWN  NEK6  NIMA (never in mitosis gene a)-related kinase 6 
0.022
5 
829.8
933 
0.01
88 
 1.365 
 
64332 DOWN  NFKBIZ 
 nuclear factor of kappa light polypeptide gene enhancer in B-cells 
inhibitor, zeta 
0.022
6 
831.4
663 
0.01
89 
 1.297  8508 DOWN  NIPSNAP1  nipsnap homolog 1 (C. elegans) 
0.022
8 
833.2
513 
0.01
89 
 1.294 
 
12620
5 DOWN  NLRP8  NLR family, pyrin domain containing 8 
0.022
7 
835.7
814 
0.01
89 
 1.391 
 
11281
7 DOWN  NPL2  N-acetylneuraminate pyruvate lyase 2 (putative) 
0.022
8 
836.7
994 
0.01
91 
 1.336 
 
27020 DOWN  NPTN  neuroplastin 
0.023
1 
836.8
578 
0.01
9 
 1.339  1728 DOWN  NQO1  NAD(P)H dehydrogenase, quinone 1 
0.023
2 
837.9
167 
0.01
91 
 1.473  7026 DOWN  NR2F2  nuclear receptor subfamily 2, group F, member 2 
0.023
1 
840.5
218 
0.01
94 
229 
 
 1.256 
 
54940 DOWN  OCIAD1  OCIA domain containing 1 
0.023
3 
842.0
335 
0.01
99 
 1.407  4973 DOWN  OLR1  oxidized low density lipoprotein (lectin-like) receptor 1 
0.023
4 
842.1
588 
0.02
01 
 1.373  5004 DOWN  ORM1  orosomucoid 1 
0.023
3 
846.7
685 
0.02
03 
 1.578  5005 DOWN  ORM2  orosomucoid 2 
0.023
6 
847.5
631 
0.02
04 
 1.310 
 
54623 DOWN  PAF1  Paf1, RNA polymerase II associated factor, homolog (S. cerevisiae) 
0.023
7 
848.4
069 
0.02
03 
 1.552  5064 DOWN  PALM  paralemmin 
0.023
7 
849.4
122 
0.02
03 
 1.300 
 
19674
3 DOWN 
 PAOX (includes 
EG:196743)  polyamine oxidase (exo-N4-amino) 
0.023
6 
849.7
346 
0.02
03 
 1.491 
 
64282 DOWN  PAPD5  PAP associated domain containing 5 
0.023
6 
854.3
986 
0.02
09 
 1.240  5094 DOWN  PCBP2  poly(rC) binding protein 2 
0.023
5 
855.1
113 
0.02
09 
 1.289  5111 DOWN  PCNA  proliferating cell nuclear antigen 
0.023
7 
858.4
269 
0.02
14 
 1.330  5118 DOWN  PCOLCE  procollagen C-endopeptidase enhancer 
0.023
6 
860.3
193 
0.02
15 
 1.327 
 
27250 DOWN  PDCD4  programmed cell death 4 (neoplastic transformation inhibitor) 
0.023
6 
865.9
134 
0.02
22 
 1.282  5143 DOWN  PDE4C 
 phosphodiesterase 4C, cAMP-specific (phosphodiesterase E1 dunce 
homolog, Drosophila) 
0.023
7 
866.7
41 
0.02
25 
 1.315  5159 DOWN  PDGFRB  platelet-derived growth factor receptor, beta polypeptide 
0.023
7 
869.2
378 
0.02
28 
 1.372  8566 DOWN  PDXK  pyridoxal (pyridoxine, vitamin B6) kinase 
0.023
7 
870.9
774 
0.02
29 
 1.373 
 
57026 DOWN 
 PDXP (includes 
EG:57026)  pyridoxal (pyridoxine, vitamin B6) phosphatase 
0.023
8 
876.3
165 
0.02
29 
 1.390 
 
64065 DOWN  PERP  PERP, TP53 apoptosis effector 
0.023
8 
880.4
625 
0.02
29 
 1.210 
 
10857 DOWN  PGRMC1  progesterone receptor membrane component 1 
0.023
9 
881.5
768 
0.02
28 
 1.288 
 
10424 DOWN  PGRMC2  progesterone receptor membrane component 2 0.024 
884.3
768 
0.02
3 
 1.339  5297 DOWN  PI4KA  phosphatidylinositol 4-kinase, catalytic, alpha 
0.024
4 
885.0
293 
0.02
32 
 1.467  9091 DOWN  PIGQ  phosphatidylinositol glycan anchor biosynthesis, class Q 
0.024
6 
887.0
663 
0.02
31 
 1.375 
 
12886
9 DOWN  PIGU  phosphatidylinositol glycan anchor biosynthesis, class U 
0.024
7 
889.1
884 
0.02
33 
 1.259  5296 DOWN  PIK3R2  phosphoinositide-3-kinase, regulatory subunit 2 (beta) 
0.024
7 
889.8
963 
0.02
34 
 1.348 
 
23646 DOWN  PLD3  phospholipase D family, member 3 
0.025
4 
890.7
387 
0.02
34 
 1.278  5372 DOWN  PMM1  phosphomannomutase 1 
0.025
9 
891.4
852 
0.02
36 
 1.474  5376 DOWN  PMP22  peripheral myelin protein 22 0.026 
895.4
254 
0.02
37 
 1.262 
 
87178 DOWN  PNPT1  polyribonucleotide nucleotidyltransferase 1 
0.026
4 
896.7
533 
0.02
39 
 1.266  8495 DOWN  PPFIBP2  PTPRF interacting protein, binding protein 2 (liprin beta 2) 
0.026
4 
898.5
937 
0.02
38 
 1.295  5515 DOWN  PPP2CA  protein phosphatase 2 (formerly 2A), catalytic subunit, alpha isoform 
0.026
3 
899.1
11 
0.02
39 
 1.323 
 
13081
4 DOWN  PQLC3  PQ loop repeat containing 3 
0.026
3 
900.8
069 
0.02
39 
 1.464  8842 DOWN  PROM1  prominin 1 
0.026
8 
901.1
124 
0.02
42 
 1.316 
 
15069
6 DOWN  PROM2  prominin 2 
0.026
8 
902.6
337 
0.02
44 
 1.410  5627 DOWN  PROS1  protein S (alpha) 
0.027
4 
903.5
739 
0.02
49 
 1.300  5636 DOWN  PRPSAP2  phosphoribosyl pyrophosphate synthetase-associated protein 2 
0.028
1 
903.9
941 
0.02
48 
 1.301 
 
78994 DOWN  PRR14  proline rich 14 
0.028
1 
905.1
038 
0.02
48 
 1.469  5652 DOWN  PRSS8  protease, serine, 8 
0.028
5 
905.1
879 
0.02
5 
 1.415 
 
56952 DOWN  PRTFDC1  phosphoribosyl transferase domain containing 1 
0.028
4 
907.2
378 
0.02
49 
230 
 
 1.490  5660 DOWN  PSAP  prosaposin 
0.028
5 
908.8
963 
0.02
49 
 1.371 
 
22949 DOWN  PTGR1  prostaglandin reductase 1 
0.028
8 
913.1
431 
0.02
52 
 1.260  5747 DOWN  PTK2  PTK2 protein tyrosine kinase 2 
0.028
8 
915.1
12 
0.02
51 
 1.354  5786 DOWN  PTPRA  protein tyrosine phosphatase, receptor type, A 
0.028
7 
915.7
674 
0.02
5 
 1.522  5792 DOWN  PTPRF  protein tyrosine phosphatase, receptor type, F 
0.028
8 
915.9
086 
0.02
52 
 1.430 
 
28411
9 DOWN  PTRF  polymerase I and transcript release factor 
0.028
8 
919.0
889 
0.02
53 
 1.395 
 
25945 DOWN  PVRL3  poliovirus receptor-related 3 
0.028
8 
919.3
379 
0.02
56 
 1.380  5859 DOWN  QARS  glutaminyl-tRNA synthetase 
0.029
4 
919.7
133 
0.02
59 
 1.286 
 
80223 DOWN  RAB11FIP1  RAB11 family interacting protein 1 (class I) 
0.029
7 
922.2
762 
0.02
59 
 1.369  9727 DOWN  RAB11FIP3  RAB11 family interacting protein 3 (class II) 
0.029
6 
925.0
475 
0.02
59 
 1.829 
 
11031 DOWN  RAB31  RAB31, member RAS oncogene family 
0.029
8 
925.3
453 
0.02
6 
 1.261 
 
32662
4 DOWN  RAB37  RAB37, member RAS oncogene family 
0.030
2 
926.4
133 
0.02
63 
 1.366  5899 DOWN  RALB 
 v-ral simian leukemia viral oncogene homolog B (ras related; GTP 
binding protein) 0.031 
928.8
746 
0.02
64 
 1.506 
 
10928 DOWN  RALBP1  ralA binding protein 1 
0.031
1 
930.0
007 
0.02
7 
 1.392 
 
51285 DOWN  RASL12  RAS-like, family 12 0.031 
930.0
506 
0.02
69 
 1.331 
 
34809
3 DOWN  RBPMS2  RNA binding protein with multiple splicing 2 
0.031
3 
932.5
875 
0.02
77 
 1.356 
 
92840 DOWN  REEP6  receptor accessory protein 6 
0.031
4 
932.9
69 
0.02
78 
 1.343 
 
29803 DOWN  REPIN1  replication initiator 1 
0.031
3 
933.3
806 
0.02
78 
 1.349 
 
23180 DOWN  RFTN1  raftlin, lipid raft linker 1 
0.031
4 
936.8
728 
0.02
78 
 1.218  6001 DOWN  RGS10  regulator of G-protein signaling 10 
0.031
4 
938.3
058 
0.02
8 
 1.242  387 DOWN  RHOA  ras homolog gene family, member A 
0.031
4 
939.2
276 
0.02
83 
 1.336  389 DOWN  RHOC  ras homolog gene family, member C 
0.031
4 
940.2
18 
0.02
86 
 1.284  6038 DOWN  RNASE4  ribonuclease, RNase A family, 4 
0.032
1 
940.4
819 
0.02
9 
 1.517  8635 DOWN  RNASET2  ribonuclease T2 
0.032
1 
941.3
478 
0.03
05 
 1.305 
 
26001 DOWN  RNF167  ring finger protein 167 0.032 
942.8
808 
0.03
11 
 1.382  6051 DOWN  RNPEP  arginyl aminopeptidase (aminopeptidase B) 
0.031
9 
942.9
217 
0.03
11 
 1.555  4736 DOWN 
 RPL10A (includes 
EG:4736)  ribosomal protein L10a 0.032 
943.2
923 
0.03
19 
 1.247  6137 DOWN  RPL13  ribosomal protein L13 0.032 
943.7
686 
0.03
22 
 1.429 
 
23521 DOWN  RPL13A  ribosomal protein L13a 
0.032
1 
944.7
884 
0.03
27 
 1.299  6138 DOWN  RPL15  ribosomal protein L15 
0.032
1 
945.1
058 
0.03
33 
 1.991  6144 DOWN 
 RPL21 (includes 
EG:6144)  ribosomal protein L21 
0.032
1 
945.7
473 
0.03
33 
 1.301  6154 DOWN  RPL26  ribosomal protein L26 0.032 
946.0
195 
0.03
34 
 1.378  6158 DOWN  RPL28  ribosomal protein L28 0.032 
947.7
589 
0.03
37 
 1.640  6130 DOWN  RPL7A  ribosomal protein L7a 
0.032
2 
950.6
867 
0.03
37 
 1.231 
 
28585
5 DOWN  RPL7L1  ribosomal protein L7-like 1 
0.032
3 
953.9
539 
0.03
4 
 1.269  6184 DOWN  RPN1  ribophorin I 
0.032
5 
955.4
844 
0.03
42 
 1.369  6185 DOWN  RPN2  ribophorin II 0.033 
956.3
052 
0.03
43 
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 1.333  6199 DOWN  RPS6KB2  ribosomal protein S6 kinase, 70kDa, polypeptide 2 0.033 
956.9
019 
0.03
43 
 1.530 
 
56681 DOWN  SAR1A  SAR1 homolog A (S. cerevisiae) 0.033 
963.9
779 
0.03
49 
 1.351 
 
51435 DOWN  SCARA3  scavenger receptor class A, member 3 0.033 
970.4
834 
0.03
48 
 1.421 
 
29970 DOWN  SCHIP1  schwannomin interacting protein 1 
0.033
2 
972.1
263 
0.03
48 
 1.337 
 
57410 DOWN  SCYL1  SCY1-like 1 (S. cerevisiae) 
0.033
3 
975.9
31 
0.03
47 
 1.680  6382 DOWN  SDC1  syndecan 1 
0.033
3 
976.4
117 
0.03
51 
 1.481 
 
22928 DOWN  SEPHS2  selenophosphate synthetase 2 
0.033
4 
976.8
96 
0.03
5 
 1.269  4735 DOWN  SEPT2  septin 2 
0.033
5 
977.2
586 
0.03
58 
 1.315  5413 DOWN  SEPT5  septin 5 
0.033
8 
982.1
059 
0.03
58 
 1.289  5104 DOWN  SERPINA5 
 serpin peptidase inhibitor, clade A (alpha-1 antiproteinase, antitrypsin), 
member 5 
0.033
8 
982.7
157 
0.03
68 
 1.284  5269 DOWN  SERPINB6  serpin peptidase inhibitor, clade B (ovalbumin), member 6 
0.034
9 
988.5
886 
0.03
68 
 1.354  462 DOWN  SERPINC1  serpin peptidase inhibitor, clade C (antithrombin), member 1 
0.035
6 
993.4
059 
0.03
68 
 1.235  6430 DOWN  SFRS5  splicing factor, arginine/serine-rich 5 0.036 
994.1
238 
0.03
71 
 1.254  6431 DOWN  SFRS6  splicing factor, arginine/serine-rich 6 
0.036
2 
997.6
468 
0.03
73 
 1.348 
 
15376
9 DOWN  SH3RF2  SH3 domain containing ring finger 2 
0.036
3 
997.7
595 
0.03
75 
 1.296 
 
51092 DOWN  SIDT2  SID1 transmembrane family, member 2 
0.036
2 
999.2
031 
0.03
75 
 1.331  7884 DOWN  SLBP  stem-loop binding protein 
0.036
2 
1002.
8427 
0.03
78 
 1.451  6554 DOWN  SLC10A1 
 solute carrier family 10 (sodium/bile acid cotransporter family), member 
1 
0.036
1 
1003.
7515 
0.03
79 
 1.301 
 
38770
0 DOWN  SLC16A12 
 solute carrier family 16, member 12 (monocarboxylic acid transporter 
12) 
0.036
1 
1003.
9048 
0.03
78 
 1.326  9121 DOWN  SLC16A5  solute carrier family 16, member 5 (monocarboxylic acid transporter 6) 
0.036
1 
1005.
2128 
0.03
82 
 1.268 
 
51312 DOWN  SLC25A37  solute carrier family 25, member 37 0.036 
1005.
9407 
0.03
83 
 1.465 
 
22296
2 DOWN  SLC29A4  solute carrier family 29 (nucleoside transporters), member 4 
0.037
6 
1006.
4934 
0.03
84 
 1.405  2542 DOWN  SLC37A4  solute carrier family 37 (glucose-6-phosphate transporter), member 4 
0.037
5 
1006.
7054 
0.03
84 
 1.487 
 
54946 DOWN 
 SLC41A3 
(includes 
EG:54946)  solute carrier family 41, member 3 
0.037
9 
1014.
7883 
0.03
94 
 1.250 
 
23446 DOWN  SLC44A1  solute carrier family 44, member 1 
0.038
3 
1014.
9258 
0.03
93 
 1.723  9056 DOWN  SLC7A7 
 solute carrier family 7 (cationic amino acid transporter, y+ system), 
member 7 
0.038
2 
1016.
409 
0.03
95 
 1.417  9368 DOWN  SLC9A3R1 
 solute carrier family 9 (sodium/hydrogen exchanger), member 3 
regulator 1 
0.038
3 
1020.
1983 
0.03
96 
 1.263  4090 DOWN  SMAD5  SMAD family member 5 
0.038
2 
1023.
458 
0.04
02 
 1.305 
 
27131 DOWN  SNX5  sorting nexin 5 
0.038
5 
1024.
7569 
0.04
02 
 1.222 
 
64847 DOWN  SPATA20  spermatogenesis associated 20 
0.038
5 
1025.
2445 
0.04
09 
 1.262 
 
56848 DOWN  SPHK2  sphingosine kinase 2 
0.038
6 
1029.
1641 
0.04
09 
 1.343 
 
10653 DOWN  SPINT2  serine peptidase inhibitor, Kunitz type, 2 
0.038
6 
1030.
2163 
0.04
12 
 1.443 
 
55304 DOWN  SPTLC3  serine palmitoyltransferase, long chain base subunit 3 
0.038
5 
1030.
2755 
0.04
15 
 1.311 
 
10402 DOWN  ST3GAL6  ST3 beta-galactoside alpha-2,3-sialyltransferase 6 
0.039
6 
1032.
6779 
0.04
16 
 1.311  6773 DOWN  STAT2  signal transducer and activator of transcription 2, 113kDa 
0.039
6 
1033.
9682 
0.04
15 
 1.290  8614 DOWN  STC2  stanniocalcin 2 
0.039
7 
1035.
1833 
0.04
16 
 2.027  2040 DOWN  STOM  stomatin 
0.040
1 
1036.
0108 
0.04
18 
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 1.575  6811 DOWN  STX5  syntaxin 5 0.04 
1041.
0031 
0.04
18 
 1.270  8802 DOWN  SUCLG1  succinate-CoA ligase, alpha subunit 
0.040
2 
1041.
0414 
0.04
2 
 1.314  6817 DOWN  SULT1A1  sulfotransferase family, cytosolic, 1A, phenol-preferring, member 1 
0.040
3 
1041.
1463 
0.04
24 
 1.580 
 
56241 DOWN  SUSD2  sushi domain containing 2 
0.040
4 
1042.
2754 
0.04
25 
 1.335 
 
55333 DOWN  SYNJ2BP  synaptojanin 2 binding protein 
0.040
3 
1042.
5665 
0.04
25 
 1.388 
 
26123 DOWN  TCTN3  tectonic family member 3 
0.040
3 
1043.
1112 
0.04
26 
 1.407  7045 DOWN  TGFBI  transforming growth factor, beta-induced, 68kDa 
0.040
3 
1043.
2405 
0.04
27 
 1.401 
 
26277 DOWN  TINF2  TERF1 (TRF1)-interacting nuclear factor 2 
0.041
5 
1043.
9309 
0.04
3 
 1.355 
 
27134 DOWN  TJP3  tight junction protein 3 (zona occludens 3) 
0.041
7 
1044.
042 
0.04
29 
 1.239  4071 DOWN  TM4SF1  transmembrane 4 L six family member 1 
0.041
7 
1044.
8326 
0.04
31 
 1.408 
 
79022 DOWN  TMEM106C  transmembrane protein 106C 
0.042
1 
1046.
0933 
0.04
31 
 1.545 
 
38752
1 DOWN  TMEM189  transmembrane protein 189 
0.042
3 
1046.
9511 
0.04
3 
 1.365 
 
44002
6 DOWN  TMEM41B  transmembrane protein 41B 
0.042
3 
1047.
901 
0.04
29 
 1.445  757 DOWN  TMEM50B  transmembrane protein 50B 
0.042
2 
1051.
2343 
0.04
33 
 1.278 
 
51669 DOWN  TMEM66  transmembrane protein 66 
0.042
5 
1051.
6246 
0.04
32 
 1.398 
 
10140 DOWN  TOB1  transducer of ERBB2, 1 
0.042
6 
1051.
7964 
0.04
32 
 1.345  8459 DOWN  TPST2  tyrosylprotein sulfotransferase 2 
0.043
5 
1052.
8136 
0.04
33 
 1.335 
 
10758 DOWN  TRAF3IP2  TRAF3 interacting protein 2 
0.043
6 
1055.
2347 
0.04
37 
 1.329 
 
89122 DOWN  TRIM4  tripartite motif-containing 4 
0.043
6 
1056.
6837 
0.04
39 
 1.287  8295 DOWN  TRRAP  transformation/transcription domain-associated protein 0.044 
1057.
189 
0.04
39 
 1.374 
 
27075 DOWN  TSPAN13  tetraspanin 13 
0.044
7 
1058.
642 
0.04
45 
 1.408 
 
90139 DOWN  TSPAN18  tetraspanin 18 
0.044
6 
1059.
4039 
0.04
5 
 1.364 
 
10099 DOWN  TSPAN3  tetraspanin 3 
0.044
7 
1062.
6395 
0.04
54 
 1.312  6302 DOWN  TSPAN31  tetraspanin 31 
0.044
9 
1062.
8833 
0.04
54 
 1.239  7263 DOWN  TST  thiosulfate sulfurtransferase (rhodanese) 0.045 
1070.
7392 
0.04
58 
 1.491 
 
33786
7 DOWN  UBAC2  UBA domain containing 2 
0.045
1 
1074.
8959 
0.04
61 
 1.385 
 
14073
9 DOWN  UBE2F  ubiquitin-conjugating enzyme E2F (putative) 
0.045
2 
1079.
2519 
0.04
66 
 1.335  9246 DOWN  UBE2L6  ubiquitin-conjugating enzyme E2L 6 
0.045
3 
1081.
4066 
0.04
67 
 1.265  9690 DOWN  UBE3C  ubiquitin protein ligase E3C 
0.045
4 
1082.
3881 
0.04
68 
 1.298  8408 DOWN  ULK1  unc-51-like kinase 1 (C. elegans) 
0.045
4 
1082.
5836 
0.04
68 
 1.294 
 
55245 DOWN  UQCC  ubiquinol-cytochrome c reductase complex chaperone 
0.046
3 
1082.
7392 
0.04
78 
 1.259  7390 DOWN  UROS  uroporphyrinogen III synthase 
0.046
7 
1083.
8441 
0.04
78 
 1.311 
 
10083 DOWN  USH1C  Usher syndrome 1C (autosomal recessive, severe) 
0.046
8 
1084.
4072 
0.04
77 
 1.321  8239 DOWN  USP9X  ubiquitin specific peptidase 9, X-linked 0.047 
1084.
566 
0.04
77 
 1.460  7411 DOWN  VBP1  von Hippel-Lindau binding protein 1 
0.047
5 
1094.
6139 
0.04
77 
 1.384  9686 DOWN  VGLL4  vestigial like 4 (Drosophila) 
0.047
9 
1100.
0318 
0.04
76 
 1.292  7429 DOWN  VIL1  villin 1 
0.048
4 
1100.
1869 
0.04
79 
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 1.271  7448 DOWN  VTN  vitronectin 
0.048
3 
1102.
0199 
0.04
79 
 1.332 
 
25676
4 DOWN  WDR72  WD repeat domain 72 
0.048
2 
1102.
1919 
0.04
83 
 1.270 
 
25844 DOWN  YIPF3  Yip1 domain family, member 3 
0.048
1 
1103.
5268 
0.04
87 
 1.353  7528 DOWN  YY1  YY1 transcription factor 
0.048
8 
1103.
8819 
0.04
87 
 1.353  7766 DOWN  ZNF223  zinc finger protein 223 
0.049
1 
1106.
8563 
0.04
92 
 1.353 
 
14046
7 DOWN  ZNF358  zinc finger protein 358 
0.049
5 
1107.
2774 
0.04
93 
 1.314 
 
65249 DOWN  ZSWIM4  zinc finger, SWIM-type containing 4 
0.049
9 
1108.
3324 
0.04
97 
 
Table 2. Analysis of genes affected by reduced GPX4 expression by (siRNA). Genes  with reduced 
expression by 1.2 or greater (ranked) for 72 hours in response to GPX4 knock-down in Caco-2 cells 
by siRNA are listed. Genes identified through the in silico analysis as upregulated due to GPX4 
knock-down includes Human gene symbols and Entrez identifiers.  
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Appendix B: Amplification and Standard Curves for qPCR 
i 
 
ii 
 
iii 
 
Figure 1. RT-qPCR for Apoptosis inducing factor  (AIF) (i) RT-qPCR amplification using  PCR 
product of AIF  (ii) RT-qPCR amplification of unknown samples using cDNA  from siRNA and 
scrambled control treated cells (iii)  standard  curves using primers for GAPDH and β-actin on 
reverse-transcribed Caco-2 cell RNA. i – Typical amplification curves generated using primers for  
GAPDH and β-actin. Fluorescence intensity generated by amplification of PCR product used to 
generate standard curve was measured and plotted against PCR cycle number to determine the 
threshold crossing point (CT values).  ii- Fluorescence intensity generated by amplification of  cDNA 
of unknown concentration was measured and plotted against PCR cycle number to determine the 
threshold crossing point (CT values). Each sample was measured in duplicate. iii –Typical standard 
curve generated for GAPDH and β-actin. The mean log concentration of each PCR and cDNA 
sample within a ten- fold dilution series was plotted against the CT value. The standard curve was 
then used to calculate the relative levels of GAPDH and  β-actin in each unknown sample. 
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Appendix C: A typical Oxygen Electrode (Oxygraph) recording of cellular 
respiration in Caco-2 cells. 
A 
 
B 
  
 
 
Figure 2. Cellular respiration and oxygen consumption assessement. (A) Oxygen flow after addition 
of specific inhibitors of the mitochondrial electron transport chains; Cr- cell resting respiration, CrO- 
respiration after addition of Oligomycin (Inhibitor of ATP synthase-Complex V), Cru- addition of 
FCCP (Uncoupler) to assess maximum respiration, CruR-addition of Rotenone (inhibitor of complex 
I) and CruRA- addition of Antimycin A (inhibitor of complex III). (B) A typical  O2 concentration 
generated from the respirometry experiment Blue-Oxygen concentration [µM] and Red-Oxygen flux 
per volume [pmol/ ml] corrected for instrumental background. 
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Appendix D: Composition of cell culture medium  
DMEM-Dulbecco’s Modified Eagle Medium (Caco-2) 
Components Concentration (mg/L) Molarity (mM) 
 
Amino Acids:  
Glycine  30 0.4 
L-Alanyl-L-Glutamine  862 3.97 
L-Arginine hydrochloride  84 0.398 
L-Cystine 2HCl  63 0.201 
L-Histidine hydrochloride-
H2O  
42 0.2 
L-Isoleucine  105 0.802 
L-Leucine  105 0.802 
L-Lysine hydrochloride  146 0.798 
L-Methionine  30 0.201 
L-Phenylalanine  66 0.4 
L-Serine  42 0.4 
L-Threonine  95 0.798 
L-Tryptophan  16 0.0784 
L-Tyrosine  72 0.398 
L-Valine  94 0.803 
 
Vitamins  
Choline chloride  4 0.0286 
D-Calcium pantothenate  4 0.00839 
Folic Acid  4 0.00907 
Niacinamide  4 0.0328 
Pyridoxine hydrochloride  4 0.0196 
Riboflavin  0.4 0.00106 
Thiamine hydrochloride  4 0.0119 
i-Inositol  7.2 0.04 
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Inorganic Salts:  
Calcium Chloride (CaCl2-
2H2O)  
264 1.8 
Ferric Nitrate (Fe(NO3)3-
9H2O)  
0.1 0.000248 
Magnesium Sulfate (MgSO4-
7H2O)  
200 0.813 
Potassium Chloride (KCl)  400 5.33 
Sodium Bicarbonate 
(NaHCO3)  
3700 44.05 
Sodium Chloride (NaCl)  6400 110.34 
Sodium Phosphate monobasic 
(NaH2PO4-2H2O)  
141 0.916 
 
Other Components:  
D-Glucose (Dextrose)  4500 25 
Phenol Red  15 0.0399 
Sodium Pyruvate  110 1 
 
